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Abstract 
Subsequent work seeks to utilize available ACTN3, IGF-I, IGF-II and myostatin data to 
gain a better understanding of the polymorphisms in association with muscle phenotype.  
Several studies investigated the relationship of these genes in athletic and nonathletic 
cohorts. The aim of the review is to find similarities in the effects of these polymorphisms 
on muscle function or exercise adaptation. α-actinin is a major structural component of the 
Z-line, present in fast twitch muscle fibers. The presence of R and X alleles of ACTN3 has 
been reported to affect the spriniting and endurance abilities of elite athletes. While the 
other three growth factors (IGF-I, IGF-II and myostatin) are thought to be important 
regulators of muscle mass by influencing satellite cells. This critical evaluation of recent 
research on hand tries to explain this complex phenomena. The ACTN3 gene search 
resulted in the highest output of relevant studies. There was a range of responses among 
subjects which may be due to the training principle of individuality, that each subject 
responds different to the same quantitative and qualitative training stimuli. It is unknown, 
wheter the ACTN3 R577X polymorphism define`s the initial levels of power ability or it 
actually affects the response to training. It also turned out, that exercise performance is 
unlikely to be reducable to a single phenotypic trait. There seems to be an interaction of 
numerous genes and it might be plausible that other polymorphisms within the pathways 
could be involved in muscle metabolism. As found out for IGF-I pathways in muscular 
hypertrophy and strength response to strength training. But the IGF-I gene search delivered 
a small output of two studies, which might not be representable. This also applies to IGF-II 
gene. The two studies included in the review do not explain associations between early 
growth and grip strength, but there might be an influence on muscle mass and function in 
later life. Likewise, myostatin seems to be more related to muscle mass than it is to 
strength. Although most studies evaluated the relationship between myostatin and muscle 
mass rather than muscle strength, muscle mass does not always correlate directly with 
muscle strength and muscle mass cannot uniformly be explained by changes in muscle 
size. 
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Die folgende Diplomarbeit erhebt verfügbare Daten über ACTN3, IGF-I, IGF-II und 
Myostatin, um ein besseres Verständnis für die Polymorphismen im Zusammenhang mit 
dem muskulären Phenotypus zu gewinnen. Mehrere Studien untersuchten die Beziehung 
dieser Gene in Kohorten von Athleten und Nichtathleten. Das Ziel dieses Reviews ist es, 
Ähnlichkeiten in den Effekten dieser Polymorphismen mit Musklefunktionen oder 
Anpassung an sportliche Bewegung zu finden. α-actinin, vorhanden in schnellzuckenden 
Muskelfasern, ist ein wichtiger struktureller Komponent der Z-Linie. Das Vorhandensein 
von R und X Allelen wurde allgemein in Zusammenhang gebracht mit Schnellkraft und 
Ausdauerleistungsfähigkeit von Eliteathleten. Während angenommen wird, dass die 
anderen drei Wachstumsfaktoren (IGF-I, IGF-II und Moystatin) wichtige Regulatoren der 
Muskelmasse sind, indem sie Satellitenzellen aktivieren. Die vorliegende kritische 
Auswertung neuester Studien, versucht diese komplexen Phänomene zu erklären. Die 
ACTN3 Suche ergab die größte Menge an relevanten Studien. Es gab eine große Variation 
an Ergebnissen, was mit dem Trainingsprinzip der Individualität in Zusammenhang stehen 
kann. Demnach reagiert jeder Einzelne unterschiedlich auf die gleiche quantitative und 
qualitative Trainingsstimulation. Es ist unbekannt, ob ACTN3 das anfängliche Niveau der 
Kraftfähigkeit bestimmt, oder ob es tatsächlich die Reaktion auf Training beeinflusst. Eine 
weitere Feststellung ist, dass sportliche Leistung nur auf eine einzelne phenotypische 
Eigenschaft reduzierbar ist. Die Interaktion von mehreren Genen könnte verantwortlich 
sein und es scheint einleuchtend, dass mehrere Polymorphismen innerhalb dieser Pfade 
eine Auswirkung auf den Muskelstoffwechsel haben. Wie IGF-I Pfade in muskulärer 
Hypertrophy und Kraftreaktionen nach Krafttraining zeigen. Die Suche nach IGF-I ergab 
aber eine kleine Anzahl von zwei Studien, was nicht wissenschaftlich vetrtretbar ist. 
Dasselbe gilt für das IGF-II Gen. Die beiden in das Review eingeschlossenen Studien 
erklären nicht die Beziehungen zwischen embrionalem Wachstum und Armkraft, aber es 
dürfte ein Einfluss auf die Muskelmasse und Funktion im Erwachsenenalter vorhanden 
sein. Ebenso scheint Myostatin mehr im Zusammenhang zu stehen mit Muskelmasse als 
mit Kraft. Obwohl die meisten Studien den Zusammenhang zwischen Myostatin und 
Muskelmasse anstatt Muskelkraft evaluierten, korreliert Muskelmasse nicht immer direkt 
mit Muskelkraft und Muskelmasse kann nicht immer mit Veränderungen der Muskelgrösse 
in Zusammenhang gebracht werden. 
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Abbreviations 
A2A receptor  Adenosin 2A receptor 
 
ActRIIA  Activin-receptor Type IIa 
 
ActRIIB  Activin-receptor Type IIb 
 
ABD   Actin-binding-domain 
 
ACTN3  Alpha-actinin3 
 
ACTN2  Alpha-actinin2 
 
ADP   Adenosindiphosphat 
 
ALS   Amyotrophic lateral sclerosis 
 
ATP   Adenosintriphosphat 
 
bHLH   Basic helix-loop-helix 
 
BMI   Body mass index 
 
PPP3R1  Calcineurin B 
 
CA   Cytosin adenine 
 
CANNTG  E box 
 
CapZ   Capping protein muscle Z-line 
 
CSA   Cross-sectional area 
 
CK   Creatine kinase 
 
DMD   Duchenne muscular dystrophy 
 
DRP   Dynamin-related protein 
 
DNA   Deoxyribonucleic acid 
 
EPO   Erythropietin 
 
ERK   Extracellular response kinase 
 
FFM   Fat free mass 
 
GDF8   Growth and differentiation factor 8 
 
 7
GH   Growth hormone 
 
GSK   Glycogen synthase kinase 
 
IBE-1   Eb-peptide fragment 
 
IGFBP   IGF-binding protein 
 
IGF-I   Insulinlike growth factor I 
 
IGF-II   Insulinlike growth factor II 
 
IGF-IR  IGF-I receptor 
 
IGF-IIR  IGF-II receptor 
 
IRS   Insulin receptor substrate 
 
KE   Knee extension 
 
LDHA   Lactate dehydrogenase A 
 
LDHB   Lactate dehydrogenase B 
 
LGfMS  Leuven Genes for Muscular Strength Study 
 
M6PR   IGF-II/Mannose-6-phosphat-receptor 
 
MAPK  Mitogen-activated protein kinase 
 
MD   Muscular dystrophy 
 
MGF   Mechano growth factor 
 
MLCK  Myosin light chain kinase 
 
MRF   Myogenic regulatory factors 
 
MSTN   Myostatin 
 
mRNA  Messenger ribonucleic acid 
 
mtDNA  Mitochondrial deoxyribonucleic acid 
 
MyD   Myeloid differentiation 
 
MV   Muscle volume 
 
MVC   Maximal voluntary contraction 
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MQ   Muscle quality 
 
NMDA  N-methyl-D-aspartic acid 
 
PI3K   Phosphatidylinositol-3-kinase 
 
PIP2   Phosphatidylinositol-4,5-biphosphatase 
 
PKB   Protein kinase B 
 
PT   Peak tourque 
 
1-RM   1-repition maximum 
 
RNA   Ribonucleic acid 
 
SLR   Spectrin-like repeat 
 
SNP   Single nucleotide polymorphism 
 
ST   Strength training 
 
TGFß   Transforming growth factor- ß 
 
UTR   Untranslated region 
 
Vo2max  Maximal oxigen uptake 
 
WHAS  Women`s health and aging study 
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1 Introduction 
 
The accommodation of the human body on environmental factors such as sports exercise 
has a considerable genetic basis. Skeletal muscle adaptations to exercise like changes in 
capillarization and muscle enzyme activities as well as fibre phenotypes and size, activate 
different levels of gene expression. These adaptation processes on the cellular level 
correspondingly influence the development of fatigue resistance by endurance training and 
the greater strength and size that results from a period of resistance training. The 
mechanisms responsible for the adaptation of cells and organs to exercise are characterized 
by genetic determinants. Looking at the DNA of a cell there is 99,9% identity between two 
human beings. Sometimes the mother cell template is incorrectly replicated and the DNA 
sequence of the individual changes. This mutations range from single nucleotide 
polymorphisms to deletions or additions of large chromosomal areas. Influenced by  
devergences in gene expression and function individual variations of exercise-related 
characteristics such as maximal oxygen uptake, muscle fibre composition, heart efficiency, 
power output, endurance or other traits occur. Polymorphisms, that mediate sports-related 
characteristics are the main subject of the study. The identification of such genetic loci 
informs about the mechanisms that regulate a phenotype. Molecular genetic research 
techniques allow to identify polymorphisms that are responsible for inherited variability in 
physical performance phenotypes. This may help to understand how exercise and genes 
can interact to modify a phenotypic trait or health outcome. The review on hand 
investigates studies corresponding to gene x phenotype interactions in concordance with 
anaerobic performances. The effects of ACTN3, IGF-I, IGF-II and myostatin 
polymorphisms on anaerobic phenotypes are in main focus. ACTN3 is a gene required for 
optimal muscle performance in endurance training. IGF-I is a growthfactor that plays an 
important role in resistance exercise by activatings satellite cells and influencing myogenic 
markers. The structure of IGF-I is very similar to the structure of IGF-II. Several of the 
features of IGF-I gene structure, expression, and regulation also apply to the IGF-II gene. 
In contrary myostatin functions as a negative growth regulator for skeletal muscle. 
Myostatin also influences satellite cell activation. The absence of myostatin results in a 
hypermuscular phenotype in a large number of different species. The genes are specified in 
Chapters 2 to 4. 
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This review establishes a correlation between outcomes on muscle phenotypes and the 
correlating genotypes underlaying the scientific questions: How do polymorphisms of 
ACTN3, IGF-I, IGF-II and myostatin influence anaerobic phenotype? Significances in 
gene activity may identify the link between genetic variation and athletic ability. Research 
questions are “What determines muscle mass?”, “What determines fast muscle fibers?” and 
“What determines slow muscle fibers?”. The signal transduction in relation to exercise 
plays a major role in this effects. The signal transduction pathways that upregulate protein 
synthesis and satellite cell proliferation after high intensity exercise will be discussed on 
Chapter 2, Chapter 3.5 and 4.1. The chapters below review the individual characteristics 
that determine the polymorphisms considered. In this chapters the focus is mainly 
concentrated on the intracellular molecular processes and how they represent an effect on 
muscle adjusting physical activity.  
The variations of gene sequences und functions is highly investigated through the different 
species. This review is based on investigations made on human beings. It is interesting to 
note that there are some large differences between animals and humans, e.g. in rat muscles 
the protein turnover is much higher than in human muscles. Perhaps the differences are 
quantitative and do not result from different signaling processes. The evidence that a 
specific variation in genes influences physical performance is easily established in animal 
studies. Scientifics “knock out” the specific gene and observe the change in efficiency. The 
gene expression can be switched on or off in the whole organism or solely in a particular 
tissue such as skeletal muscle. Such an effect cannot be observed in human being, as 
shown on the Heritage- study of Bouchard. The study was designed to evaluate the role of 
genetic and non genetic factors in cardiovascular, metabolic and hormonal responses to 
aerobic exercise. Extensive data were gathered on 128 families before and after 20 weeks 
of supervised training. The families showed considerable individual differences in the 
response to regular exercise. This large variation occurred at all ages and at all levels of 
initial fitness and was similar for African-Americans and Caucasians and for women and 
men. There was 2.5 times more variance between families than within families for the 
gains in VO2 max and the maximal heritability reached 47%. However, families showing 
advantageous gene variants had better test results then others. In conclusion, human studies 
are necessary to verify findings on other models but they have to be descriptive and 
invasive.  
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Next to genetic characteristics environmental factors have strong influences on physical 
performance. The finnish cross- country skier Eero Mäntyranta represents an example. In 
1964 he won Olympiagold although his body proportions have been disadvantageous for 
cross- country skiing. Due to a gene mutation he had exceptionally high levels of 
Erythropietin (EPO) circulating in his body. Reduced Erythropoietin- receptors enable 
easier docking of the hormone compared to wild forms. His body produced an enormous 
amount of  red blood cells and was perfectly optimised to the viscous blood. Mäntyranta 
was the only successful competitive athlete in his familiy although similar high 
haemoconcentration was present in almost a quarter of his family members.   
The discovery of the genes observed and its significance for the regulation of muscle 
growth has made sensational provides. In fact the scientific achievements have agricultural 
as well as therapeutical worth and are essential for the future of sports and exercise 
science. Popular- scientific articles give the impression that these genes give the starting 
point for genetic manipulation in purpose to improve performance in sports. In this case 
there would be a potential risk to the health of the athletes and science would risk the life 
of humans. Such investigations remain unnoticed, uncontrolled and untreated. The study 
on hand involves moral and ethical issues underlaying therapeutical purposes. The main 
reason of the study regards optimisation of sports exercise and specialisation of 
competitive athletes. Associations between polymorphisms and mitochondrial function in 
athletic performance may contribute to a better understanding of efficient ATP production 
and anaerobic glycolysis which can be considered in training stimulations across individual 
sports activities. Actually, we are looking at the results of a very complex myogenic 
system. Microarray studies have shown that the expression of hundreds of genes is 
changed in response to exercise in skeletal muscle. A combination of several gene variants 
is needed in order to understand this physiological processes according to heredity. Many 
other gene activities must be observed to get a better understanding 
 
 
 
.  
 
.  
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1.1 Satellite cells 
 
Muscle cells are long cylinders with multiple nuclei and cytoplasm consisting of still more 
long tiny fibers called myofibrils. These myofibrils are made of stacks of contractile units 
called sarcomers. Each sarcomere is a lattice of the proteins actin and myosin. According 
to the sliding- filament model of Huxley and Henson these protein filaments slide across 
one another to contract the sarcomere. The thinner actinfilaments shift along the big 
myosinfilaments in direction to the centre of the sarcomer without shortening or thickening 
(Stryer, 1996, S. 411- 438). Each molecule of myosin contains a globular subunit called the 
myosin head. The myosin heads have binding sites for the actin molecules and ATP. The 
activation of the muscle fiber causes the myosin heads to bind to actin. The thin filament 
draws a short distance past the thick filament and the linkages break in support with ATP. 
Subsequently the myosin head reforms farther along the thin filament (induced by ADP) to 
repeat the process. This sliding produces muscle contractions. This contraction is needed to 
provide the steady support for standing upright or to explosive power required to run a 
sprint- distance. To meet these constant and constantly changing demands, muscle has an 
intrinsic ability to adapt to different types of work by changing fibre type and muscle mass. 
There are for example different fiber types suited to long- lasting effort or quick bursts of 
strength. The force they generate can damage the muscle fiber unless it is channelled 
outward.  
Dystrophin, the protein missing in Duchenne muscular dystrophy patients, conducts this 
energy across the muscle cell`s membrane, protecting the fiber (Hawke & Garry, 2001, S. 
544). But muscle fibers are still injured by normal use. That is believed to be one way that 
exercise builds muscle mass and strength: Microscopic tears in the fibers caused by the 
exertion set off a chemical alarm that triggers tissue regeneration, which in muscle does 
not mean production of new muscle fibers but rather repairing the outer membrane of 
existing fibers and plumping their interior with new myofibrils. Manufacturing this new 
protein requires activation of the relevant genes within the muscle cell`s nuclei, and when 
the demand for myofibrils is great, additional nuclei are needed to bolster the muscle cell`s 
manufacturing capacity. Satellite cells, located between the basal lamina of the muscle and 
the sarcolemma of myofibers, answer this call. These satellite cells are pluripotent muscle-
derived stem cells that promote postnatal muscle growth and repair. (Asakura, Seale, 
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Girgis- Gabardo & Rudnicki, 2002, S. 124; Hawke & Garry, 2001, S. 540; Adams, 2002, 
S. 1160; McCroskery, Thomas, Maxwell, Sharma & Kambadur, 2003, S. 1135). 
The satellite cells reenter the cell circle and express myogenic markers (McCroskery et al. 
2003, S. 1135). In this stadia they are also termed myoblasts. Some of their progeny fuse to 
existing muscle fibers or fuse together to form new myofibers during regeneration of 
damaged skeletal muscle (Hawke & Garry, 2001, S. 534). The total number of satellite 
cells remains constant over repeated cycles of degeneration and regeneration (McCroskery 
et al., 2003, S. 1135). The profile of gene expression of the quiescent satellite cell as well 
as their activated and proliferating progeny is largely unknown. Several satellite cell 
markers have been identified and are restricted to either the quiescent, activated, or 
proliferative state or are expressed more broadly. One group of this cell markers is the 
family of the myogenic regulatory factors (MRFs). This subset of the Basic helix- loop- 
helix  (bHLH) family includes MyD, myf5, myogenin and MRF4 (Hawke, & Garry, 2001, 
S. 536). These markers seem to be qualified for the analysis of adaptation processes on 
resistance training. Psilander Damsgaard and Pilegaard (2003, S. S. 1038-1044) showed 
that myogenin, MyoD and MRF4 mRNA levels are transiently elevated in human skeletal 
muscle after a single bout of heavy resistance training, supporting the idea that the MRFs 
may be involved in regulating hypertrophy and/or fiber- type transitions (Psilander et al., 
2003, S. 1038). Each of these myogenic bHLH proteins forms heterodimeric DNA binding 
complexes that include other bHLH proteins of the E2 gene family (E12 and E47) and bind 
a canonical DNA sequence, CANNTG (E-box), within enhancer elements of genes that 
encode terminal differentiation markers of the skeletal muscle lineage (Hawke & Garry, 
2001, S. 536; Wyzykowsky, Winata, Mitin, Taparowsky & Konieczny, 2002, S. 6204 ). In 
addition it has been shown that these MRFs regulate the transcribtion of myosin- heavy 
chains (MHC) (Willoughby & Nelson, 2002, Myosin heavy- chain, S. 1262).  
Myogenin for example interacts with the enhancer of the myosin light- chain and the 
muscle creatine kinase (Cserjesi & Olson, 1991, S.  4854). 
The existence of satellite cells has been known since 1961 (Katz, 1961, S. 221-225). 
Within the last decade, biological researchers have begun to make remarkable strides 
regarding the role of satellite cells in muscle growth and regeneration. Many of these 
investigations have made significant findings relating to various growth factors like IGF-I 
and the stimulation of satellite cell proliferation and/or differentiation (Spangenburg & 
Booth, 2001, S. 533). Satellite cells respond to IGF-I by undergoing a greater number of 
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cell divisions, whereas a different growth- regulating factor, myostatin inhibits their 
proliferation (Hawke & Garry, 2001, S. 540). 
 
 
2 ACTN3 
 
One essential question in the physiological understanding of sports- related activities is  
how a muscle differentiates between glycolytic or oxidative muscle fibers. The health- 
related ACTN3 gene may give an answer. ACTN3, also named as Actinin or alpha 3 is 
located at chromosome 11q13-11q14. The gene is determined at nucleotide 1747 in exon 
16, which leads to the replacement of an arginine codon by a stop codon. By absence of a 
DdeI restriction site the allele 577R (codon CGA) can be distinguished and the allele 577X 
(codon TGA) by its presence (Niemi & Majamaa, 2005, S. 965). Marked by a molecular 
mass of 94-103 kDa, the ACTN3 gene is one of four known loci, which encode α-actinin 
1, α-actinin 2, α-actinin 3 and α-actinin 4. These proteins can be categorised into two 
broad groups: nonmuscle cytoskeletal (calcium- sensitive) isoforms and muscle sarcomeric 
(calcium-insensitive) isoforms. α-actinin 1 and α-actinin 4 are thought to play a role in 
anchoring actin as non-muscle/smooth muscle isoforms. Human skeletal muscle contains 
the two sarcomeric isoforms α-actinin 2 and α-actinin 3, but very few of the interactions 
investigated have been directly confirmed for α-actinin 3. The ACTN3 expression is 
highly specialised and limited to fast glycolytic type 2 fibres in skeletal muscle (100% type 
2b and 50% 2a), while the related ACTN2 protein expression is present in all types of 
muscle fibers (Kremerskothen, Teber, Wendholt, Liedtke & Boeckers, 2002, S. 687-681; 
Macarthur & North, (2004), S. 786-895). Functional redundancy occurs when two genes 
perform overlapping functions so that inactivation of one of the genes has little or no effect 
on the phenotype. α-actinin 2 expression in skeletal muscle completely overlaps α-actinin 
3 expression (Mills, Yang, Weinberger, Vander Woude, Beggs, Easteal & North, 2001, 
S.1336). Loss of the encoded protein α-actinin-3 in fast fibers compensates an upregulation 
of the protein α-actinin-2 (Macarthur, Seto, Raftery, Qinlan, Huttley, Hook, Lemckert, 
Kee, Edwards, Berman, Hardeman, Gunning, Easteal, Yang, & North, 2007, S. 1261). α-
actinin-2 and α-actinin-3 differ in sequence adjacent to the actin-binding domain and have 
high sequence similarity and lack of significant functional differences as they form 
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ACTN3 homodimmers and heterodimmers in vitro and in vivo  (80% amino acid sequence 
identity and 90% sequence similarity) (Beggs et al., 1992, S. 9284; Mills et al., 2001, S. 
1336; Chan, Tong, Beggs & Louis, 1998, S. 134-139). 
The α- actinins were first idenitified by Ebashi and Ebashi in 1965 (Ebashi & Ebashi, 
1965, S. 7-12). α- actinins belong to a larger group of proteins referred to as the spectrin 
superfamily. Next to α- actinins this superfamily encodes a diverse group of cytoskeletal 
proteins including the α and ß spectrins, dystrophin and a protein called DRP (Beggs, 
Byers, Knoll, Boyce, Bruns & Kunkel, 1992, S. 9281-9288). The spectrins are located on 
the inner surface of the plasma membrane, where they play a role in maintaining cellular 
integrity and flexibility as components of the membrane cytoskeleton (Bennett, 1990, S. 
1029-1065). This fact is also confirmed by binding studies reviewed by Mills, Yang, 
Weinberger, Vander Woude, Beggs, Eastal & North (2001, S. 1335). The research group 
suggests that the α-actinins play a role in thin filament organization and the interaction 
between the sarcomeric cytoskeleton and the muscle membrane. In addition it regulates the 
myofibre differentiation and coordination.  
A major function of the α-actinin dimers is their actin filament cross-linking activity. 
(Abb.1) α−actinin-2 and -3 are structural components of the Z line that anchor the actin- 
containing thin filaments and stabilizes the muscle contractile apparatus (North, 2008, S. 
384-394; Macarthur & North, 2004, S. 786; Mills et al., 2001, S. 1335). In smooth muscle 
α-actinin is found at dense bodies and dense plaques that have a similar anchoring function 
(Endo & Masaki, 1982, S. 1457-1468; Endo & Masaki, 1984, S. 2322-2332; Geiger, 
Dutton, Tokuyasu & Singer, 1981, S. 614-628). The α-actinins have various functional 
domains (North, 2008, S. 384-394). They consist of two calponin- homology domains 
(CH) at the N-terminus which confer the ability to bind actin (ABD- actin-binding-
domain).(Baron, Davison, Jones & Critchley, 1987, S. 17623-17629; Beggs et al., 1992, S. 
9281-9288; Dubreil, 1991, S. 219-226). The central rod domain consists of spectrin-like 
repeats (SLRs). The C- terminal region contains an EF- hand calcium- binding domain that 
may be functional, as in nonmuscle α-actinins and α-spectrins, or degenerate as in the 
muscle α-actinins and dystrophin (Blanchard, Ohanian & Critchley, 1989, S. 280-289; 
Macarthur & North, 2004, S. 786-895; Arimura, Suzuki, Yanagisawa, Imamura & 
Hamada, 1988, S. 649-655; Noegel, Witke & Schleicher, 1987, S. 391-396; Koenig, 
Monaco & Kunkel, 1988, S. 219-226).  
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Abbildung 1: Localisation and domain structure of the sarcomeric α-actinins (Macarthur & 
North, 2004, S.787) 
 
One of the proposed roles for this protein is a mechanical stabilizer of the sarcomer, while 
another possible function may be as an influencer of signaling and methabolic pathways, 
enabling a muscle fiber to differentiate towards a fast-twitch, glycolytic profile (Chan, 
Seto, MacArthur, Yang, North & Head, 2008, S. C903). The sarcomeric α- actinins have a 
strong affinity to bind to themselves. They form head-to-tail dimmers through interactions 
between their SLRs (Blanchard et al., 1989, S. 289; Flood, Rowe, Critchley,  Gratzer, 
1997, S. 431-435) This protein-protein interaction seems to be the primary function of the 
SLRs, in the formation of dimmers and in binding with a variety of structural and signaling 
proteins (Djinovic-Carugo, Gautel, Ylanne, & Young, 2002, S. 119-123). The most well 
characterised interaction of the α-actinins is with the thin filament protein actin. The 
sarcomeric α-actinins also bind to myozenin, the actin cross-linking protein myotilin, the 
massive proteins titin and nebulin, the thin filament capping protein CapZ, the intermediate 
filament proteins synemin and vinculin, and the sarcolemmal membrane proteins 
dystrophin and ß1 integrin (Mills et al., 2001, S. 1335; Papa, Astier, Kwiatek, Raynaud & 
Bonnal, 1999, S. 187-188; Salmikangas, Mykkanen, Gronholm, Heiska, & Kere, 1999, S. 
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1329-1336; Ohtsuka, Yajima, Maruyama, & Kimura, 1997, S. 65-67; Nave, Furst & 
Weber, 1990, S. 163-166). Through interactions with dystrophin and integrin the α-
actinins participate in the two major protein complexes linking the sarcomere to the muscle 
fibre membrane (Hance, Fu, Watkins, Beggs& Michalak, 1999, S. 216-222, Otey, Pavalko 
& Burridge, 1990, S. 721-729). In addition MacArthur & North (2004, S. 788) clarify an 
α-actinin interaction with an array of signaling proteins, including the PDZ- LIM domain- 
containing proteins and a number of membrane receptors and ion channels, including the 
adenosine A2A receptor, the NR1 and NR2B subunits of the NMDA glutamate receptor, the 
L-type calcium channel, and the Kv1.4 and Kv1.5 potassium channels. The researchers 
also describe an interaction with members of the calsarcin family, a group of proteins that 
localise to the Z line in striated muscle and bind to the Ca²+ and calmodulin- dependent 
protein phosphatise calcineurin. Calcineurin is an important signaling protein in skeletal 
muscle playing a role in the determination of muscle fibre type and in muscle hypertrophy 
(Olson & Williams, 2000, S. 510-519; Chin, Olson, Richardson, Yang, & Humphries, 
1998, S. 2499-2509). The α-actinin interaction with metabolic enzymes, including the 
glycogenetic enzyme phosphorylase and the enzymes fructose-1,6-bisphophatase and 
aldolase is still unclear.  
The interactions of the α-actinins with their binding partners are regulated in several ways. 
In non- muscle the binding appears to be controlled by calcium. Calcium- mediated 
inhibition of actin binding does not affect striated and smooth muscle α-actinin isoforms, 
due to sequence changes in the EFh region that eliminate their calcium-binding properties 
(Noegel et al., 1987, S. 396). Sarcomeric as well as cytoskeletal α-actinins are regulated by 
phosphatidylinositol-4,5-biphosphatase (PIP2). PIP2 increases the affinity for titin and 
inhibits binding to CapZ (Papa et al., 1999, S. 187-188; Young & Gautel, 2000, S. 6331-
6340). The PIP2 binding site of α-actinin is located between the ABD and the first spectrin- 
like repeat with recognisable similarity to the target region of titin (Macarthur & North, 
2004, S. 788). MacArthur & North (2004, S. 786-793) declare a detailed summury of the 
PIP2 activity:  
„In the absence of PIP2, this N-terminal region acts as a pseudoligand for the C-
terminal titin-binding site of the other α-actinin molecule in the dimmer, sterically 
blocking the interaction with titin. The binding of PIP2 to α-actinin relieves this self-
inhibitory binding between α-actinin and titin, and presumably also modifies the 
binding affinity of α-actinin for both actin and CapZ.”  
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The diverse array of known binding partners suggests that these proteins regulate 
functional important pathways in skeletal muscle, helping to maintain the integrity of both 
the contractile apparatus and the crucial link between the sarcomere and the plasma 
membrane, and potentially playing important roles in the communication between the 
sarcomeric machinery and other cellular pathways and in the regulation in muscle 
metabolism.  
Observations made by Dixson, Michael, Forstner & Garcia (2003, S. 1-10) presented 
evidence that α- actinin 2 was the first of the four α- actinins to arise by gene duplication, 
followed by the divergence of α-actinin 3 and then α-actinin 1 and 4. This undermines the 
hypothesis that the expression pattern of the α-actinins has diverged during mammalian 
evolution. Gene duplication and alternative splicing have resulted in functional diversity. 
Some of the isoform diversitys of α-actinins are the result of transcription from different 
genetic loci. Biochemical studies identified a number of different α-actinin isoforms in 
various tissues and species including protists (Noegel et al. 1987, S. 391-396), 
intervertebrates (Fyrberg, Kelly, Ball, Fyrberg & Reedy, 1990, S. 1999-2011) and birds 
(Arimura, Suzuki, Yanagisawa, Imamura & 1998, S. 649-655, Beggs et al., 1992, S. 9281-
9288). Alternative splicing occurs in both vertebrates and intervertebrates, but affects 
different regions of the transcript in the two lineages (MacArthur & North, 2004, S. 790). 
Sequence comparison of human and chicken skeletal muscle α-actinin genes suggest that 
human ACTN2 and ACTN3 have both evolved very slowly since their divergence more 
than 300 million years ago, implying strong functional conservation (North, Yang, 
Wattanasirichaigoo, Mills, Tong, Easteal & Beggs, 1999, S. 353-354). ACTN2 and 
ACTN3 are differently expressed in human and mouse as ACTN2 expression does not 
completely overlap ACTN3 expression in mouse postnatal skeletal muscle (North, 2008, S. 
386). There is marked variation in the frequency of α-actinin-3 deficiency in different 
ethnic groups. 25% and 18% of people with Asian and European ancestry do not express 
α-actinin-3 (homozygous null for 577X) compared to less than 1% of a South African 
Bantu population. This raised the possibility that ACTN3 genotype confers a fitness 
advantage to humans under certain environmental conditions or at the extremes of 
performance (North, 2008, S. 384).  
In 2003 Yang, MacArthur, Gulbin, Hahn Beggs, Easteal & North (2003, S. 627-631) 
demonstrated that the ACTN3 genotype influences elite athletic performance. Interestingly 
it turned out that the frequency of the null allele 577x in sprint and power athletes is 
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significantly lower, suggesting that α-actinin-3 is required for optimal muscle performance 
at high velocity (Macarthur, & North, 2004, S 894-895). In contrast a higher frequency of 
the null allele in endurance athletes suggests that this variant may provide an advantage for 
long-distance performance. This leads to the conclusion of MacArthur and North (2004) 
that „the R577x variant has been maintained in the human population for a significant 
period of our evolutionary history balancing selection, and that the frequency of this allele 
in some ethic groups may have been due to recent population-specific positive selection.” 
 
 
3 IGF-I and IGF-II 
 
3.1 Insulin-like growth factor I (IGF-I) 
 
Looking at the processes of activity- induced muscle adaptation, one crucial link is 
missing: How is the human body activating satellite cells as a response to increased 
loading meanwhile deciding whether a fast or a slow muscle fiber should be activated? A 
factor, that is taking part in this reactions has to accomplish specific properties. The factor 
has to operate locally in the activated muscle and must be produced there meanwhile 
muscle contraction. He also has to be able to activate satellite cells and influence myogenic 
markers. The insulinlike growth factor-I (IGF-I) seems to accomplish these processes and 
therefore could have an effect on hypertrophy (Adams, 2002, S. 1159- 1167, Machida & 
Booth, 2004, S. 337-340).  
IGF-I is part of the growthfactors. In general the growth hormone (GH) or somatotropin 
(STH) is responsible for the growth- processes in the different tissues. Frequently GH has 
an effect on an account of somatomedins made in the liver. The aminoacidsequences of 
these somatomedins resemble 40 percent to insulin. That’s why somatomedins are called 
insulinlike growth factors. There are three forms: somatomedin A or insulinlike growth 
factor-II (IGF-II),  somatomedin B which is derived from vitronectin and somatomedin C 
which is the most important factor and another name for insulinlike growth factor-I. IGF-I 
and IGF-II are about the same size. IGF-I contains 70 amino acids and IGF-II 67 amino 
acid residues (Brissenden, Ullrich & Franke, 1984, S. 781-784). 
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The former hypothesis that IGF-I is produced in the liver could be defeated. It has long 
been appreciated that there is local control of growth because if a muscle is exercised it is 
that muscle that undergoes hypertrophy and not all the skeletal muscles of the body 
(McKoy, Ashley, Mander, Yang, Williams, Russell & Goldspink, 1999, S. 584). Today it 
is rather known that the major source of circulating IGF-I is the liver, but it is also 
produced in a wide variety of tissues such as skeletal muscle (Adams, 2002, S. 2509; 
Chew, Lavender, Clark & Ross, 1995, S.1939- 1945; Laron, 2001, S. 311-316). Although 
they are of similar size, muscle IGF-I isoforms are not completely homologous to the liver 
isoforms (McKoy et al., 1999, S. 584). Studies reporting the increase in amount of 
circulating IGF-I did not show any changes in muscle (Adams & McCue, 1998, S. 1718). 
This suggests that IGF-I is a locally produced growth factor that has endocrine and 
paracrine/autocrine modes of action. This is confirmed by the fact that the IGF-I 
production in muscle is regardless of the circulating GH (Eliakim, Moromisato, Brasel, 
Roberts Jr & Cooper, 1997, S. 1557-1561) and that locally infused IGF-I results in local 
muscle reactions (Adams & McCue, 1998, S. 1716- 1722). Several studies showed that an 
overload in skeletal muscle induces an increase in IGF-I expression accompanied by 
muscle hypertrophy (Adams & Haddad, 1996, S. 2509- 2519; Adams & McCue, 1998, S. 
S. 1716-1722; Yang, Alnaqeeb, Simpson & Goldspink, 1997, S. 613-622; Lee, Barton, 
Sweeney & Farrar, 2004, S. 1097-1104; Hawke & Garry, 2001, S. 540). This makes it 
propable for IGF-I to be concerned in hypertrophy processes.  
Except IGF-I, the mechano growth factor could accomplish the criterias mentioned above. 
Chew et al. (1995) were the first, who identified this alternatively spliced IGF-I transcript 
in human liver. The mature 70-amino acid peptide has B,C,A and D domains. In addition 
there is an E- peptide which differs. By alternative splicing of IGF-I messenger RNA 
(mRNA) the E-peptide produces different proteins. If the splicing does not occur, IGF-IEa, 
the “normal” IGF-I peptide develops. Splicing indicates the insertion of 49 base pairs in 
the cDNA between the coding parts of D- and Ea- peptide. The inserted factor is called 
IGF-IEc- peptide. The predicted final residues of the Ec- peptide are frameshifted exon 6 
codons ending in a frame stop codon. The predicted peptide sequences of Ec and Eb differ 
at the cleavage site of the Eb- peptide fragment (IBE1), which has been shown to have 
mitogenic activity. The Ec- peptide sequence is 73% homologous to the rat Eb- peptide 
sequence (Chew et al., 1995, S. 1939). Lately, Yang et al. could proof the production of 
IGF-IEa and IGF-IEb in skeletal muscle. Interestingly IGF-I was not found in non- loaded 
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muscle (Yang, Alnaqeeb, Simpson & Goldspink, 1996, S. 487-495). Following studies also 
found IGF-IEc mostly in mechanical stimulated muscle. So it was termed mechano growth 
factor (MGF) (Goldspink, 2002, S. 285- 290). Today MGF appears to be misnamed 
because it is not stimulated by mechanical signal it is expressed following muscle damage. 
There are two main muscle forms: one which is similar to the main IGF-I isoform 
produced in the liver (IGF-Ea) and another that is apparently designed for an autocrine/ 
paracrine mode of action (IGF-IEc or MGF). The liver IGF-I forms are induced by GH and 
the muscle IGF-I isoforms are induced by mechanical stress. (McCoy et al., 1999, S. 590; 
Yang & Goldspink, 2002, S. 156- 160; Laron, 2001, S. 311-316). The muscle IGF-I 
isoforms have different exons from the liver types and they are not glycosylated. Therefore 
they are smaller and have a shorter half life than liver IGF-I (Goldspink, 2000, S. 159-
169). It seems that IGF-I is the key agent in the signaling pathways that allow individual 
skeletal muscles to adapt to increased loading. IGF-I appears to be able to stimulate and/or 
coordinate both the anabolic processes necessary to increase muscle protein and the 
recruitment of satellite cells, thereby providing new myonuclei and preserving the 
equilibrium between the number of myonuclei and the size of myofibers (Adams & 
McCue, 1998, S. 1721, Hawke & Garry, 2001, S. 540). IGF-I gene is differentially spliced 
in response to local muscle overload and damage. Initially, it is spliced to produce mainly 
MGF splice variants and this appears to initiate muscle satellite (stem) cell activation. 
Additionally, this provides the extra undamaged nuclei required for muscle fibre repair 
with some upregulation of protein synthesis. Thereafter, the splicing switches towards 
producing systematic IGF-I Ea, which upregulates protein synthesis over a longer time 
scale. This makes it clear that IGF-I  and MGF must have different functions. Studies of 
Hill & Goldspink (2003, S. 409-418) showed that MGF was rapidly expressed and then 
declined within a few days following both types of damage. IGF-IEa was more slowly 
upregulated and its increase was commensurate with the rate of decline in MGF 
expression. It was also found that the kinetics of expression is different for these two IGF-I 
splice variants.  
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3.2 Insulin-like growth factor-II (IGF-II) 
 
Skeletal muscle secrets somatomedin A which is named insulinlike growth factor-II (IGF-
II). The structure of IGF-I and IGF-II is very similar. Several of the features of the IGF-I 
gene structure, expression, and regulation also apply to the IGF-II gene. Brissenden et al. 
(1984) assigned the IGF-II gene to chromosome 11p15. The short arm of chromosome 11 
also encodes the c- Ha- ras1 oncogene and the lactate dehydrogenase A (LDHA) gene 
(Brissenden et al. 1984, S. 781-784).  The short arm of chromosome 12 where IGF-I is 
localized, encodes the structurally related genes c-Ki-ras2 and the lactate dehydrogenase B 
(LDHB) gene (Tricoly, Rall & Scott, 1984, S. 784- 786; Holthuizen, Cleutjens & Veenstra, 
1993, S. 77-89). The IGF-II gene is an imprinted gene with parental allele expressed and 
maternal allele silenced (Kaneda & Feinberg, 2005, S. 11236-11240). IGF-II spans 30 kb 
and comprises 9 exons (E1-E9) and 4 distinct promotors (P1-P4). Nonomura, Nishimura, 
Miki, Kanno, Yokoyama & Okuyama (1997, S. 2575- 2577) see the regulation of the IGF-
II gene as extremely complex: „with the four promoters reported to be under differential, 
developmental, and regional controls.” Transcripts initiated at the P2, P3, and P4 
promoters display monoallelic paternal activity predominating most embryonic non-
hepatic tissues. These three promotors are preconnected to exons E4, E5 and E6. IGF-II 
transcripts from the P1 promotor are induced from both parental alleles (Nonomura et al., 
1997, S. 2575). P1, which is preconnected to E1, mostly controls the postnatal expression 
of  liver IGF-II (Pagter- Holthuizen, Jansen & van Schaik, 1987, S. 259- 263). Exons 7,8 
and 9 contain a long 3`non- translated region. These exons encode prepro IGF-II protein 
containing a carboxy-terminal peptide of 89 amino acids and a signal peptide of 24 amino 
acids. (O`Dell & Day, 1998, S. 768-769). O`Dell & Day (1998, S. 767- 768) define the 
IGF-II structure: „Exons 1 to 6 are non- coding and form alternative 5`- untranslated 
regions (UTRs) of different RNA molecules which are expresses from the four promotors 
in a tissue- and development- specific way”.  Adults show activity of P2 to P4 only in non-
hepatic tissues while the activity is switched off in liver (Pagter- Holthuizen et al. 1987, S. 
259; Reeve, 1996, S. 470-475). In rodent animals the IGF-II gene spans 12 kbp and is also 
close to the insulin gene. (Holthuizen et al., 1993, S. 77). In rats the gene is situated at 
chromosome 1 (Soares, Turken & Ishii, (1986), S. 737), while in mice the gene is localized 
at chromosome 7 (Rotwein & Hall, 1990, S. 725). Since the promoter P1 is missing in rats 
and mice, the IGF-II transcription is adjusted postnatally (Rotwein & Hall, 1990, S. 729-
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731; Humbel, 1990, S. 445-462). Contrary to the missing P1 promoter in roden animals, 
prenatal human IGF- II serum concentrations are low during birth and increase meanwhile 
age of infancy (Zapf, Walter & Frosch, 1981, S. 1329). As a consequence of the IGF-II 
gene structure in the different species, different IGF-II-mRNAs at a length from 1,8 kb to 
7,5 kb can be transcribed (Rotwein, 1991, S. 31-38). Furthermore, the simultaneous 
production of  several IGF-II transcripts in one cell occurs through differential splicing. 
This has been shown by colorectal cancer cells  (Lahm, Amstad & Wyniger, 1994, S. 452-
459). Next to the A- and B- domain, that is characteristic for Insulin as well as the IGFs, 
the IGFs have an additional C- domain that is present in proinsulin. The C- domaine in 
proinsulin is proteolytically cleaved during structural maturation (O`Dell & Day, 1998, S. 
768). The D-domain does not exist in insulin. This domain located on the C- terminal end 
has the greatest variability in the different species (Rotwein, 1991, S. 31-38).    
The effects of IGF-II were discused contrary. IGF-II, generally occurs at higher 
concentrations prenatally, and is usually considered to be a fetal growth factor, with IGF-I 
contributing more to postnatal growth (LeRoith & Roberts, 2003, S. 127-137). Recently, 
DeChiara, Efstratiadis & Robertson (1990, S. 78-80) showed that a germ-line disruption of 
the IGF-II gene by homologous recombination results in mice with an IGF-II deficiency 
which are phenotypically smaller. IGF-II is awarded a growthfactor in the development of 
the central nervous system and a fetal growth factor in rodent (DeChiara et al., 1990, S.78-
80). Although the role of IGF-II and the mechanisms by which it functions remain obscure, 
it has been reported that IGF-II mediates anabolic effects in skeletal muscle, such as amino 
acid and glucose uptake, and suppresses degradation of proteins (Florini, 1987, S. 577-
598). It has been shown that IGF-II is induced during muscle regeneration in rodents. Time 
course studies by Levinovitz, Jennische, Oldfors, Edwall & Norstedt (1992, S. 1227-1234) 
showed that IGF-I and IGF-II were present during muscle regeneration. The expression of 
IGF-I exceeds that of IGF-II. This suggests that the regulation and function of these growth 
factors are different during muscle regeneration. The IGF-II gene is also activated in a 
number of  different types of tumors, but the mechanism of activation is completely 
unknown.  
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3.3 IGF- receptors (IGF-IR and IGF-IIR) 
 
Peptidehormones perform their biological effects through specific receptors named IGF-I-
receptor (IGF-IR) and IGF-II-receptor (IGF-IIR), better known as IGF-II/Mannose-6-
phosphat-receptor (M6PR). (Abb. 1) Most of the biological IGF- signals like their anabolic 
and mitogenic effects mediate about the IGF-IR (Butt, Firth & Baxter, 1999, S. 256-262). 
The IGF-I receptor is able to bind IGF-I with a ten to fifteen times higher affinity than 
IGF-II and has structural similarities and properties with the insulin receptor (Germain-
Lee, Janicot & Lammers, 1992, S. 413-417). Moreover the insulin receptor binds the IGFs 
with low affinity (Ballard, Ross, Upton & Francis, 1988, S. 721-726; Casella, Han & 
D`Ercole, 1986, S. 9268-9273; Delaine, Alvino, McNeil, Mulhern, Gaugin, DeMeyts, 
Jones, Brown, Wallace & Forbes, 2007, S. 18886-18894; O`Gorman, Weiss, Hettiaratchi, 
Firth & Scott, 2002, S. 4287-4292; Rechler & Nissley, 1986, S. 152-159; Roth & Kiess, 
1994, S. 31-38). 
By means of ligand binding a specific tyrosine kinase activity and a protein 
phosphorylation cascade activates other intracellular second messenger systems (O´Dell & 
Day, 1998, S. 767-771). The substances formed in the signalcascades are responsible for 
cell-responses like apoptoses or changes in cell-mobility and intrude in the regulation of 
the cell cycle as well as gene expression (DeMyets, 1994, S. 135-148). In this manner IGF-
IR acts as a key agent in the IGF- signaling pathways containing not only transforming and 
growthstimulating, but also antiapoptosic and mytogenic qualities (Baserga, Hongo & 
Rubini, 1997, S. F105-F126; Baserga, Resnicoff, D`Ambrosio & Valentinis, 1997, S. 65-
98; Butt, Firth & Baxter, 1999, S. 256-262; Grothey, Voigt & Schober, 1999, S. 166-173; 
LeRoth & Roberts, 2003, S. 127-137).  Unlike IGF-II, IGF-I and Insulin bind with low 
affinity to IGF-IIR (Braulke, 1999, S. 242-246). IGF-IIR is a membrane associated 
receptor of approximately 220kDa (O´Gorman et al., 2002, S. 4287-4294). The M6P 
receptor is involved in transporting IGF-II from the Golgi apparatus to the lysosomes 
where IGF-II and extracellular enzymes are proteolytically reduced (O`Dell & Day, 1998, 
S.767-771; O´Gorman et al., 2002, S. 4287-4294). He may compete with IGF-IR for IGF-
II targeting lysosomal enzymes for internalisation and degradation of IGF-II (Abb. 2). The 
type II receptor is also found in the circulation, cleaved from the cell surface receptor. IGF-
IIR binds a significant amount of IGF-II particularly in the foetal circulation and may 
function as an IGF-II- specific binding protein (Gelato, Rutherford, Stark & Daniel, 1989, 
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S. 2935-2943). IGF-IR and IGF-IIR have been identified in embryonic and foetal tissues 
and the high density of both receptors in placenta suggests that a paracrine release of IGF 
peptides may influence placental growth and function, with consequent influence on foetal 
development (O´Dell & Day, 1998, S. 770). The IGF-II concentration in plasma is up to 
100 times higher than that required for its effect in vitro. A consequence of association 
with specific IGF-binding proteins (IGFBPs) (O´Dell & Day, 1998, S. 770). Unlike to 
Insulin the IGFs are not circulating in serum. They are able to bind to six characterized 
binding proteins with high affinity named IGFBP-1,-2,-3,-4,-5 and -6 which are found in 
the circulation and extracellular fluids (Sara & Hall, 1990, S. 591-614).  
 
 
 
 
 
Abbildung 2: Interaction of IGF-II with receptors (O`Dell & Day, 1998, S.769) 
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3.4 IGF binding proteins (IGFBP) 
 
The IGFBPs influence IGF action positively and negatively. Human IGFBP genes are 
localised on different chromosomes with various lenghts: 
Bindungsprotein Chromosom  Länge (kb) 
IGFBP-1    7q  5,5  
IGFBP-2    2q  32,0  
IGFBP-3    7q  8,9  
IGFBP-4    17q  15,3  
IGFBP-5    2q  33,0  
IGFBP-6    12  4,7  
(Ehrenborg, Zazzi, & Lagercrantz, 1999, S. 376-380; Hwa, Oh, & Rosenfeld, 1999, 761-
787) 
IGFBPs consist of four exons, that are coding the respective domains, except IGFBP-3 
which is the only one binding protein that contains an additional untranslated fifth exon in 
the 3`end. The N- terminal and the C-terminal domain are highly conservated containing 
the IGF- binding sites. The IGFBPs have been isolated and characterized from several 
mammalian species, and at least one binding protein, IGFBP5, has been identified in non-
mammalian vertebrates (Upton, Chan, Steiner, Wallace & Ballard, 1993, S. 29-32). This 
suggests that modulation of IGF action by specific binding proteins is important in vivo 
(James, Jones, Busby & Clemmons, 1993, S. 22305-22312). Some of the binding proteins 
are membrane associated and some are soluble. Specific proteases can regulate the 
degredation of the IGFBPs. The IGFBPs bind IGF with different affinity. In general 
membrane-bound forms enhance IGF action by attracting IGFs to the region of the 
receptor and the soluble forms are inhibitory (O´Dell & Day, 1998, S. 770). IGF binds to 
as many as 10 distinct serum proteins, but in adults 90% of the circulating IGFs are 
complexed with IGFBP-3 (Borst, De Hoyos, Garzarella, Vincent, Pollock, Lowenthal & 
Pollock, 2001, S. 651). It is unclear if IGFBP-3 is the primary carrier of IGF-I in skeletal 
muscle, but there is evidence that it does exist there (Hand, Kostek, Ferrell, Delmonico, 
Douglass, Roth, Hagberg & Hurley, 2007, S. 1678).  
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3.5 The IGF- signaling pathways 
 
The IGF-I receptor phosphorylates tyrosine, an amino acid in its structure which is 
essential for starting the downstream signaling cascade (Spurway & Wackerhage, 2006, S. 
198). Then the autophosphorylated receptor attracts scaffolding proteins by protein-protein 
interaction which facilitate the activation of specific signal transduction pathways. One 
pathway activated by IGF involves Ras- Raf signaling to extracellular response kinases 
(ERKs) 
The activities of the pathways are conditional (Adams, 2002, S. 1160). There are reports 
that both ERK and PI3K activity act in concert in some cell types and both may be 
required for the differentiation of myoblasts (Mehrhof, Muller, Bergmann, Li, Wang, 
Schmitz, Dietz & von Harsdorf, 2001, S. 2088-2094; Yu, Roshan, Liu & Cantley, 2001, S. 
32252-32258). In contrast other reports show that activity of one pathway may actually 
inhibit the other (Rommel, Clarke, Zimmermann, Nunez, Rossmann, Reid, Moelling, 
Yancopoulos & Glass, 1999, S. 1009-1013; Samuel, Ewton, Coolican, Petley, McWade & 
Flotini, 1999, S. 55-64; Zimmermann & Moelling, 1999, S. 1741-1744). The processes of 
cellular proliferation and differentiation are generally thought to be exclusive (Adams, 
2002, S. 1161). In a number of cell types, activation of one of the two primary signaling 
pathways associated with ligation of growth factor receptors will generally inactivate 
portions of the other (Abb. 3 vs Abb. 4). Spurway & Wackerhage (2006, S. 199) suspect 
that the ERK pathway, which is associated with tyrosine kinase activity of the IGF-IR, as 
probably more related to muscle fibre phenotype regulation than to growth. As shown on 
Abbildung 3 the phosphorylation targets of ERKs include transcription factors and 
additional protein kinases. 
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Abbildung 3: The Ras-ERK signalling cascade (Adams, 2002, S. 1160) 
(MAPK/ERK kinase; Raf, MAPK kinase kinase; Ras protein, member of the Ras GTPase 
family; Shc, SH2- containing collagen-related proteins (couples IGFR1 tyrosine kinase to 
Ras) 
 
Insulin receptor substrate (IRS) proteins are the scaffolding proteins that regulate the 
activation of the PKB pathway in response to IGF-1, IGF-2 and insulin. These four IRS 
isoforms (IRS 1-4) are phosphorylated at tyrosine residues by active IGF-1/ insulin 
receptors (Spurway & Wackerhage, 2006, S. 202). Phosphorylated IRS attract 
phosphatidylinositol-3-kinase (PI3K) to the receptor which is essential for the activation of 
PKB further downstream. IRS-1 seems to be most important for IGF-1- stimulated muscle 
growth, as these isoforms control growth and glucose metabolism. PI3K phosphorylates 
regulatory peptides (phosphatidylinositols- PtdIns) that can be phosphorylated and 
dephosphorylated just like proteins. PI3K uses ATP to phosphorylate PIP2 to PtdInsP3 
(PIP3). PIP3 than binds to PIP3- dependent protein kinase-1 (PDK1) and protein kinase B 
(PKB) proteins and stimulates their translocation from cytosol to the cell membrane 
(Abb.4). PDK1 is able to phosphorylate PKB at Thr 308 (Spurway & Wackerhage, 2006, 
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S. 202). There are three PKB isoforms: PKBα (Akt1), PKBβ (Akt2) and BKPγ (Akt3). 
Once phosphorylated, Akt can act on a broad spectrum of subtrates that can influence cell 
survival, proliferation and protein synthesis (Vivanco & Sawyers, 2002, S. 489-501). 
mTOR phosphorylation by Akt leads to mTOR activation and the subsequent activation of 
S6K1. Activation of the Akt/mTOR pathway may also promote muscle growth by 
inhibiting glycogen synthase kinase (GSK)-3β, α serine/threonine kinase that can block 
translation that is iniciated by eukaryotic initiation factor-2B and may reduce protein 
synthesis (Tidball, 2005, S. 1905). Numerous observations support the likely importance of 
the Akt/mTOR/S6K pathway as promoting muscle growth. Akt1 phosphorylation and 
expression are elevated during muscle hypertrophy and reduced during atrophy (Bodeine, 
Stitt, Gonzalez, Kline, Stover, Bauerlein, Zlotchenko, Scrimgeour, Lawrence, Glass & 
Yancopoulos, 2001, S. 1014-1019).  
The intracellular pathways that subserve IGF-IR ligation also represent potential points for 
interactions between IGF-I induced responses and those initiated by other mediators. There 
is evidence that there are interactions between the calcineurin and IGF-I signaling 
pathways in skeletal muscle. Whether calcineurin is part of a mechanical signal 
transduction pathway that modulates skeletal muscle growth or adaptation remains unclear. 
However, many observations are consistent with the hypothesis that mechanical loading 
increases IGF-I release and IGF-I can stimulate Ca²+ influx and therby activate calcineurin 
(Perrone, Fenwick-Smith, & Vandenburgh, 1995, S. 2099-2106; Tidball, 2005, S. 1904). 
Signaling via the calcineurin/nuclear factor of activated T-cell pathway produces a shift 
towards a slower phenotype (Type I) in muscle but can also increase muscle mass. This 
may show evidence that mechanical loading and IGF-I could affect muscle through 
overlapping signaling pathways. 
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Abbildung 4: The IRS-PI3K signalling cascade. Also shown is the pathway for protection 
from apoptosis and that which mediate increased cytoplasmic calcium levels. (Adams, 
2002, S. 1161) 
(Act, protein kinase B: BAD, proapoptotic regulator of programmed cell death; Bcl2, 
regulator of programmed cell death, promotes cell survival; DAG, diacylglycerol; 4E- 
BP1, eukaryotic initiation factor 4 binding protein; eEF2, eukaryotic elongation factor-2 
(k=kinase); GSK3, glycogen synthase kinase 3; IRS, insulin receptor substrate; mTOR, 
mammalian target of rapamycin; PI3-kinase (PI3K), phosphotidylinositol 3-kinase; PIP2, 
phosphatidylinositol 3,4-bisphosphate; PIP3, phosphatidylinositol 3,4,5-triphosphate; 
PDK1, PI3K-dependent kinase; PKC, protein kinase C; S6K1, p70 S6 kinase) 
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4 Myostatin 
 
In skeletal muscle little is known about the control of tissue size. Over 40 years ago, 
Bullough (1962, S. 307-342) recognised that tissue size is controlled by the activities of 
negative growth regulators that he dubbed chalones. According to this hypothesis, 
individual tissues secrete distinct chalones. They circulate throughout the body and act to 
inhibit the growth of the tissue producing the specific chalone. It has been shown that 
skeletal muscle might utilize this general type of regulatory mechanism to control tissue 
mass and myostatin appears to be the key mediator of this loung-sought colone (Lee, 2004, 
S. 62).  
Myostatin (MSTN), formerly known as growth and differentiation factor 8 (GDF8) is a 
member of the transforming growth factor- ß superfamily (TGF-ß) (Rodgers, Roalson, 
Weber, Roberts & Goetz, 2007, S. E371-E372). The superfamily comprises over 35 
members that play an essential role in growth and differentiation of embryonic 
development and regulation of tissue homeostasis in adults (Rios, Fernandez-Nocelos, 
Carneiro, Arce & Devesa, 2004, S. 2795-2803). The myostatin protein sequence has all the 
hallmarks present in other family members (Lee, 2004, S. 62). The protein is produced as 
an inactive dimeric precursor that undergoes two proteolytic processing events resulting in 
a 26-kDa N-terminal propeptide signal sequence, a dibasic proteolytic processing site, and 
a 12.5-kDa C-terminal fragment that is the major myostatin ligand and the biological active 
species. (McPherron, Lawler & Lee, 1997a, S. 83-90; Thomas, Langley, Berry, Sharma, 
Kirk, Bass & Kambadur, 2000, S. 40235-40243; Lee, 2004, S. 61-86; Bradley, Yaworsky 
& Walsh, 2008, S. 2119-2124). The myostatin sequence in the C-terminal region shows 
significant homology to other family members. (Abb. 5) Together with the highly related 
protein GDF-11, myostatin defines a distinct subgroup within the larger superfamily 
(McPherron et al.,1997a, S. 83-84; Gamer, Wolfman, Celeste, Hattersley, Hewick & 
Rosen, 1999, S. 222-232; Lee, 2004, S. 61-62). The propeptide plays an important role in 
regulating the activity of the C-terminal dimmer. Following proteolytic processing, the 
propeptide and the C- terminal dimmer remain in a latent complex. Activation of latent 
myostatin can occur by proteolytic cleavage of the propeptide by members of the BMP-
1/tolloid family of metalloproteinases (Lee, 2004, S. 67), which causes dissociation of the 
latent complex. Interestingly, it has been shown that one member of the BMP-1/tolloid 
family, TLL-2 is expressed specifically in skeletal muscle during embryogeneses (Scott, 
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Blitz, Pappano, Imamura & Clark, 1999, S. 28-300). Next to propetide there are other 
binding proteins that are capable of regulating myostatin activity in vitro, including 
follistatin (Lee, 2004, S. 61-67; Zimmers, Davies, Koniaris, Haynes & Esquela, 2002, S. 
1486-1488), FLRG (Hill, Davies, Pearson, Wang & Hewick, 2002, S. 40735-40741) and 
Gasp-1 (Hill, Qiu, Hewick, Wolfman, 2003, S. 1144-1154). FLRG and GASP-1 seem to be 
involved in regulatoring the activity of the myostatin C-terminal dimmer extracellularly 
(Hill et al., 2002, S. 40735-40741). 
 
 
 
 
Abbildung 5: Sequence comparisons of members of the TGF-ß superfamily (Lee, 2004, S. 
62) 
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During embryogenesis, myostatin expression is detected in the myotome compartement of 
developing somites and acts to regulate the final number of muscle fibers that are formed. 
In adult tissues, myostatin protein is produced by skeletal axial and paraxial muscle, 
circulates in the blood, and acts to limit muscle fiber growth (Lee, 2004, S. 63). These 
findings suggest that myostatin may play two distinct regulatory roles: one during early 
development and a second during adult homeostatic processes. The myostatin expression is 
restricted exclusively to cells of the skeletal muscle lineage (McPherron et al., 1997a, S. 
83-90). Although to a lower extent, myostatin expression has been detected in adipose 
tissue (McPherron et al., 1997a, S. 83-90; Lee, 2004, S. 63), mammary gland (Ji, Losinski, 
Cornelius, Frank, Willis, Gerrard, Depreux & Spurlock, 1998, S. R1265-R1273), 
cardiomyocytes, purkinje fibers of the heart (Sharma, Kambadura, Matthews, Somers, 
Devlin, Conaglen, Fowke & Bass, 1999, S. 1-9), and hemopoietic cells (Fernandez, Rios, 
Arce, Diaz, Alonso, Perez, Bello & Devesa, 2002, S. 323-326). 
Myostatin functions as a negative regulator for muscle growth, such that the absence of 
myostatin results in a hypermuscular phenotype in a large number of different species 
(Wagner, 2005, S. 2519-2524; Roth, Martel, Ferrell, Metter, Hurley & Rogers, 2003, S. 
706-709). The function of myostatin was elucidated by gene targeting studies in mice 
(McPherron & Lee, 1997b, S. 12457-12461). In this “mighty mice” the gene encoding 
myostatin has been knocked out. Homozygous inhibition of the myostatin gene in mice 
produces a considerably increase in skeletal muscle mass, resulting from a combination of 
muscle cell hyperplasia and hypertrophy (McPherron et al., 1997a, S. 83-90; McPherron & 
Lee, 2002, S.595-601; Lin, Arnold, Della-Ferra, Azain, Hartzell & Baile, 2002, S. 701-
706). „Every skeletal muscle examined appears to be affected by the mutation, and males 
and females are affected proportionately” (Lee, 2004, S. 63). Significantly, heterozygous 
mice are also affected, albeit to a lesser degree, suggesting that the effect of myostatin is 
dose dependent. 
Naturally occurring mutations of the myostatin gene produce the compact phenotype in 
mice (Szabo, Dallman, Muller, Patthy, Soller & Varga, 1998, S. 671-672). In contrast, 
systematic overexpression of the myostatin gene leads to a wasting syndrome characterized 
by extensive muscle loss (Schuelke, Wagner, Stolz, Hübner, Riedbel, Kömen, Braun, 
Tobin & Lee,2004, S. 2682-2689). 
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4.1 The myostatin signaling pathway 
 
 The mechanism of this regulatory factor encompasses an autocrine/paracrine regulatory 
loop by undergoing a complex signaling pathway (Abb. 6). There is considerable evidence 
that myostatin signals by a mechanism similar to that of other TGF-ß-related ligands. 
Myostatin signals through a TGF-ß/activin/nodal-like pathway by binding to and activating 
a receptor heterodinamic complex composed of the type II receptor ActRIIB together with 
a type I receptor partner of either ALK4 or ALK5, that is expressed by myogenic stem 
cells and proliferating myoblasts (Rebbapragada, Benchabane, Wrana, Celeste & Attisan, 
2003, S. 7230-7242). The activated receptor triggers multiple intracellular signaling 
cascades including the SMAD and MAPK pathways that activate the AKT and p21/Rb 
pathways and inhibit expression of the myogenic regulatory factors (Bradley et al., 2008, 
S. 2119). The phosphorylisation of Smad2 and Smad3 propagates the intercellular signal 
that ultimately leads to activation of TGF-ß-responsive promotors (Rebbapragada et al.,  
2003, S. 7230-7242).  
 
 
Abbildung 6: The complex myostatin system (Bradley et al., 2008, S. 2120)  
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Myostatin and GDF-11 are the newest members of a growing list of ligands that appear to 
be capable of signaling through activin type II receptors. GD-11 is capable of  binding both 
ActRIIB and ActRIIA, and it appears that GD-11 binds more strongly to ActRIIB than 
toActRIIA (Oh, Yeo, Lee, Schrewe, Whitman & Li, 2002, S. 2749-2754). The fact that 
Myostatin and GDF-11 have a relatively widespread expression pattern and that some of 
these ligands, including myostatin itself, circulate systematically, arises the key question 
how specifity of signaling is achieved. For myostatin, one possible mechanism might be 
selective activation of the latent complex of the target side. An attractive hypothesis is that 
the BMP-1/tolloid proteinases are activated only at sites and times at which suppression of 
muscle growth is desired (Lee, 2004, S. 61-86). 
An alternative mechanism is selective utilization of coreceptors in order to engage the type 
II receptor. In a study of Lee and McPherron (Lee & McPherron, 2001, S. 9306-9311) the 
receptor binding affinity of myostatin that has been determined for COS-1 cells transferred 
with ActRIIB is somewhat lower than typical affinities reported for other TGF-ß family 
members and their cognat type II receptors. This raises the possibility that a receptor 
component for myostatin, such as a coreceptor, may have been limiting in COS-1 cells. 
Another possibility for achieving specifity of signaling is restricted expression of the 
appropriate type I receptors. Only those cells expressing both the activin type II receptors 
and the appropriate type I receptors would be capable of transducing the myostatin signal 
(Lee, 2004, S. 61-86). The type I receptor can enhance the affinity of the ligand for the 
type II receptor (Attisano & Wrana, 2002, S. 1646-1647).  
Finally, there is considerable genetic data showing that the nuclear protein c-ski, which 
normally functions to block myostatin signaling by blocking activities of Smad proteins 
normally activated by myostatin, (Lee, 2004, S. 73) is a potent regulator of muscle growth . 
C-ski is capable of interacting with and blocking the activity of Smad 2,3 and 4 (Luo, 
Stroschein, Wang, Chen & Martens, 1999, S. 2196- 2197; Stroschein, Wang, Zhou & Lou, 
1999, S. 771-774; Akiyoshi, Inoue, Hanai, Kusanagi & Nemoto, 1999, S. 35269-352677).  
Several studies have demonstrated that myostatin is capable of blocking both proliferation 
(Thomas et al., 2000, S. 40235-40243; Taylor, Bhasin, Artaza, Byhower & Azam, 2001, S. 
E221-E228; Joulia, Bernardi, Garandel, Rabenoelina, Vernus & Cabello, 2003, S. 263-
275) and differentiation (Rios, Carneiro, Arce & Devesa, 2001, S. 561-566; Joulia et al., 
2003, S. 263-275) of myoblasts during development by regulating MyoD expression. This 
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suggests that a major target for myostatin signaling in adult animals is the cell cycle and in 
special the satellite cell. „Studies with isolated satellite cells demonstrated that myostatin is 
capable of up- regulating p21 expression, down- regulating Cdk2 expression, and 
inhibiting cell proliferation” (Lee, 2004, S. 73). Myostatin mutant mice have been shown 
to have an increased number of satellite cells per unit length and a higher proportion of 
activated satellite cells than muscles of wild-type mice. McCroskery et al. (2003, S. 11135-
1147) clarifys an increase in the proliferation rate of fast and slow fiber- specific satellite 
cells in lack of myostatin. The same study demonstrated that myostatin is expressed in 
satellite cells and regulates satellite cell quiescence. In the absence of myostatin there is 
increased self-renewal of satellite cells, possibly by increased proliferation of satellite cell-
derived myoblasts. Increased activation of satellite cells, and subsequent enhanced 
proliferation with delayed differentiation of myostatin- null myoblasts could be the 
primary reason for the increased postnatal muscle growth and hypertrophy in myostatin- 
null mutations (McCroskery et al., 2003, 1144-1145). It seems likely that other cells are 
also capable of responding to myostatin. Overexpression of myostatin in adult mice has 
been shown to induce a dramatic systemic wasting syndrome (cachexia) characterized by 
extensive loss of muscle. As mentioned before this was accompanied by loss of adipose 
tissue mass (Lee, 2004, S. 75). This raises the possibility that myostatin may also have direct 
effects on adipocytes. Alternatively, the effects on muscle mass and fat stores may reflect 
the activity of some other mediator of cachexia whose activity is induced by myostatin.  
Whether there is direct signaling on adipocytes or an indirect effect, mice lacking 
myostatin have a reduction in total body fat, which is particularly pronounced in older 
animals (Lin et al., 2002, S. 705; McPherron & Lee, 2002, S. 12457). That makes it clear 
that myostatin can influence fat metabolism and adipocyte function. This leads to the 
speculation that circulating levels of myostatin change under different environmental 
conditions or different physiological states, such as physical activity, illness, pregnancy or 
age. These changing levels alter the metabolic homeostatic balance between fat storage and 
muscle growth.  
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4.2 The ancient gene 
 
Mutations in the myostatin gene have been shown to be responsible for the double-
muscling phenotype in cattle. This phenotype defines three breeds of cattle named Belgium 
Blue, Piedmontese and Austuriana de los Valles. Investigations of a larger number of 
double- muscled breeds identified at least seven different mutations, including premature 
stopcodons, frameshift mutations and point mutations at highly conserved amino acid 
residues (Grobet, Martin, Poncelet, Pirottin, Brouwers, Riquet, Schoeberlein, Dunner, 
Menissier, Massabanda, Fries, Hanset & Georges, 1997, S. 71-74; Kambadur, Sharma, 
Skith & Bass, 1997, S. 910-915; McPherron & Lee, 1997b, S. 12457-12459; Cappucio, 
Marchitelli, Serracchioli, Nardone & Filippini, 1998, S. 51; Marchitelli, Savarese, Crista, 
Nardone, Marsan & Valentini, 2003, S. 392-395). 
Genetic analysis of the Belgian Blue revealed that this trait segregated as a single locus on 
bovine chromosome 2 with a semidominant mode of inheritance (Lee, 2004, S. 61-86). 
Together with mapping studies this shows that the human myostatin gene is located 
homologous to the mutation in the bovine myostatin gene of the double muscling locus 
(Grobet et al., 1997, S. 71-74; Kambadur et al., 1997, S. 910-915; McPherron & Lee, 1997, 
S. 12460). Actually, the gene is located in band 2q32.2. The predicted myostatin protein 
sequences in the C-terminal domain are identical among humans, mice, rats, chickens, 
turkeys and pigs. The predicted protein sequences in fish are significantly diverged from 
those of other vertebrates, indicating that myostatin function has been remarkably well 
conserved through evolution (Rios et al., 2004, S. 64). It is the profound metabolic 
consequences resulting from altered myostatin activity that explain the extraordinary 
degree to which myostatin has been conserved through evolution (Lee, 2004, S. 61-86). It 
is known that the circulating levels of myostatin protein in humans are lower than in mice 
(Schuelke et al., 2004, S. 2622-2628; Zimmers et al., 2002, S. 1486-1588), raising the 
possibility that the balance of the relative roles played by myostatin and by these other 
regulators may have shifted further away from myostatin in humans compared to mice 
(Lee, 2007, S. 789). In this respect it will be essential to determine the identity of other 
ligands that cooperate with myostatin, to develop the best possible strategies for 
manipulating this pathway for the treatment of human patients with muscle wasting and 
muscle degenerating diseases. Myostatin blockade might be beneficial for a variety of 
primary and secondary myopathies including muscular dystrophy (MD) like Duchenne 
 38
MD (DMD) or Becker`s MD, amyotrophic lateral sclerosis (ALS), sarcopenia, limb girdle 
muscular dystrophie, ageing and muscle loss due to chronic infections (e.g. HIV) or 
immobilization. Additionally, it might prove to be useful for the management of systematic 
metabolic disorders such as obesity and type II diabetes (Li & Murthy, 2001, S. 593-605). 
 
 
5 Methods 
 
5.1 Objectives 
 
1. To examine the effects of ACTN3, IGF-I, IGF-II and myostatin polymorphisms on 
anaerobic phenotypes. 
2. To perform a systematic review in this area. 
 
 
5.2 Types of studies 
 
All abstracts were reviewed by the following inlcusion criterias:  
a.) Does the study include genotype analysis of ACTN3, IGF-I, IGF-II or myostatin 
polymorphism? 
b.) Does the study include observations on human muscle tissue phenotype? 
 
 
5.3 Types of participants 
 
The participants were healthy adult men and women from all kinds of races without age 
limit. The investigations were made for athletics and nonathletics separately. Athletics 
were defined as participating in competitions of national or international elite level. 
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5.4 Types of interventions 
 
Two main analyses were undertaken: 
1.) Genotype was compared to exercise intervention.   
2.) Genotype was compared in observational studies. 
Interventions were defined as resistance/strength/power/weight formed with 
concentric/eccentric or isometric action and training/exercise. 
 
 
5.5 Types of outcome measures 
 
Primary outcome measures: 
Studies were included if the participants genotype and the effect on muscle phenotypes 
was measured.  
Secondary outcome measures:  
Measurements on muscle strength values characterized by 1-repetition maximum, maximal 
power output by cross- sectional area, fiber type distribution, lean body mass, muscle 
volume, muscle quality & peak tourque were extracted.  
 
 
5.6 Identification of studies 
 
Three electronic databases (Elektronische Zeitschriftenbibliothek MedUniGraz, 
Österreichische Zeitschriftendatenbank, Pubmed) were searched from September 2008 to 
February 2009 using seventeen text words in all relevant combinations: ACTN3, α-actinin-
3, anaerobic, exercise, genotype, GDF8, growth differentiation factor 8, IGF-I, IGF-II, 
Insulinlike growth factor, muscle, myostatin, phenotype, polymorphism, R577X, strength, 
training. The search maschine www.google.com was also used. Hand search included the 
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reference lists of all retrieved publications and the “Human gene map for performance and 
health-related fitness phenotypes” from 2000 to 2008.  
 
 
5.7 Assessement of study quality 
 
Quality assessment and internal validity of the included trials are summarized in Tabelle 1-
3. The levels of evidence vary from cross section studies (9 study) to cohort studies (5 
studies), case- controll trials (14 studies) and randomised controlled trials (9 studies).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Author Year Probands Parameters Intervention Results Levels of 
evidence 
Clarkson, P. 
M.et al. 
2005 157 subjects: 
78 men 
(n=78) & 
women 
(n=79) 
age: 19-22 
- genotype analysis of 
ACTN3 & MLCK 
- CK 
- Mb 
- dynamic (1- RM ) & 
isometric strength (MVC) 
- 2 sets of 25 max. 
eccentric contractions of 
nondominant arm elbow 
flexor (3s contraction 
followed by 12s rest) 
seperated by 5 min rest 
period 
- 3 max. MVC (3s 
contraction 1 min rest) on 
force transducer 
1.) Body composition: 
RX (n=78) > XX (n=41) > RR (n=35) 
- no relationship of age, BMI or sex 
1.) baseline CK activity: 
- RX (126.6 +/- 6.6) > XX (99.1 +/- 9.1) 
(P=0.035) 
- RR (106.2 +/- 9.9) = RX (126.6 +/- 6.6) 
- variation attributable to ACTN3 genotype: 
3.5% 
2.) Effect on muscle strength: 
- no association with baseline strength or 
change in strength 
- no association with blood proteins after 
exercise 
 
cross-
section 
study 
Clarkson, P. 
M.et al. 
2005 602 subjects 
men (n=247) 
& women 
(n=355) 
age: 18- 40 
 
- genotype analysis by 
TaqMan assay 
- muscle size via MRI 
(CSA of biceps brachii) 
- dynamic (1-RM) & 
isometric strength (MVC) 
before and after exercise 
training 
- height 
- CSA 
- body mass and age as 
covariants 
- subset of ethnic groups 
- 12-wk ~45- 60 min of 
progressive 
elbow/flexor/extensor 
resistance training of 
nondominant arm (biceps 
preachercurl, biceps 
concentration curl, standing 
biceps curl, overhead triceps 
extension, and triceps kickback) 
2s concentric & 2s 
eccentric 
- weeks 1-4: 3 sets 12 rep. 
of 12-rep. max. weight 
- weeks 5-9: 3 sets 8 rep of 
8 rep max weight 
RX (n=263) > RR (n=176) > XX (n=164) 
(43.5% : 29.3% : 27.2%) 
Allele frequencies: X=0.489 R=0.511 
Men: 
RX (n=114) > RR (n=68) > XX (n=65) 
(46.2% : 27.5% : 26.3%) 
Allele freqgencies: X=0.493 R=0.506 
Women: 
RX (n=148) > RR (n=108) > XX (n=99) 
(41.7% : 30.4% : 27.9%) 
Allele frequencies: X=0.487 R=0.513 
1.) Effect on muscle strength: 
- no association between RX genotype & 
muscle strength in men 
cross-
section 
study 
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- weeks 10-12: 3 sets 6 rep 
of 6 rep. max. weight 
- sign. between RX and strength in women 
(validated in ethnic subpopulations) 
- women baseline MVC: 
RX (69.7 +/-1.8) >RR (67.9 +/- 2.1) > XX (61.5 
+/- 2.2) (adjusted to baseline body mass & age 
by analysing of covariance) 
RX (70.6 +/- 1.9) > RR (96.8 +/- 2.3) > XX 
(61.5 +/- 2.3) (adjusted for biceps CSA & age) 
- Absolut change in 1-RM: 
women: 
XX (8.7 +/- 0.4) > RX (8.0 +/- 0.3) > RR (7.2 
+/- 0.4) 
- Relative change in 1-RM: 
XX (68.5 +/- 3.6) > RX (63.9 +/- 2.9) > RR 
(55.5 +/- 3.5) 
- relative increase in in both strength measures 
women > men (P<0.05) 
- men > baseline biceps, muscle size, 1-RM, 
MVCgain & absoulte gains in muscle size & 
strength 
women > relative isometric strength (MVC)  
(22 vs. 16%) & sign.; > relative 1-RM strength 
than men (64 vs. 40%) 
- 2.1 % of variability in absolute 
difference in 1-RM strength, 1.8% of 
variability in relative difference in 1-
RM & 2.2% of variability in baseline 
MVC strength are attributable to 
ACTN3 genotype 
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Vincent, B. 
et al. 
2007 90 healthy 
young men 
age: 18-29 
- genotype- analysis by 
TaqMan SNP (DNA 
extraction & SNP 
genotyping) 
- fiber type composition by 
immunohistochemistry 
- biopsy of right vastus 
lateralis 
- quadriceps CSA 
- %body fat, fat mass & fat 
free mass 
- physical activity 
questionnaire (h/wk) 
- Phase I: Relationship of 
R577X & muscle strength 
(n=90) 
-Phase II: 
1.) Comparing of fiber type 
distribution & strength 
between RR (n=22) & XX 
(n=22) 
2.) muscle α-actinin 2/3 
protein content 
- static & dynamique 
tourges of knee-extensor 
muscles 
(2 max. isometric extensions (5s) 
at 45° knee flexion as static 
torque; dynamic tourques at 100, 
200, 300 and 400°/s as registered 
tourque (45°) during one 
extension movement; eccentric 
torque as 1 max. knee extension 
contraction, while knee flexion 
was forced at an angular velocity 
of 100°/s) 
 
1.) Body composition 
XX: n=19     RX: n=40     RR: n=26 
XX : RX : RR = 0.24 : 0.44 : 0.31 
Allele frequencies: X=0.47 R=0.53 
2.) Effect on fiber type composition: 
577XX (n=21)     577RR (n=22) 
Type I:   55+/-3         50+/-2 
Type II:  35 +/-2        37+/-2 
Type IIx:  9+/+1        14+/+2 (P<0.05) 
I : II : IIx = 52 : 36 : 12 (%) 
- IIx fibers > 5% in RR than XX (P=0.04) 
- Relat. Surface area by IIx: RR > XX (P=0.03) 
- no sign. diff. in surface area for I & IIa 
3.) Effect on muscle strength: 
Absolute tourque: 
577XX (n=22) 577RX (n=40) 577RR(n=28)     
211+/-6               207+/-4                195+/-5 
Eccentric tourque: 
219+/+7                215+/-3                212+/-4 
Relative Tourque (300°/s): 
0.26+/-0.03        0.28+/-0.02       0.043+/-0.02 
(P=0.04) 
Relative dynamic power: 
XX < XX (wild type) 
Maximal tourque: 
similar in groups for static & dynamic co- & 
eccentric contractions 
4.) Protein content 
RR > XX (80%) 
Staining intensity: 
RR = XX (large variation in subjects) 
cross-
section 
study 
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α-actinin3 protein content: 
RR: IIX > IIa (>10; n=11) 
α-actinin3 average red fibers 
IIx > IIa (~17%) (P= 0.04) 
Delmonico, 
M. J. et al. 
 
2007 157 healthy y 
Caucasian  
men (n=71) & 
women 
(n=86) 
age: 50- 85 
- genotype analysis by 
EDTA- anticoagulated blood 
samples 
- Body Composition by DXA
- MV by CT in trained & 
untrained thighs 
-  PP & PV at baseline & 
following ST 
- 1-RM before & after ST 
- BMI 
- %fat & FFM 
- baseline values & change 
or drift in control leg, 
- medication use 
(diuretics, ACE inhibitors, 
hormone replacement therapy & 
antiinflammatories/pain reducers) 
- ~ 10 weeks 3times/wk 
unilateral ST of knee 
extensors of right leg 
< 75 yrs: 5 sets 
> 75 yrs: 4 sets 
1.) Body composition: 
Men: 
RR (n=29) > RX (n=27) > XX (n=15) 
Women: 
RX (n=33) > RR (n=33) > XX (n=24) 
2.) Effect on muscle strength: 
- men before 307 (88); after 388 (98) > women 
before 160 (47); after 1189 (205) 
- MV > in men before 1758 (268); after 1916 
(303) (9.0 +/- 1%) 
- MV > women before 1085 (208); after 1180 
(205) (8.8 +/- 1%) 
women: 
Absolute PP: 
XX (242 +/- 10) > RX (210 +/- 10) > RR (200 
+/- 11) (age & baseline covaried) 
Absolute MPQ: 
XX (2.2 +/- 0.1) > RR (2.0 +/- 0.1) > RX (1.9 
+/- 0.1) (age & baseline covaried) 
Relative MPQ: 
XX (2.1 +/- 0.1) > RR (1.9 +/- 0.1) > RX (1.8 
+/- 0.1) (age & baseline covaried) 
Absolute peak movement: 
XX (4.8 +/- 0.2) > RX (4.5 +/- 0.2) > RR (4.3 
+/- 0.1) (covaried for age & baseline) 
Relative peak movement: 
XX (4.2 +/- 0.1) > RX (3.8 +/- 0.1) & RR (3.8 
cross-
section 
study 
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+/- 0.1) 
men: 
-no differences in any of baseline muscle 
function measures 
untrained leg: 
Absolute PP change: 
men: RR > RX > XX (p< .05) 
women: RR > RX > XX (no sign.) 
Relative PP change: 
women: 
RR > RX > XX (RR : XX p=.02) (adjusted for 
age & changes) 
sign. within group increases: RR (p=.007) RX 
(p=.03) 
men: 
no differences in change (only RR: p=.01) 
Norman, B. 
et al. 
2009 120 
moderately 
well-trained 
men (n=61) & 
women 
(n=59) 
age: 19-32 
(BMI: < 30 
kg/m²; > 3-4 
yrs of 
training; 
training h/wk: 
> 2-10 
- genotype analysis by 
QIAamp 
- muscle biopsies from 
vastus lateralis 
- fiber type composition 
(I, IIa, IIb, IIc) 
- leisure time sports activities 
questionnaire 
- FFW 
- average power output 
- PP & MP 
- FI 
-MVC 
- 2 bouts of exercise with 
20 min rest between 
- 30-s exercise on cycle 
ergometer 
max. speed; resistance: 
7.5% of body mass 
subset of 21 men 12 RR & 
9 XX: 
- knee angle: 90-180° 
- maximal contraction: 30, 
60, 90, 120, 180 & 300°/s 
- muscle fatigue on 
isokinetic exercise 
- 30 maximal concentric 
KE (90° to full extension at 
1. Body composition: 
XX (n=23) = RR (n=23) > RX (n=17) 
- no sign. diff. in age, physical status or activity 
level 
1.) Fiber-Type composition 
- no sign. differences in fiber type composition 
in genotypes 
Men: 
577XX  (n=12)  577RX (n=9)   577RR (n=16) 
I:    52+/-14            54+/-10            49+/-17 
IIa: 31+/-15            36+/-  6            39+/+14 
IIb: 16+/-10              9+/-  5            12+/-13 
Women: 
577XX (n=11)   577RX (n=8)   577RR (n=7) 
I:    59+/-  8            62+/-13            66+/-  7 
randomised 
controlled 
trial 
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120°/s) 
- isometric contraction: 
110°, 4-6s 
 
IIa: 34+/-10            31+/-13            25+/-  8 
IIb:   7+/-  8              7+/-  6              8+/-  5 
- women > I (P=0.014) than men 
- women < IIb (P=0.026) 
Value: 
I: IIa : IIb 0.73 : 0.79 : 0.49 
- Type I fibers proportion training h/wk: 
r=0.377; P=0.0005 (positive correlation) 
- Type I: sign.: training status (P=0.011) & sex 
(P=0.001), no effect of genotype (P=0.816) 
- Type II: sign.: sex (P=0.024), no effect of 
training status (P=0.166) & genotype (P=0.712) 
2.) Effect on muscle strength: 
- weight: RR (n=12) > XX (n=9) 
- FFW: RR > XX 
- no sign. diff. in absolute MVC related to 
body mass 
- no sign. diff. in fatigability RR : XX 
3.) mRNA expression 
RR 6.98 +/- 5.5 AU > XX 0.40 +/- 0.4 AU 
(P<0.001) 
ACTN3 expression (11 RR): 
negative corr. between ACTN3 & 5typeI 
positive corr. between ACTN3 & 5Type IIb 
 
Tabelle 1: ACTN3 nonathletics with intervention 
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Author Year Probands Parameters Results Levels of 
evidence 
San Juan, A. F. 
et al. 
2006 23 healthy women 
age 61-80 
- moderately active 
lifestyle 
- genotype analysis by 
enzymatic digestion of 
amplicons with DdeI 
- blood analysis 
- anthropometric 
measurements 
- graded exercise test 
- bench press test (1-RM) 
- functional test 
sit-stand test for lower body & 1 
mile walk test for functional 
endurance 
- gas exchange 
- peak oxygen uptake 
- V02max 
- peak power output 
- ventilatory threshold 
1.) Body composition: 
(RX & RR) (n=18, 78%) > XX (n=5, 22%) 
- no sign. difference between XX & (RX + RR) 
- deficiency of XX does not effect health status, 
longevity & aerobic fitness 
- no sign. differences in ventilatory threshold 
(VO2max at VT: (RX & RR) 12.0(0.8) > XX 
11.5(1.1), Vo2Peak: (RX + RR) 20.7(1.3) > XX 
18.4(2.0), 1-mile walk test: XX 980(43) > (RX 
+ RR) 932(18), sit- stand test: (RX + RR) 
9.5(0.3) > XX 9.1 (0.3) 
randomised 
controlled 
trial 
Moran, C. N. et 
al. 
2007 992 adolescent greeks: 
men (n=525) & women 
(n=467) 
2 age groups: 
11- & 12, 17- & 18; 
classified in: 
men: 124 inactives , 
157 mildly actives (2-4 h/ 
week), 
97 intermediatly actives 
(4-6 h/week) & 134 
highly actives 
(6 h/week) 
genotype analysis by 
TaqMan SNP assay 
- Body composition (BMI, 
triceps & subscapular 
skinfolds); 
power/strength related 
phenotypes: handgrip 
strength, sitting bb throw, 
vertical jump, 40m sprint & 
agility run; 
endurance- related 
phenotype: shuttle run test & 
a proxy for aerobic 
1.) Body composition: 
RR=34%, RX=48%, XX=18% 
Allele frequencies: X=0.42 R=0.58 
2.) Effect on muscle strength: 
- sign. effect of genotype & 40m sprint in men 
P=0.003 
- men: RR (5.92) > XX (6.13); RX (6.00) > XX 
(6.13) ( not sign.) 
- no association between RX & strength/power 
phenotypes 
- no association with RX & shuttle run results 
(no influence on endurance performance) 
- no association with RX & body composition 
cross-
section 
study 
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women: 205 inactives, 
117 mildly actives, 76 
intermediately actives & 
54 highly actives 
capacity/Vo2 max 
- health questionnaire 
- no association in female subjects 
- no effect of physical activity level alone, nor 
any interaction between genotype & physical 
activity level 
(RX P=0.019; physical activity level P=0.205; 
interaction: P=0.265) 
- no interaction between genotype & age 
(RX, P=0.018; age: P<0.001; interaction: 
P=0.344 
- lower (faster) group of sprint time: 
RR is overrepresented (OR=1.7; 95%CI 1.1-
2.5; P=0.013 
XX is under-represented (OR=0.3; 95%CI 0.1-
0.7; P=0.003 
- higher (slower) quartile group: RR is not 
sign. under-represented  
(OR=0.7; 95%CI 0.4-1.1; P=0.090),  
- XX sign. over-represented  
(OR=1.6; 95%CI 0.9-3.0; P=0.098) 
Delmonico et 
al. 
2008 Health ABC cohort: 1367 
subjects: 
men (n=726)& women 
(n=641) 
(in the 5yr follow-up 
study there was a loss of 
n= 372); 
2nd cohort: a subset of 
the MrOS Study 1152 
white men 65 yrs or older 
- genotype analysis by 
TaqMan assay 
ABC study: 
- midthigh CSA of right leg 
at baseline & 5 yrs after 
- isokinetic knee extensor 
muscle tourque at baseline 
& 5 yrs after (60°/s on right 
leg) 
- muscle quality defined as 
MT/midthigh muscle CSA at 
baseline & after 5 yrs 
1.) Body Composition: 
ABC study: 
(RX= 777 (50%) > RR= 473 (30%) > 
XX=301(19%) (x²=0.32, df=1, p=.570) 
men: RX (n=384) > RR (n=234) > XX (n=144) 
women: RX (n=330) > RR (n=186) > XX 
(n=125) 
- sign.difference in men between genotype 
groups only for phys.act. (RR > XX > RX; 
P=.020) 
- no differences in other charcteristics in men, 
no differences in participant characteristics in 
cohort study 
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- PLL by self-reported 
walking ¼ mile or climbing 
10 steps without resting 
(2 consecutive 6 mo 
intervals) 
- physical performance at 
baseline & after 5 yrs using 
EPESE 
SPPB:5 chair stands, test of 
gait speed & standing 
balance 
- 400m walk 
MrOS study: 
- FFM by dual-energy x-ray 
absorptiometry 
- grip strength in both hands 
- Leg power (9 
measurements on each leg) 
- Leg power quality as 
power/thigh FFM 
- time to complete a walking 
course over 6m 
- 5 chair- stand test without 
using arms 
women 
MrOS study (men>65yrs): 
RX=551 (48%) > RR= 361(31%) > XX=240 
(21%) (x²=1.23, df=1,p=.540) 
- RX < RR < XX (P=0.39) 
- no other baseline characteristic differences 
between genotype groups 
2.) Effect on muscle strength: 
ABC study: 
- no adjusted differences between genotype 
groups in men & women for phenotypes 
- sign. difference across genotypes for adjusted 
increases in 400m walk-time (P=.030) (XX > 
RR (P=.008) & RX (P=0.75) 
- no sign. difference in women in 400m walk-
time 
incident PLL risk in men & women: 
- RR (35%) < XX (hazard ratio=0.65; 
95%CI=0.44-0.94) 
MrOS study: 
- no adjusted differences between genotype 
groups for any phenotype 
- no sign. differences between genotype groups 
for age-related adjusted changes in muscle or 
performance phenotypes in m & w 
McCauley T. et 
al. 
2008 79 activ but not-strength-
trained UK Caucasian 
men (University 
students): age: 20.1 +/- 
2.2 
body mass: 75.3+/-11.1kg 
- genotype analysis by PCR 
- blood samples 
- height 
- body mass 
- skinfold thickness 
- muscle function test on 
- no differences between ACTN3 & knee 
extensor isokinetic tourque (ANOVA 0.64< P < 
0.99) or relat. tourque any velocity (240:30 deg 
s; RR 60 +/- 6% RX 58 +/-4% XX 60 +/-6% 
ANOVA P=0.19) 
- no differences between ACTN3 & time course 
cohort study 
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height: 1.79+/-0.06m, 
BMI: 23.2+/-3.9kg, FFM: 
57.1+/-8.4kg 
knee extensors on both legs 
voluntary 
(3 or 4 max. voluntary 
contractions, 3s duration 
with 3s rest) 
- electrically stimulated 
measuring contractile 
properties: TPT, HRT, peak 
RFD 
(3 twitches analysed with 
30s rest) 
of twitch or peak RFD (RR 4493 +/- 1241 Ns; 
RX 4748 +/- 1344 Ns XX 4611 +/- 1226 Ns; 
ANOVA P=0.65 
-isometric strength was independent of ACTN3 
(RR 599 +/- 81 RX 619 +/-92 N XX 606 +/-103 
N; ANOVA P=0.66 
Walsh, S. et al. 2008 848 subjects 
age: 22-90 
men (n=454) & women 
(n=394) 
- genotype analysis by 
DANN 
- knee extensor shortening & 
lengthening peak tourque 
values using isokinetik 
dynamometry 
- FFM by DEXA 
- Body mass 
- Height; 
1. Body composition: 
men: RX (n=213) > RR (n=161) > XX (n=80) 
women: RX (n=174) > RR (n=167) > XX 
(n=53) 
- women XX : RR; XX : (RR & RX) < levels of 
body mass, BMI, fat mass and FFM (P< 0.05); 
2.) Effect on muscle strength: 
- Knee extensor peak tourque; age & height as 
covariate: women XX < RX 
shortening: 30°/s P=0.003; 180°/s P=0.007 
lengthening: 30°/s P=0.004; 180°/s P=0.004 
- XX : RR similar but not all comparisons sign 
shortening: 30°/s P=0.073; 180°/s P=0.091 
lengthening: 30°/s P=0.144; 180°/s P=0.036 
- no sig. diff. in men 
- Knee extensor peak tourque; FFM differences 
covaried in place if height: 
XX > (RX + RR) shortening peak torque at 
30°/s P=0.049 
5.) subanalysis women > 50 yrs (age & height 
randomised 
controlled 
trial 
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Tabelle 2: ACTN3 Nonathletics without intervention 
 
 
 
 
as covariates) 
XX < (RX & RR) 
KE shortening 30°/s XX (78.4 +/- 4.1 N*m) vs. 
(RX + RR) (89.1 +/- 1.6 N*m) P=0.015; 
180°/s XX (55.6 +/- 2.9 N*m) vs. 
(RX + RR) (61.3 +/- 1.1 N*m) P=0.07 
KE lengthening 30°/s XX (112.4 +/- 6.9 N*m) 
vs. 
(RX + RR) (127.3 +/- 2.6 N*m) P=0.046 
180°/s XX (109 +/- 6.6) vs. 
(RX + RR) (127 +/- 2.5 N*m) P=0.012 
- FFM differences covaried in place if height: 
strength values no longer differed sign. between 
genotype groups 
- no significant differences in men > 50 yrs 
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Author Year Probands Parameters Results Levels of 
evidence 
MacArthur D. 
G. et al. 
1999 - Caucasian control 
group (n=152), 
- elite (national level) 
sprint athletes (n=83) 
- elite endurance 
athletes (n=183) 
- genotype 
frequencies by 
amplifying a 291 bp 
region spanning 
exon 16 using PCR 
 
1.) Body composition: 
Control: 
RX (n=78; 0.51) > RR (n=46; 0.30) > XX (n=28 (0.18) 
Endurance: 
RX (n=59; 0.32) > RR (n=59; 0.32) > XX (n=47; 0.26) 
Sprint: 
RX (n=41; 0.49) > RR (n=37; 0.45 > XX (n=5; 0.06) 
- hiqhly significant differences in ACTN3 genotypic 
frequencies between elite sprint athletes and controls, with 
the frequency of the XX genotype approximately threefold 
lower in sprint athletes compared to controls, and more than 
four- fold lower in sprinters compared to endurance athletes 
Endurance (n=183) > Control (n=152) > Sprint (n=83) 
- the endurance group displayed a higher frequency of the 
XX genotype than controls, but this difference was not 
statistically significant 
case 
controll 
trial 
Yang, N. et 
al. 
2003 - white elite athletes 
at Australian 
international level 
(n=429): 
14 different sports: - 
elite Sprint athletes 
(n=107) men (n=72) 
& women (n=35); 
- endurance athletes 
(n=194) (122 men 
(n=122) & women 
(n=72); - 128 athletes 
were excluded; 
- 436 unrelated white 
controls (150 blood 
- genotype analysis 
by log-linear 
modeling approach 
(described by 
Hutley & Wilson) 
1.) Body composition: 
controls (n=436): RX 226(52) > RR 130(30) > XX 80(18) 
sprint (n=107):  RR 53(50) > RX 48(45) > XX 6(6) 
endurance (n=194): RX88(45) > RR 60(31) > XX 46(24) 
men: 
controls (n=134): RX 73(54) > RR 40(30) > XX 21(16) 
sprint (n=72): RR 38(53) > RX 28(39) > 6(8) 
endurance (n=122): RX 63(52) > RR 34(28) > XX 25(20) 
women: 
controls (n=292): RX 147(50) > RR 88(30) > XX 57(20) 
sprint (n=35): RX 20(57) > RR 15(43) > XX 0(0) 
endurance (n=72): RR 26(36) > RX 25(35) > XX 21(29) 
Allele frequencies: 
contr: X 44% R 56% sprint: X 28% R 72% endu: X 46% R 
54% 
cross-
sectional 
study 
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donors, 71 healthy 
children, 215 healthy 
adults): men (n=134) 
& women (n=292) 
men: 
contr: X 43% R 57% sprint: X 28% R 72% endu: X 46% R 
54% 
women: 
contr: X 45% R 55% sprint: X 29% R71% endur: X 47% R 
53% 
2.) Effects on genotype: 
- genotype profiles of control group did not differ (x²= 
0.19;P= .996) 
- no significant allele or genotype frequency differences 
between elite athlete group as whole and controls 
- subset of athletes in sprint and endurance showed strong 
evidence of allele frequence variation (x²=23;P=.001) 
- significant allele frequency differences between sprint & 
controls for both m (x²==14.8;P<.001) & f (x²=7.2;P<.01) 
- sprint < XX (6% vs. 18%); no f sprint and Olympians 
were XX 
- sprint > RR (50% vs. 30%) & < RX (45% vs. 52%) 
compared with controls 
- Endurance > XX (24%) than controls (18%) 
- allele frequencies in sprint & endurance deviated in 
opposite directions and differed from each other in both m 
(x²=13.3; P<.001) & f (x²=5.8;P=<.05) 8.) f sprint > RX 
than RR (20 vs. 15) & f endurance RX < RR (25 vs. 26); 
nor effect in m 
- f endurance RX < than f controls (35% vs. 50%) 
- ACTN3 577R allele provides advantage for power & 
sprint athletes 
Li-Ling Chiu 
et al. 
2005 259 elite Taiwanese 
olympic game level 
athletes from 19 
- genotype analysis 
by PCR-RFLPon 
exon 16 (577R had 
1. Body composition: 
IND (n=125) (RR+RX) 107(86) > RX 66(53) > RR 41(33) 
> XX 18(14) 
cross-
section 
study 
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different sports  
classified in 
- individual sports 
(IND) men (n=71) & 
women (n=54) 
-team sports (TEAM) 
men (n=62) & 
women (n=72) 
- controls (n=603) 
(CON) Taiwanese 
general population 
men (n=361) & 
women (n= 242) 
205 and 85 bp 
fragments, 577X PCR 
had 108, 97 and 85 bp 
fragments) 
 
Allele fregencies: X 102(41) R148(59) 
men (n=71) (RR+RX) 59(83) > RX 37(52) > RR 22(31) > 
XX 12(17) 
Allele frequencies: X 61(43) R81(57) 
women (n=54) (RR+RX) 48(89) > RX 29(54) > RR 19(35) 
> XX 6(11) 
Allele frequencies: X 41(38) R67(62) 
TEAM (n=133) (RR+RX) 99(74) > RX 63(47) > RR 36(27) 
> XX 34(26) 
Allele frequencies: X 131(49) R135(51) 
men (RR+RX) 50(81) > RX 33(53) > RR 17(27) > XX 
12(19) 
Allele frequencies: X 57(46) R 67(54) 
women (n=71)  (RR+RX) 49(69) > RX 30(42) > RR 19(27) 
> XX 22(31) 
Allele frequencies: X 74(52) R 68(48) 
CON (n=603) (RR+RX) 485(80) > RX 294(49) > RR 
191(32) > XX 118(20) 
Allele frequencies: X 530(44) R676(56) 
men (n=361) (RR+RX) 299(83) > RX 182(50) > RR 
117(32)> XX 62(17) 
Allele frequencies: X 306(42) R 416(58) 
women (n=242) (RR+RX) 186(77) > RX 112(46) > RR 
74(31) > XX (56(23) 
- no linkage association in genotypes of ACTN3 and ACE 
genes in CON 
- distribution of ACTN3 and ACE genotypes not sign. diff. 
between athletes and CON. 
- Females had significantly lower (p<.05) frequency of 
ACTN3 577X genotype in IND (11%) compared to CON 
(23%) and TEAM (31%). 
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- non of athletes exhibited both ACTN3 577XX and ACE 
DD genotypes 
Niemi A.-K. 
& Majamaa, 
K. 
2005 - finnish elite track & 
field athletes (n=141) 
(endurance athletes 
n=52, sprinters n=89) 
including 3 pairs of 
twins (endurance 
athletes n=2, 
sprinters n=1) & 5 
pairs of siblings 
(endurance n=1, 
sprinters n=1); 
- anonymous Finish 
control subjects 
(n=1060); subgroup 
of top athletes 
(endurance n=20, 
sprinters n=23) 
- MtDNA 
haplogroup & 
subhaplogroup 
analysis 
1.) Body composition: 
top endurance: 
RR 10(50%) > RX 7(35%) > XX 3(15%) 
endurance: 
RR  20(50%) > RX 16(40%) > XX 4(10%) 
control: 
RX 55(~46%) > RR 54(45%) > XX 11(~9%) 
sprinter: 
RR 35(~51%) > RX 27(~40%) > XX 6(~9%) 
top sprinter: 
RX 12(~52%) > RR 11(~49%) 
2.) Effects on genotype 
- frequencies of mtDNA haplogroups differed between 
endurance & sprint (P=0.039) 
- frequencies of haplogroups J & K > among sprinters 
- none endurance belonged to haplogroup K, frequency of 
haplogroup K was 9.0% in sprinters 
- none endurance belonged to haplogroup J2 
- 4 endurance belonged to haplogroup I, but none of the 
sprinters 
- spinters: < frequency of 577XX genotype & < 577RR than 
endurance (stratisfied in subsets= inverse correlation) 
- association between haplogroup J & longevity 
(subhaplogroup J2 more frequent in very ald than among 
controls 
- haplogroup K is associated with longevity 
cross-
sectional 
study 
Lucia, A. et 
al. 
2006 102 Caucasian 
(European ancestry) 
elite endurance 
- genotype analysis 
by EDTA 
- Vo2max 
1.) Body composition: 
controls: RR: 28.5%; RX: 53.6% and XX:17.9% 
cyclists: RR: 28.0%; RX: 46.0% and XX: 26.0% 
case-
controll 
trial 
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athletes: 
- unrelated male 
spanish top- level 
cyclists (n=50) 
age: 26.9 +/- 0.4 
- Olympic- class 
spanish male middle- 
distance runners 
(n=52) age: 26.8 +/- 
0.6 yrs 
- control group of 
healthy, sedentary, 
unrelated male 
Caucasians (n=123) 
(European descent) 
age: 19- 50 
- VE 
- ventilatory 
equivalent for 
oxygen & carbon 
duioxide 
- endtidal partial 
pressure of oxygen 
& carbon dioxide 
runners: RR: 25.0%; RX: 57.7%; XX: 17.3% 
- distribution frequency of R and X alleles similar in the 3 
groups 
Allele frequencies: controls: X= 44.7% R=55.3%; 
cyclists: X= 49% R=51%; runners: X=46.1% R=53.9% 
- all 3 genotypes were present in 7 cyclists who finished 
Tour Vuelta or Giro in top-3 position 
- no sign. diff. found in Vo2max, VT & RCT between RR, 
RX & XX within groups 
- no differences were found in indices of endurance 
performance (VO2peak or ventilatory thresholds) between 
athlete carriers of each R577X genotype. 
Paparini, A. 
et al. 
2007 Caucasian males 
(n=144): 
- unrelated healthy 
subjects from 
northern, central & 
southern Italy 
(n=102), 
- Italian endurance 
athletes (n=42) 
(rowing at Olympic 
level) 
- real-time PCR 
genotyping of 
R577X & Q 523R 
plymorphisms, 
verified by 
traditional PCR-
RFLP approach 
1.) Body composition: 
ACTN3Q523R: 
male athletes (n=42): 
RQ 25(59.52) > QQ 9(21.43) > RR 8(19.05) 
Allele frequencies: Q 0.51  R 0.49 
male controls (n=102): 
RQ 48(47.06) > QQ 31(30.39) > RR 23(22.55) 
Allele frequencies: Q 0.54  R 0.46 
ACTN3R577X: 
male athletes (n=42): 
RX 25(59.52) > RR 9(21.43) > XX 8(19.05) 
Allele frequencies: X 0.49  R 0.51 
male controls (n=102): 
RX 48(47.06) > RR 32(31.37) > XX 22(21.57) 
Allele frequencies: X 0.45  R 0.55 
case-
controll 
trial 
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2.) Effects on genotype: 
- haplotype distribution confirmed the presence of linkage 
disequilibrium between the polymorphisms, both in the 
Italian general population and athletes (respectively: x² = 
54.4, P<0.001 & x² = 24.5, P<0.001) 
- no sign. diff. in haplotype distributions between controls & 
athletes (X=1.323; P<1) 
- controls: homozygous subjects (21.6%) was deficient for 
Actn3. No significant differences were observed in athletes 
(19.05%) 
- concordance between PCR-RFLP and real-time PCR 
results was 100 and 93% for polymorphisms Q523R and 
R577X 
Saunders, C. 
J. et al. 
2007 - Caucasian male 
triathletes (n=457) 
who completed 
South African 
Ironman 
- 3 subgroups based 
on performance: 
Fast Triath (n=152), 
Mid Triath (n=152) 
& Slow Triath group 
(n=153), 
- healthy Caucasian 
male controls 
(n=143) from Cape 
Town area 
- genotype analysis 
by EDTA 
vacutainer tube, 
- age 
- height 
- weight 
- BMI 
- overall time 
- swim time 
- bike time 
- run time 
- south africanborn 
1.) Body composition: 
frequency of 577XX genotype in fastest triathletes: 
RR 35.5%  RX 47.4%  RX 17.1% 
frequency of R577X genotypes in fastest triathletes: 
RR31%  RX 45%  RX 24% 
2.) Effects on genotype: 
- fast group sign. younger, weighted less & had lowest BMI 
- no sign. diff. in genotype  (P=0.486) or allele frequencies 
(P=0.375) within fastest, middle or slowest & control group 
- no sign. linear trend for distribution between the 4 groups 
(P=0.091) 
- no genotype effects on any physiological variable nor the 
split & overall performance 
- no association of the R577X polymorphism with 
endurance performance 
case-
controll 
trial 
Yang, N. et 
al. 
2007 - East African cohort 
(n=198) 
- Ethiopian controls: 
- genotype analysis 
(buccal swab 
samples, TaqMan 
1.) Body composition 
Ethiopians: 
general control (n=105): 
case-
controll 
trial 
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general Ethiopian 
(n=105), Arsi 
province (n=93) 
- Ethiopian elite 
endurance athletes 
(n=76) 
- Kenyan controls ( 
n=158) 
- Kenyan elite 
endurance runners 
(n=284) 
- Nigerian cohort 
(n=120): 60 controls 
& 62 power athletes 
SNP Assay) RR 46(44 = RX 46(44) > XX 13(12) 
Allele frequencies: X 72(34)  R138(66) 
Arsi control (n=93): 
RX 47(50) > RR 37(40) > XX 9(10) 
Allele frequncies: X 65(35)  R 121(65) 
total control (n= 198): 
RX 93(47) > RR 83(42) > XX 22(11) 
endurance runners (n=76): 
RR 35(46) = RX 35(46) > XX 6(8) 
Allele frequencies: X 47(31)  R 105(69) 
Kenyans: 
control (n=158): 
RR 133(84) > RX 23(15) > XX 2(1) 
Allele frequencies: X 27(9)  R 286(91) 
endurance runners (n=284): 
RR 212(75) > RX 69(24) > XX 3(1) 
Allele frequencies: X 75(13)  R 493(87) 
Nigerians: 
control (n=60): 
RR 50(83) > RX 10(17) > XX 0(0) 
Allele frequencies: X 75(13)  R 493(87) 
power athletes (n=62): 
RR 54(87) > RX 8(13) > XX (0) 
Allele frequencies:  X 8(6)  R 116(94) 
Japanese (n=97): 
RX 57(59) > XX 23(24) > RR 17(17) 
2.) Effects on genotype: 
- XX: absent in Nigerians, extremely low in Kenyans 
(~1%), higher in Ethiopians (11%) 
- Japanese  > XX (24%) in line with other Asian 
- Ethiopian endurance athletes did not differ from general 
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population (P=0.69) or Arsi region ((P=0.72) 
- Kenyan endurance differ from Kenyan control group 
(P=0.036) tendency towards differences in genotype 
frequency (P=0.063) 
- endurance: no increase in XX, exces of heterozygotes 
(24%), deficiency of homozygotes relative to controls 
(15%) 
- sign. diff. in X allele female Kenyan athletes compared to 
conrols (P=0.09) 
- no differences between Nigerian control subjects & 
Nigerian power athletes (P=0.62) 
- α-actinin-3 deficiency is not a major influence on 
performance in African athletes 
Ahmetov, I. 
et al. 
2008 - Russian endurance-
oriented athletes 
(n=456) (regional or 
national competitive 
standard) 
- 4 subgroups: 
highly elite (n=30) 
elite (n=90) 
sub-elite (n=105)  
average (n=222) 
- associations 
between genotype & 
data from Russian 
Cup Rowing 
Tournament: highly 
& elite athletes 
(n=54) & female 
rowers (n=20); 1211 
- genoype analysis 
(mouthwash 
samples, PCR 
digested with 
BstDEI) 
- data from Rusian 
Cup Rowing 
Tournament 
1.) Body composition: 
totals (n=456): 
RX 55 > RR 39.3 > XX 5.7 (P< 0.0001) 
Allele frequencies: X 33.2  R 66.8 
men (n=293): 
RX 52.9 > RR 40.3 > XX 6.8 (P<0.01) 
Allele frequencies: X 33.3  R 66.7 
women (n=163): 
RX 58.9 > RR 37.4 > XX 3.7 (P<0.01) 
Allele frequencies: X 33.1  R 66.9 
biathlon (n=40): 
RX 55 > RR 42.5 > XX 2.5 (P=0.1) 
Allele frequencies: X 30  R 70 
cc skiing (n=98): 
RX 49 > RR 45.9 > XX 5.1 (P=0.019) 
Allele frequencies: X 29.6  R 70.4 
race walking (n=21): 
RX 52.4 > RR 33.3 > XX 14.3 (P=0.95) 
case-
controll 
trial 
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controls: men 
(n=532) & women 
(n=679) (citizens 
from Russia) 
Allele frequencies: X 40.5  R 59.5 
road cycling (n=34): 
RX 52.9 > RR 47.1 > XX 0 (P=0.049) 
Allele frequencies: X 26.5  R 73.5 
rowing (n=187): 
RX 62.6 > RR 32.1 > XX 5.3 (P=0.0002) 
Allele frequencies: X 36.6  R 63.4 
swimming 0.8- 25 km (n=42): 
RR 52.4 > RX 30.9 > XX 16.7 (P=0.059) 
Allele frequencies: X 32.1  R 67.9 
triathlon (n=34): 
RX 64.7 > RR 35.3 > XX 0 (P=0.038) 
Allele frequencies: X 32.3  R 67.7 
controls (n=1211): 
RX 49 > RR 36.5 > XX 14.5 (P=1.00) 
Allele frequencies: X 39  R 61 
men controls (n=532): 
RX 47 > RR 36.3 > XX 16.7 
Allele frequencies: X 40.2  R 59.8 
women controls (n=679): 
RX 50.6 > RR 36,7 > XX 12.7 
Allele frequencies: X 38  R 62 
2.) Effects on genotype: 
- biathletes (P=0.034), cross-country skiers (P=0.0097) road 
cyclists (P=0.01), rowers (P=0.0003) & triathletes (P=0.01): 
< XX compared to controls (14.5%) 
- none of highly elite athletes had XX (P=0.016) (XX < in 
elite, subelite & average athletes) 
- ACTN3 genotype distribution in men & women sign. diff. 
compared to men & women controls, XX under-represented 
in both sexes compared to controls (men: 6.8% vs. men 
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controls: 16.7%; P<0.0001; women: 3.7% vs. women 
controls 12.7%; P=0.0004) 
Association study: 
- from 54 rowers, only 3 had XX (showed the slowest 
rowing times compared to RX & RR) 
- no significant differences in competition results of RR & 
RX 
Drzhevskaya, 
A. M. et al. 
2008 - power-oriented 
male & female 
athletes (n= 486) 
subdevided in highly 
elite, elite, sub-elite 
& average 
- 1,197 healthy 
unrelated controls of 
Moscow 
genotype analysis 
from mouthwash 
samples 
1.) Body composition: 
athletes: 
RX 53.9 > RR 39.7 > XX 6.4 (P=0.0001) 
Allele frequencies: X 33.3  R 66.7 (P=0.004) 
men: 
RX 55.9 > RR 37.7 > XX 6.4 (P=0.0001) 
Allele frequencies: X 34.3  R 65.7 (P=0.021) 
women: 
RX 48 > RR 45.5 > XX 6.5 (P=0.067) 
Allel frequencies: X 30.5  R69.5 (P=0.034) 
controls: 
RX 49 > RR 36.8 > XX 14.2 
Allele frequencies: X 38.7  R 61.3 
men: 
RX 46.8 > RR 36.8 > XX 16.4 
Allele frequencies: X 39.8  R 60.2 
women: 
RX 50.7 > RR 36.8 > XX 12.5 
Allele frequencies: X 37.8  R 62.2 
- < XX (6.4 vs. 14.2%; P<0.0001) & X allele (33.3 vs. 
38.7%; P=0.0004) in athletes compared to controls 
2.) Effects on genotype: 
- decreasing linear trend of XX with increasing athlete level 
- X allele frequencies in men (34.3 vs. 39.8%; P=0.021) & 
case-
controll 
trial 
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women (30.5 vs. 37.8%; P=0.034) were different to controls 
- XX underrepresented in both sexes compared to controls 
(men: 6.4 vs. 16.4%; P<0.0001; women: 6.5 vs. 12.5%; 
P=0.067) 
Muniesa A. 
C. et al. 
2008 - nonathletic 
controls (n=123) 
- professional cyclists 
(n=50) 
- Olympic-class 
runners (n=52) 
- World-class rowers 
(n=39) (medalists in the 
World championships, 
lightweight category). 
- power – endurance 
sport 
- genotype analysis 
by EDTA 
 
1.) Body composition: 
rowers: 
RX 43.6% > RR 33.3% > XX 23.1% 
cyclists: 
RX 46% > RR 28% > XX 26% 
runners: 
RX 57.7% > RR 25% > XX 17.3% 
controls: 
RX 53.7% > RR 28.5% > XX 17.9% 
2.) Effect on genotype: 
- no sign. genotype distributions; ACE < (P<0.05) in rowers 
(10.3%) than in total (22.3%) 
case- 
controll 
trial 
Papadimitriou 
et al. 
2008 - elite Greek track & 
field athletes (n=101) 
men (n=73) & 
women (n=28) at 
international level – 
2 subgroups of power 
& endurance athletes 
- unrelated healthy 
Caucasian Greek 
controls (n=181) 
- genotype analysis 
 
1.) Body composition: 
power athletes (n=73): 
RR 47.49 > RX 35.62 > XX 16.44 (P<0.02) 
Allele frequencies: X 34.2  R 65.8 
sprinters (n=34): 
RR 73.53 > RX 17.65 > XX 8.82 (P<0.001 compared with 
con) 
Allele frequencies: X 17.6  R 65.8 
endurance (n=28): 
RR 50> RX 25 & XX 25 
Allele frequencies: X 37.5  R 62.5 
controls (n=181): 
RX 55.8 > RR 25.97 > XX 18.23 
Allele frequencies: X 46.1  R 53.9 
2.) Effects on genotype: 
case- 
controll 
trial 
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- Differences in frequencies of alleles (p=0.017) & 
genotypes (p=0.016) between elite power & controls 
- power had lesser frequency of X than controls (more 
prominent in sprinters) 
- all Olymic/European-level-sprinters had at least 1 R allele 
(None had XX) 
- sprinters: <  XX (8.82% vs. 18.23%) & > RR (73.53% vs. 
25.97%) (P=0.0001) 
- increased XX in elite endurance group compared to 
sprinters & control 
- Olympic/European endurance level had RR 57% 
- no sign. diff. in frequencies of alleles (p=0.252) or 
genotypes (p=0.238) between endurance & controls or 
between power & endurance for allele & genotype 
comparisons 
Roth, S. M. et 
al. 
2008 - black & white elite 
bodybuilders & 
strength athletes 
(n=75) 
predominantly male 
- control group of 2 
subgroups (n=876): 
white group (n=668) 
men (n=363) & 
women (n=305) 
black group (n=208) 
men (n=98) & 
women (n=110) 
age: 19 - 90 
- Baltimore 
longitudinal Study of 
- genotype analysis 1.) Body composition: 
athletes: 
RX 62.6 > RR 30.7 > XX 6.7 (P=0.005) 
control: 
RX 45.6 > RR 38.1 > XX 16.3 
white athletes: 
RX 65.4 > RR 25.0 > XX 19.9 (P=0.018) 
white controls: 
RX 47.5 > RR 32.6 > XX 19.9 
black athletes: 
RX 56.5 > RR 43.5 > XX 0 (P=0.10) 
black controls: 
RR 55.8 > RX 39.4 > XX 4.8 
2.) Effects on genotype: 
- deviation in total athletes (P=0.001), white athletes 
(P=0.01) & black athletes (P=0.06) 
case-
controll 
trial 
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Aging - no sign frequency differences between m & w within 
controls - athletes: < XX (6.7%) compared to controls 
(16.3%; P=0.005) 
- XX < in white athletes (9.7%) compared to controls 
(19.9%; P=0.018) 
- no black athlete with XX 
- no differences in allele frequency between bodybuilders & 
powerlifters 
- controls: > RR compared to athletes 
Santiago, C. 
et al. 
2008 - male elite soccer 
players (n=60) 
age: 17-32; 
participating in the 
spanish first (n=18), 
second (n=27) and 
third division (n=15); 
Vast majority 
(96.7%) of Caucasian 
origin-Spanish 
(91.7%) & non-
Spanish European 
(5%); 
- 102 Spanish world-
class male endurance 
athletes (n=102) 
age: 19-38: 
50 professional 
cyclists and 52 
Olympic-class 
runners; 
- Control group of 
- genomic DNA 
extracted from 
peripheral EDTA 
treated 
anticoagulated 
blood obtained 
according to 
standard 
phenol/chloroform 
procedures followed 
by alcohol 
precipitation 
1.) RR (48.3%) & RX (36.7%)in soccer players 
significantly different from controls RR (28.5%) & RX 
(53.7%) and endurance athletes RR (26.5%) & RX (52%) 
(p=0.041); 
- % distribution of the R and X alleles in soccer players 
tended to be significantly different from the other two 
groups (p=0.061) - elite soccer players tend to have the 
sprint/power genotype 
case-
controll 
trial 
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Tabelle  3: ACTN3 Athletics without intervention 
 
 
123 healthy 
sedentary Spanish 
males (n=123) age: 
19-50 
Gomez-
Gallego, F. et 
al. 
2009 - elite male 
professional road 
cyclists (n=46) 
age: 26-28 
- healthy 
sedentary 
men as 
controll group 
(n=46) 
age: 35-42 
- spanish descent for 
>3 generations  
- genotype analysis 
by EDTA 
ACE & ACTN3 as 
independent factor 
& age & body mass 
as covariates 
- Vo2max 
- PPO 
- VT 
- RCT 
- GE & DE 
Cyclists: 
1.) Body composition: 
(RR+RX) (n=35) > XX (n=11) 
2.) Effect on muscle: 
- XX < PPO (0.035) < VT (0.029) < RCT (0.001) & sign. 
effect on covariate body mass (0.001) 
- sign. “combined genotype” (ACE+ACTN3) for PPO 
(p=0.004, power=0.916; VT (p=0.007, power=0.871) & 
RCT (p<0.001, power=1.000) 
- sign. covariate effects: 
PPO for age: p=0.01, power=0.959 
PPO for body mass: p=0.016, power=0.697 
VT for body mass: p=0.003, power=0.880 
RCT for age: p=0.034, power=0.580 
RCT for body mass: p<0.001, power=1.000 
- Post hoc: 
strong/power genotype (DD+RR/RX) similar RCT 
endurance (II+XX) sign.> vs. intermediate (II+RR/RX; 
p=0.036) & (DD+XX; p=0.004) 
- no sign. differences in controls 
cross-
section 
study 
 66 
 
Author Year Probands Parameters Intervention Results Level of evidence 
Kostek, 
M. C. et 
al. 
2005 Caucasian men 
(n=32) & 
women (n=35) 
age: 52- 83 
- genotype analysis 
by RT-PCR for 
IGF-I (192bp) & 
SNP 
- body composition 
- total FFM 
- 1- RM of knee- 
extensors before & 
after 
- MV 
- MQ 
- 3 times/ week 5 sets 
(<75yrs) or 4 
sets(>75yrs) of 
unilateral knee 
extension exercise of 
dominant leg ( 5 rep 
increased continously 
until 10 rep) for 10 
weeks 
- shortening phase: ~2s 
lengthening phase: ~3s 
- rest periods: 30, 90, 
150, 180s 
- untrained leg in 
relaxed position 
1.) Body composition: 
total: 
192/- 34(51) > 192/192 24(36) > -/- 9(13) 
men: 
192/- 18 > 192/192 10 > -/- 4 
women: 
192/- 16 > 192/192 14 > -/- 5 
192/192 men: n=10 women: n=14 
192/- men: n=18 women: n=16 
-/- men: n=4 women: n=5 
2.) Effects on muscle: 
- IGF-I promoter groups: no significant differences in 
age, height, body mass, %body fat or FFM at 
baseline or training response 
192 carriers sign. > 1-RM strength (67.3+/-6.3 N) 
than nonacarriers (39.8+/-7.6 N) covaried for sex & 
age (P<0.05) 
- no sign. diff. between 192 homozygotes & 
nonhomozygotes for change in 1-RM 
- MV & MQ increased in all groups after exercise 
(P<0.01) 
- no sign  diff. in MV & MQ at baseline & after in 
IGF1 promoter genotype groups covaried for sex & 
age 
- 192 homozygote not sign. diff. from heterozygote & 
noncarriers 
 
 
randomised 
controlled trial 
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Hand, B. 
D. et al. 
2007 black (n=12) & 
white (n=46) 
men (n=58) & 
black (n=21) & 
white (n=49) 
women (n=70) 
age: 50- 85 
- genotype analysis 
by EDTA 
- 1-RM before & 
after ST 
- body composition, 
-FFM 
- MV at baseline & 
after ST 
- MQ at baseline & 
after ST 
- unilateral knee 
extension strength 
training of dominant 
leg 3 times/week for 10 
weeks 
- untrained leg in 
relaxed position 
1.) Body composition: 
IGF1 CA Promoter Gene Polymorphism: 
total: 
192/- 63(49) > 192/192 39(30) > -/- 26(20) 
Allele frequencies: 192 141(55)  - 115(45) 
white: 
192/- 47(49) > 192/192 34(36) > -/- 14(15) 
Allele frequencies: 192 115(61)  - 75(39) 
black: 
192/- 16(48) >  -/- 12(36) > 192/192 
Allele frequencies: 192 26(39)  - 40(61) 
- sign. diff. between races in allele frequencies 
(P<0.05) 
IGFBP3 A-202C Promoter Gene Polymorphism: 
total: 
A/C 62(48) > A/A 33(26) = C/C 33(26) 
Allele frequencies: A 128(50)  C 128(50) 
white: 
A/C 46(48) > C/C 27(28) > A/A 22(23) 
Allele frequencies: A 90(47)  C 100(53) 
black: 
A/C 16(48) > A/A 11(33) > C/C 6(18) 
Allele frequencies: A 38(58)  C 28(42) 
PPP3RI 5-bp I/D Promoter Gene Polymorphism: 
total: 
I/I 100(78) > I/D 27(21) > D/D 1(1) 
Allele frequencies: I 227(89)  D 29(11) 
white: 
I/I 82(86) > I/D 13(14) > D/D 0(0) 
Allele frequencies: I 177(93)  D 13(7) 
black: 
randomised 
controlled trial 
 68 
I/I 18(55) > I/D 14(42) > D/D 1(3) 
Allele frequencies: I 50(76)  D 16(24) 
- sign. differences between races in allele frequencies 
(P<0.001) 
2.) Effects on muscle: 
- men: sign. > 1-RM (33+/-1.0) than women (22+/-
1.0) & greater increase: men (41+/-1.2) & women 
(27+/-1.2) 
-. men: sign. > MV (1.770+/-34) than women 
(1,330+/-38) 
- men sign. > MQ (18.8+/-0.56) than women (16.2+/-
0.63) 
- blacks: sign. > MV at baseline (1.589+/-39) than 
whites (1.380+/-31) 
- blacks: sign. > MQ increase (20.7+/-0.062) than 
whites (19.4+/-0.46) 
- change in strength influenced by combination of 
gene polymorphisms for IGF-I CA repeat main 
effects & IGF-I CA repeat X PPP3R1 I/D interaction 
effects 
- IGF1: combined effect: 3.46= 1.22 + ½ (4.48) 
(P<0.01) 
- IGFBP3: combined effect: 4.84= 2.83 + ½ (4.02) 
(P>0.05) 
- PPP3RI: combined effect: 2.27=0.03 + ½ (4.48) 
(P>0.05) 
- combined gene effect for IGF-I CA repeat 
influenced strength & MQ responses to ST 
IGF1: combined effect: 3.71= 0.95 + ½ (5.54) 
(P<0.05) 
PPP3RI: combined effect: 2.99 = 0.22 + ½ (5.54) 
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(P>0.05) 
- contribution to %variability attributable to IGF-I 
CA repeat X PPP3RI I/D interaction was ~4.5% & 
5.5% 
- no combined effects for PPP3RI I/D 
- sign. difference between PPP3RI I/D genotype 
groups 
- no sign. influence of IGFBP-3 A202C gene 
polymorphism on muscle phenotypic responses to ST 
 
Tabelle 4: IGF-I Nonathletics with intervention 
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Tabelle 5: IGF-II Nonathletics with intervention 
Author Year Probands Parameters Intervention Results Levels of 
evidence 
Devaney, 
J. M. et 
al. 
2007 men 
(n=73) & 
78 
women 
(n=78)  
age: 22-
30 
- genotype 
analysis 4,7 & 10 
days postexercise 
- MVC  
- blood sample  
- CK activity 
- Mb 
concentration; 
- 50 max isotonic 
eccentric contractions 
of elbow flexor of 
nondominant arm 
 
Gene SNP Homozyg
ous Wild 
Type 
Heterozyg
ous 
Homozyg
ous rare 
allele 
Allele 
Frequency 
Wild T. 
Allele 
Frequency 
Rare 
IGF-II C16646T 135 
(87.1%,CC) 
19 
(12.3%CT) 
1 (0.6%TT) 0.932 0.068 
IGF-II G13790C 69 
(44.2%GG) 
58 
(37.2%GC) 
29 
(18.6%CC) 
0.628 0.372 
IGF-II T13705C 153 
(99.3%TT) 
1 (0.7%TC) 0 (CC) 0.997 0.003 
IGF-II G12655A 70 
(45.4%GG) 
60 
(39.0%GA) 
24 
(15.6%AA) 
0.649 0.351 
IGF-II G17200A 89 
(54.6%GG) 
56 
(34.4%GA 
18 
(11.0%TT 
0.718 0.282 
IGFBP-3 A8618T 85 
(56.7%AA) 
50 
(33.3%AT) 
15 
(10.0%TT) 
0.733 0.267 
IGFBP-3 -C1592A 111 
(70.3%CC) 
42 
(28.0%CT) 
5 
(3.2%AA) 
0.835 0.165 
IGF-I -C1245T 103 
(65.6%CC) 
44 
(28.0%CT) 
10 
(6.4%TT) 
0.796 0.204 
IGF2AS A1364C 55 
(36.2%AA) 
68 
(44.7%AC) 
29 
(19.1%CC) 
0.586 0.414 
IGF2AS G11711T 45 
(27.8%GG) 
75 
(46.3%GT) 
42 
(25.9%TT) 
0.509 0.491 
INS C1045G 106 
/65.5%CC) 
46 
(28.4%CG) 
10 
(6.17%GG) 
0.796 0.204 
 
- no sig. Associations of phenotypes with IGF-I  
- IGF-II SNP & IGFBP-3 SNP not associated with any variable - 
men: IGF-II, IGF-II antisense & IGFBP-3 SNP sign. associated 
with muscle damage  
- homozygous rare IGF-II C13790G allele & rare allele ApaI 
(G17200A) SNP > strength loss immediately after exercise, 
>soreness & > postexercise serum CK activity  
- homozygous wild type IGF2AS > strength loss & > muscle 
soreness  
- homozygous wild type IGF2AS SNP> strength loss, > muscle 
soreness, > CK & myoglobin response to exercise 
cohort study 
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Author Year Probands Parameters Results Level of 
evidence 
Sayer, A. 
A. et al. 
2002 men (n=397) & women 
(n=296) average age: 
67.5 
- genotype analysis 
- blood sample 
- grip strength 
- self-reported walking speed 
1.) Body composition: 
genotype array: 
men: 
GG 202 > GA 162 > AA 33 
women: 
GG 168 > GA 112 > AA 16 
mean(sd): 
men: 
GA 39.1(6.9) > AA 38.4(5.6) > GG 37.5(7.3) 
women: 
GA 23(5.3) > GG 22.3(5.5) > AA 21.7(4) 
mean grip strength according to bw & genotype: 
men < 112: 
AA 38.4(4.9) > GA 38.1(5.9) > GG 34.9(8.1) 
men =128: 
GA 39.5(7) > GG 38.6(6.9) > AA 36.3(4.3) 
men > 128: 
AA 40.9(7.1) > GA (39.8(7.6) > GG 39.1(6.1) 
women <112: 
GG 22.3(5.8) > GA 22.2(5) > AA 20.2(3.2) 
women =128: 
AA 24.4(5.7) > GA 22.8(5.9) > GG 21.7(5.7) 
women >128: 
GA 25.1(4.3) > GG 23.2(5.8) > AA 22.7(2.1) 
2.) Genotype interactions: 
- grip strength sign. associated with gender, age, height, 
weight & self-reported speed (P<0.05) 
- strongest correlates of adult grip strength:age (men: 
r=-0.18;P=0.0003 & women: r=-0.19;P=0.0007) 
cohort study 
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- height > weight in men (r=0.29;P=0.0001) & women 
(r=0.20;P=0.0007) 
- birth weight sign. corr. with adult weight in women 
- IGF2 not associated with height, weight 
- birth weight > GG men & women (not sign.) 
- GG associated with lower IGF-II levels 
- IGF.II not associated with adult grip strength in men 
& women 
- univariate analyses: grip strength in men associated 
with IGF2 genotype (P=0.05) & birth weight (P=0.04) 
after ádjustment age & current height 
- IGF2 & birth weight simultaneously in men: sign. to 
grip strength allowing for age & adult height 
Schrager, 
A. et al. 
2004 Baltimore longitudinal 
study: 
Cohort 1: men (n=94) 
age: 22-80  
Cohort 2: men (n=246) 
&  women (n=239) 
age: 20-94 
- genotype analysis of IGF2 
ApaI 
- Cohort1 (1960 -1985): 
isometric grip strength & SP 
- Cohort2 (1992 -2002): FFM 
& isokinetik peak tourque 
- 1-A arm power 
- 4-A arm power 
- BMI 
- LTPA 
 
1.) Body composition: 
genotype array: 
Cohort1: men: 
GG 49 > GA 32 > AA 13 
Allele frequencies: G 69.1%  A 30.9% 
Cohort2: 
total: 
GG 238 > GA 190 > AA 57 
Allele frequencies: G 68.7%  A 31.3% 
men: 
GG 119 > GA 95 > AA 32 
women: 
GG 119 > GA 95 > AA 25 
FFM, strength & power by IGF2 genotype & gender in 
cohorts 1 & 2 at age 35: 
men: 
GA 55.1+/-1.6 > GG 54.6+/-1.3 > AA 54.1+/-2.4 
2.) Genotype interactions: 
cohort study 
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- cohort 1: no sign. differences among genotype groups 
for levels of strength or SP at first visit 
- AA men sign. < isokinetic arm PTs than GG men 
(P<0.05) 
- AA women sign. < isokinetik Arm PTs & PTl than 
GG & GA women (P<0.05) 
- homozygous comparing: G/G women (age 35) > total 
FFM > isokinetic arm PTs & PTl & leg PTs 
(maintained at age 65) 
- no sign. association in change in grip strength, SP & 
aging with IGF2 ApaI genotype 
- men in cohort 1: grip strength: A/A < 3.7%, G/A < 
2.6% & G/G < 1.7% SP: A/A < 7.5% G/A < 4.4% G/G 
< 3.3% per decade 
- cohort 2: G/G > loss in FFM than A/A 
 
Tabelle 6: IGF-II Nonathletics without intervention 
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Author Year Probands Parameters Intervention Results Level of 
evidence 
Ferrell, 
R. E. 
1999 - Caucasian (n=96) & 
African American (n=96) 
from general population 
- additional 72 subjects 
screened for exon 2 
variant 
- men (n=127): African 
American (n=32) , 
Caucasian (n=91) & 
Asian (n=4) 
- women (n=26): African 
American (n=9), 
Caucasian (n=16) & 
Asian (n=1) (WC dybulider 
top 100 n=18, competititive 
bodybuilder top 100 n=25, 
elite power lifters n=7, 
university football players 
n=9, untrained subjects n=33, 
nonathletes n=61) 
- genotype analysis by 
EDTA 
- general population: 
sequencing of 
myostatin gene regions 
& genotyping of 
common variants 
- subjects: categorized 
by increase in muscle 
mass from strength 
training 
- MV 
-FFM 
- questionnaire about 
ability to increase 
muscle mass 
(5=>400cm³, 0=no 
increase) 
- 9 weeks of heavy resistance 
strength training of knee 
extensor  
 
1: Body Composition: 
Caucasians Exon 1 (A55T)  n=167: 
Ala/Ala (n=155) > Ala/Thr (n=12) > 
Thr/Thr (n=0) 
Allele frequencies:  
p(Ala)=0.964 q(Thr)=0.036 
Caucasians Exon2(K153R) n=96: 
Lys/Lys (n=88) > Lys/Arg(n=7) >  
Arg/Arg (n=7) 
Allele frequencies: 
p(Lys)=0.963q(Arg)=0.037 
African Americans Exon 1 (A55T) n=96: 
Ala/Ala (n=75) > Ala/Thr (n=19) >  
Thr/Thr (n=2) 
Allele frequencies: 
p(Ala)=0.880 q(Thr)=0.120 
African Americans Exon 2(K153R) n=93: 
Lys/Lys (n=66) > Lys/Arg (n=24)  
> Arg/Arg (n=3) 
Allele frequencies: 
p(Lys)=0.839 q(Arg)=0.161 
2. Effect on strength training: 
- muscle mass response to strength training 
is not signifficantly influenced by variation 
at the myostatin locus 
- no sign. impact in muscle mass response 
to strength training in either Caucasians or 
African Americans 
 
case-
controll trial 
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Ivey, F. 
M. et 
al. 
2000 - 11 young men  
age: 20-30  
- 11 young women  
age: 20-30 
- 12 older men  
age: 65-75  
- 11 older women  
age: 65-75 
- genotype analysis  
- CSA 
- 1-RM 
- MV via MRI (before 
& after ST & 
detraining) 
- 9-week unilateral ST 
program of knee extensor of 
dominant leg  
3 times/week: 5 sets:  
set 1: 5 rep at 50% 1-RM,  
set 2: 5 rep at increased 5-
RM value 
set 3: 10 rep (first 4 or 5 rep 
at 5-RM value)  
set 4: 5 rep at 5-RM & 10 
more rep, set 5: 5 rep at  
5-RM & 15 more rep; resting 
periods: 30, 90, 150 & 180 s 
- 31 weeks detraining period 
 
 
1.) Body composition: 
n= 32: men n=18 & women n=14 
2.) Effect on muscle 
- men > MV than women 
- no significant difference in MV response 
to ST between young & older 
- loss of absolute MV after 31 weeks of 
detraining: men > women, but no sign 
difference  young & old 
- only women analyzed: less common 
myostatin allele > (68%) MV in response to 
ST 
 
randomised 
controlled 
trial 
Thomis 
M. et 
al. 
2004 - Twins from Leuven 
Twin & Training Study 
(n=25 pairs) 
- age: 17-30 
- Study 1: genotype-
dependent similarity in 
training responses 
- Study 2: genotype x 
training interaction (pre 
& posttraining) 
- 1RM 
- muscle cross-
sectional are 
- 5 sets of biceps curls 3 
times/week for 10 weeks 
set1: 14 rep 60% 1RM, set2: 
12 rep 75% 1RM, set3: 10 
rep 80% 1RM, set4: 8 rep 
85% 1RM, set5: 5 rep 70% 
1RM 
- all measurements increased sign. 
- 1 subject carrier of K/R  
- no training response phenotypes 
randomised 
controlled 
trial 
 
Tabelle 7: Myostatin Nonathletics with intervention 
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Author Year Probands Parameters Results Level of 
evidence 
Seibert, J. 
E. et al. 
2001 WHAS II study: 
- women (n=286) 
age: 70-79 88.1% 
Caucasian, 18.8% 
African 
American, 0.2% Asian or 
Hispanic 
- overall strength by 
dynamometer defined 
as the sum of the 
strongest measures of 
hip, knee, and grip 
strength on the 
dominant side 
- BMI 
1. Body Composition: 
African American: 
K/K (n=39) > K/R (n=13) > R/R (n=3) 
Allele frequencies: 
Caucasians (0.02) < African Americans 
(0.05) Nla III; (0.07) Hae III and (0.17) 
ApaI polymorphism 
Caucasian: 
K/K (n=225) > K/R (n=6) > R/R (n=0) 
Combined: 
K/K (n=264) > K/R (n=19) > R/R (n=3) 
2. Effect on muscle strength: 
suggested lower muscle strength in those 
African-American women: < muscle 
strength in R than K (K/K: 72.50+/-13.9 kg 
(n=39) vs K/R: 67.14+/-11.4 kg (n=13) vs 
R/R: 63.1+/-11.3 kg (n=3) 
adjustment for race in a linear regression 
model: R < strength levels (P=.04)  
(sign. decreased when BMI & race added 
(P=.09). 
case-
controll trial 
Corsi, A. 
M. et al. 
2002 InCHIANTI project: 
- men (n=189) and 
women (n=261)  
- of Italian population  
- mean age +/- standard 
deviation 69.5+/- 15.2, 
range 22-96; 
genotype analysis by 
EDTA 
- isometric strength in 
eight muscle groups by 
handheld dynamometer 
-  
- 6 heterozygous & 1 homozygous for 
K153R 
- 153R allele associated with lower muscle 
strength (155R +: 18.8 +/- 2.2 kg; 153R-: 
26.5 +/- 1 kg; P=0.5 
- not sagnificant after adjusting for age 
new missense single-nucleotide variation at 
codon 185, with a G to C substitution 
randomised 
controlled 
trial 
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Tabelle 8: Myostatin Nonathletics without intervention 
implicating the change of an arginic residue 
with a threonine 
Huygens, 
W. et al. 
2004 - male Caucasian sibs 
(n=329) from 146 
families 
(sib-pairs n=115, trios 
n=25, quads n=6) 
age: 17-36 
- nonactive 
- genotype analysis by 
EDTA 
- muscle mass 
- maximal concentric 
knee strength 
- linkage patterns 
between knee extension 
& flexion peak tourque 
with markers 
- skinfold 
- cross- sectional 
muscle & bone area 
- only two estimated muscle cross-sectional 
areas marginally linked 
randomised 
controlled 
trial 
 6 Results  
 
 
6.1 Types of included studies 
 
All studies published before April 2009 and related to the role of genetic polymorphisms 
on anaerobic phenotype were identified. The initial search identified 122 matches of which 
82 were discarded as not containing genome-wide linkage data. The literature selected was 
published between 1999 and 2009.  
The search for ACTN3 gene yielded 5 studies for “nonathletics with intervention”. The 
levels of evidence subdevide this group in: 1 randomised controlled trial from Sweden 
(Norman, B. et al., 2009) and 4 cross-section studies evaluated in Belgium (Vincent, B. et 
al., 2007), and in the USA (Clarkson, P. M.et al., 2005; Clarkson, P. M.et al. 2005; 
Delmonico, M. J. et al., 2007).  
The category of ACTN3 “nonathletics with intervention” consists of 5 studies: 2 
randomised controlled trials from USA (Walsh, S. et al., 2008) and Spain (San Juan, A. F. 
et al., 2006), 2 cohort studies participated in USA (Delmonico et al., 2008) and UK 
(McCauley T. et al., 2008) and 1 cross- section study was held in Greece (Moran C. E. et 
al., 2007).  
The highest output of 15 studies found refer to ACTN3 and “athletics without 
intervention”. This group consists of 12 case-controll trials. 3 of these studies were 
established in Spain (Santiago, C. et al., 2008; Lucia, A. et al., 2006; Muniesa, A. C. et al., 
2008), 1 in Italy (Paparini, A. et al., 2007), 1 in Greece (Papadimitriou, I. D. et al., 2007) 1 
in Taiwan (Li-Ling Chiu et al., 2005), 2 in Russia (Ahmetov, I. et al., 2008; Drzhevskaya, 
A. M. et al., 2008), 1 in South Africa (Saunders, C. J. et al., 2007), 1 in the USA (Roth, M. 
S. et al., 2008), 2 in Australia (MacArthur D. G. et al., 1999; Yang, N. et al., 2007). 3 
cross-section studies were evaluated in Australia (Yang, N. et al., 2003), Spain (Gomez-
Gallego, F. et al., 2009) and Finland (Niemi A.-K & Majamaa, K., 2005).  
Fewer studies than expected were found for IGF-I “nonathletics without intervention” (2 
randomised controlled trials). Both studies were developed in the USA (Kostek, M. C., 
2005; Hand, B. D. 2007).  
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The IGF-II group consists of two cohort studies also investigating “nonathletics without 
intervention”. 1 of these studies was examined in the UK (Sayer, A. A. et al., 2002) and the 
other in the USA (Schrager, : A. et al., 2004). Only one study was found for IGF-II with 
association to trainings intervention in nonathletics (Devaney, J. M. et al., 2007) 
The myostatin gene is determined by “nonathletics with intervention” (2 randomized 
controlled trials and 1 case-controll trial) and the “nonathletics without intervention” group 
(2 randomised controlled trials and 1 case- controll trial). Investigations on the 
“nonathletics with intervention” group took place in the USA (Ivey, F. M. et al., 2000; 
Ferrell, R. E., 1999) Italia (Corsi, A. M. et al., 2002) and Belgium (Thomis M. et al., 
2004). Myostatin was observed for “nonathletics without intervention” in the USA 
(Seibert, J. E. et al., 2001) and Belgium (Huygens, W. et al., 2004).  
The athletics mostly took part in individual kinds of sports like alpine – skiing 
(Drzhevskaya, A. M. et al., 2008), bodybuilding (Drzhevskaya, A. M. et al., 2008; Roth, S. 
M. et al., 2008), Cross-country skiing (Yang, N. et al., 2003), cycling (Gomez-Gallego, F. 
et al., 2009; Muniesa A. C. et al., 2008; Santiago, C. et al., 2008), endurancerunning 
(Lucia, A. et al., 2006; MacArthur D. G. et al., 1999; Niemi A.-K. et al., 2005; Santiago, C. 
et al., 2008; Yang, N. et al., 2003; Yang, N. et al., 2007; Zanoteli, E. et al., 2003), 
figureskating (Drzhevskaya, A. M. et al., 2008), ice-hockey (Drzhevskaya, A. M. et al., 
2008), powerlifting (Drzhevskaya, A. M. et al., 2008; Yang, N. et al., 2007), ski jumping 
(Drzhevskaya, A. M. et al., 2008), speedskating (Drzhevskaya, A. M. et al., 2008), 
sprinting (Yang, N. et al., 2003), swimming (Yang, N. et al., 2003), track & field (Niemi 
A.-K., 2005; Papadimitriou et al., 2008; Yang, N. et al., 2003), triathlon (Saunders, C. J. et 
al., 2007), weighlifting (Drzhevskaya, A. M. et al., 2008) and wrestling (Drzhevskaya, A. 
M. et al., 2008) as well as teamsport: rowing (Ahmetov, I. et al., 2008; Paparini, A. et al., 
2007; Yang, N. et al., 2003), soccer (Santiago, C. et al., 2008) and volleyball (Li-Ling Chiu 
et al., 2005). Interestingly, the ACTN3 gene is the only gene observed for Athletics and the 
subjects did not obtaine exercise intervention. The ACTN3 gene x exercise intervention 
has also been found in 5 studies with nonathletic cohorts. 
Exercise interventions included concentric, eccentric and isometric strength training of 
knee extensor (6 studies) and arm elbow flexor muscle (4 studies). Interventions ranged 
from 9 to 12 weeks. Most studies required 10 weeks of  knee extensor resistance training 
(Vincent, B. et al., 2007; Norman, B. et al., 2009, Delmonico, M. J. et al., 2007; Hand, B. 
D. et al., 2007; Kostek, M. C. et al., 2005). 2 studies had 9 weeks knee extensor resistance 
 80
training intervention (Ivey, F. M. et al., 2000; Ferrell, R. E., 1999). The study of  Clarkson, 
P. M.et al. (2005) observed relative strength loss, blood creatin kinase and myoglobin 
concentration four, seven and ten days after eccentric exercise of the arm elbow flexor. The 
same research group investigated 12 weeks of  elbow flexor and elbow extensor resistance 
training in association with genotype analysis. Training interventions of the arm elbow 
flexor were also available in a Twin study held by Thomis M. et al. (2004) and in the study 
of Devaney, J. M. et al. (2007). 
 
 
6.2 Types of excluded studies 
 
Limits were set on the search including: published in english, human studies and the 
exclusion of reviews. The search included different levels of evidence therefore the 
selected studies are of different quality.  
Most of the interests relate to ACTN3 gene and the influence on athletic performance. 
Pubmed offered 31 potentially relevant trials in context to genotype and anaerobic muscle 
performance (Abb. 7). Two potentially appropriate syrves later turned out to be reviews so 
that in summary 3 reviews were excluded (MacArthur, D. G. & North, 2004; North, 2008; 
North et al., 1999). 1 animal study was also excluded (MacArthur, D. G. et al., 2008). 3 
clinical trials examined genotype and McArdles desease interaction (Gonzalez- Freire, M. 
et al., 2009; Lucia, A. et al., 2007; Rubio, J. C. et al., 2007). North K. N. et al. (1996) 
described defficiency of α-actinin-3 in merosin-positive congenital muscular dystrophy. 
Vainzof, M. et al. (1997) observed the defficiency of ACTN3 in different forms of 
muscluar dystrophy such as limbe-girdle MD, sarcoglycanopathies and Duchenne MD. 
The survey of Yngvadottir, B. et al. (2009) on human nonsense SNPs and the survey of 
Luzia, A. et al. (2007) did not include genotype data. Finally one excluded study was 
published in Russian (Krakhmaleva, I. N. et al., 2005). By hand searching the reference 
lists, 6 additional trials were found (Himanshu, G. et al., 2007; MacArthur, D. G. et al., 
1999; Moran, C. N. et al., 2007; Li-Ling Chiu et al., 2005; San Juan, A. F. et al., 2006; 
Yang, N. et al., 2007). These leads to a final result of 27 included studies. The study of 
Himanshu, G. et al (2007) was also found by hand search but later excluded because the 
study observed gene prevalence in North India without relation to muscle phenotype. 
 81
 
 
 
 
Abbildung 7: Systematic search strategy for “(ACTN3 OR R577X) AND genotype” in 
PubMed. 
 
 
trials identified as 
potentially relevant: 31
potentially appropriate 
trials: 19 
trials included: 25 
6 trials found by hand search 
3 reviews excluded 
1 animal study excluded 
5 clinical trials excluded 
2 studies without genotype excluded 
1 study was not in english  
intervention: 
5 studies 
without intervention: 
20 studies 
nonathletics : 
2 randomised controlled trials 
1 cross-section study 
2 cohort studies 
athletics: 
12 case- controll trials 
3 cross-section studies 
nonathletics: 
1 randomised controlled trial 
4 cross-section studies 
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The IGF-I gene search delivered the most potentially relevant trials and the most clinical 
trials excluded (Abb. 8). The clinical trials observed acidosis (Janziszak, K. et al., 1998),  
acromegalie (Bianchi, A. et al., 2009; Bogazzi, F. et al., 2002; Mecardo, M. et al., 2008; 
Mendoza, V. et al., 2005; Mulatero, P. et al., 2006), Alzheimer (Kranzler, J. H. et al., 1998; 
Mustafa, A. et al., 1999; Rivera, E. J. et al., 2005), cancer (Al-Zahrani, A. et al., 2006; 
Bågeman, E. et al., 2007;  Bianchi, A. et al., 2008; Birmann, B. M. et al., 2009; Brokaw, J. 
et al., 2007; Bustin, S. et al., 2001; Canzian, F. & Mckay, J. D., 2005; Canzian, F. et al., 
2005; Caruso-Nicoletti, M. et al., 1992; Chen, C. et al., 2006; Chen, X. et al., 2008; Cheng 
I. & Stram D. O., 2006; Cheng, I. et al., 2006; Chia, F. M. et al., 2008; Chiang, D. Y. et al., 
2008; Chokkalingam, A. P. et al., 2001; Chu, L. W. et al., 2008; Cleveland, R. J. et al., 
2006; DeLellis, K. et al., 2003; Diorio, C. et al., 2008; Dossus, L. et al., 2008; Esteban, F. 
et al., 2008; Fall, K. et al., 2008; Fan, J. et al., 2006; Figer, A. et al., 2002; Friedrichsen, D. 
M. et al., 2005; Gonzalez-Zuloeta Giovannucci, E. et al., 2002; Ladd, A. M. et al., 2007; 
Hadsell, D. L. et al., 2001; Han, S. G. et al., 2008; Hong, C. C. et al., 2003; Hong, C. C. et 
al., 2004; Hudelist,G. et al., 2007; Jernström, H. et al., 2001; Jernström, H. et al., 2005; 
Jernström, H. et al., 2006; Johansson , M. & McKay, J. D. et al., 2007; Johansson, M. et 
al., 2007; Kelemen, L. E. et al., 2008; Khoury-Shakour S. et al., 2008;  Lai, J. H. et al., 
2004; Le Marchand, L. et al., 2005; Lembessis, P. et al., 2003; Li, H. et al., 2007; Li, L. et 
al., 2004; Li, Z. Q. et al., 2007; Luporini, S. M. et al., 2001; Maor, S. et al., 2007; Majeed, 
M. et al., 2005; McKay, J. D. et al., 2007; Missmer, S. A. et al., 2002; Moore, S. C. et al., 
2009; Morimoto, L. M. et al., 2005; Mu, L. et al., 2008; Natrajan, R. et al., 2006; Patel, A. 
V. etal., 2008; Pechlivanis, S. et al., 2007; Reeves, S. G. et al., 2008; Rosmond, R. et al., 
2000; Sarma, A. V. et al., 2008; Schernhammer, E. S. et al., 2003; Schildkraut, J. M. et al., 
2005; Siahpush, S. H. et al., 2007; Silha, J. V. et al., 2006; Slattery, M. L. et al., 2004; 
Slattery, M. L. et al., 2005; Slattery, M. L. et al., 2007; Slattery, M. L. et al., 2008; 
Sonntag, W. E. et al., 2005; Streicher, K. L. et al., 2007; Suzuki, H. et al., 2008; Taboada, 
G. F. et al., 2007; Tamimi, R. M. et al., 2007; Theiss, A. L. et al., 2005; Tilli, M. T. et al., 
2005; Tsuchia, N. et al., 2005; Voskuil, D. W. et al., 2004; Voskuil, D. W. et al., 2008; 
Wagner, K. et al., 2004; Wagner, K. & Hemminki, K., 2005; Wagner, K. et al., 2005; 
Wagner, K. et al., 2006; Wagner, K. et al., 2007; Weber, M. S. et al., 2000; Wen, W. et al., 
2005; Wong, H. L. et al., 2005; Wong, H. L. et al., 2008; Zang, J. et al., 2008; Yang, X. F. 
et al., 1996; Yu, H. et al., 2001; Zhang, X. et al., 2007; Zhang, H. et al., 2009), 
cardiovascular desease (Bleumink, G. S. et al., 2004; Bleumink, G. S. et al., 2005; Boquist; 
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S. et al., 2008; Cheng, J. et al., 2008; Hietaniemi, M. et al., 2005; te Velde, S. J. et al., 
2005; Jimeno, L. et al., 2005; Ukkola, V. et al., 2008; Ruigrok, Y. M. et al., 2005; van 
Houten, V. A. et al., 2008; van Duyvenvoorde, H. A. et al., 2008; Yazdanpanah, M. et al., 
2006), dementia (Garcia, J. et al., 2006) diabetes (Almind, K. et al., 1999; Buongiorno, A. 
M. et al., 2007; Cama, A. et al., 1992; Dozio, N. et al., 1995; Eerligh, P. & Frayling, T. M. 
et al., 2002; Eerligh, P. et al., 2004; Heath, K. E. et al., 2008; Hittmeier, L. J. et al., 2006; 
Hovind, P. etal., 2007; Kido, Y. et al., 2002; Koeleman, B. P. et al., 2004; Landmann, E. et 
al., 2006; Longo, N. et al., 1992; Nielsen, E. M. et al., 2004; Peeters, R. P. et al., 2005; 
Rietveld, I. et al., 2006; Rosmond, R. et al., 2002;  San Milan, J. L. et al., 2004; 
Shimokawa, I. et al., 2003; Stephens, R. H. et al., 2005; Uthra, S. et al., 2007; Vaessen, N. 
et al., 2001; Vella, A. et al., 2008; Vigoroux, C. et al., 1997;  Wortley, K. E. et al., 2005; 
Yazdanpanah, M. et al., 2006), dysplasia (Kwinta, P. et al., 2008), growth hormone 
defficiency (Abuzzahab, M. J. et al., 2003; Adamis, D. et al., 2007; Bandmann, O. et al., 
1997; Barbosa, E. J.et al. 2009; Barrenas, M. et al., 2000; Behmel, A. et al., 1988; Binder, 
G. et al., 1999; Binder, G. et al., 2003; Binder, G. et al., Bonafe, M. et al., 2003; Bozzola, 
M. et al., 1989; Carrascosa, A. et al., 2008; Chen, X. et al., 2003; Cheng, I. et al., 2007; 
Costalonga, E. F. et al., 2009; Cotterill, A. M. et al., 1998; Coutinho; D. C. et al., 2007; 
Desai, M. P. et al., 2005; Ealey; K. N. et al., 2008; Fang, P. et al., 2007; Ferreira, L. V. et 
al., 2005; Ferreira, L. V. et al., 2007; Fielder, P. J. et al., 1991; Fielder, P. J. et al., 1992; 
Grill, J. D. et al., 2005; Guevara-Aguirre, J. et al., 2007; Gleeson, H. et al., 2007; Gloria-
Bottini, F. et al., 1994; Goddard, A. D. et al., 1997; Hale, D. E. etal., 2000; Hayashida, C. 
Y. et al., 2000; Henningson, M. et al., 2007; Hess, O. et al., 2007; Johnston, L. B. et al., 
1999; Kaji, H. et al., 1997; Kay, D. C. et al., 2008; Höybye, C. et al., 2003; Höybye, C. et 
al., 2004; Höybye, C. et al., 2005; Ibáñez, L. et al., 2002;  Joseph, M. et al., 1996; Jörge, A. 
A. et al., 2004; Kallio, J. et al., 2001; Kaspar, B. K. et al., 2005; Kawashima, Y. et al., 
2005; Kennedy, M. J. et al., 2008; Kiess, W. et al., 2005; Kionshita, Y. et al., 2007; Ko, J. 
M. et al., 2009; Laron, Z. et al., 1989; Laszmezas, C. et al., 1993; Lettre, G. et al., 2007; 
Limal, J. M. et al., 2006; Maheshwari, H. G. et al., 1998;  Marzullo, P. et al., 2002; Masala, 
A. et al., 2003; Meyer, S. et al., 2007; Meyer, S. et al., 2008; Morimoto, L. M. et al., 2005; 
Naves, L. A. et al., 2007; Okubo, Y. et al., 2004; Pantel, J. et al., 2003; Raile, K. et al., 
2006;  Ransome, M. I. et al., 2008; Roldan, M. B. et al., 2007; Sanchesz, J. E. et al., 1998; 
Schmid, C. et al., 2007; Sen, F. et al., 2008; Sjoberg, M. et al., 2001; Tauber, M. T. et al., 
1998; Toyoshima, M. T. et al., 2007; van der Klaauw, A. A. et al., 2008; Vivenza, D. et al., 
2004; Wasserstein, M. P. et al., 2003; Walenkamp, M. J. et al., 2006; Walenkamp, M. J. et 
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al., 2007; Walker, J. F. et al., 1998; Walton-Betancourth, S. et al., 2007; Wan, L. et al., 
2007; Woods, K. A. et al., 1997; Zankl, A. et al., 2000; Zimmermann, A. et al., 2007) 
leprechaunism (Jospe, N. et al., 1996; Takahashi, Y. et al., 1997), osteoporosis (Baroncelli, 
G. I. et al., 1999; Bezzera, F. F. et al., 2008; Brenner, R. E. et al., 1993; Côté G. et al., 
2007; Dresdner Pollack, R. et al., 2000; Garnero, P. et al., 2005; Kim, J. G. et al., 2002; 
Lakatos, P. L. & Bajnok, E. et al., 2004; Lakatos, P. L. et al., 2004; Lee, D. O. et al., 2008; 
Mersebach, H. et al., 2007; Meulenbelt, I. et al., 1998; Miyao, M. et al., 1998;  Pereira, R. 
C. & Stadmeyer, 2006; Pereira, R. C. et al., 2006; Rivadeneira, F. et al., 2003; Rivadeneira, 
F. et al., 2004; Rosen, C. J. et al., 1998; Sheu, Y. T. et al., 2006; Takacs, I. et al., 1999; 
Wang, Y. et al., 2006; Wright, N. M. et al., 1996; Zhai, G. et al., 2004), pregnancy 
(Bajoria, R. et al., 2001; Choi, J. S., 2009; Day, I. N. et al., 2002; Fehringer, G. et al., 2008; 
Harrington, S. C. et al., 2007; Johnston, L. B. et al., 2003; Rivadeneira, F. et al., 2006; 
Setiawan, V. W. et al., 2006; Twickler, T. B. et al., 2002; Vaessen, N. et al., 2002; van der 
Vorm, E. R. et al., 1993), retinopathie (Balogh, A. et al., 2006; Dunai, G. et al., 2008; 
Ramocki; N. M. et al., 2008; Rietveld, I. et al., 2006), silver- russel syndrom (Binder, G. et 
al., 2006; Binder, G. et al., 2008), schizophrenia (Moises, H. W. et al., 2002; Perrin, M. A. 
et al., 2007) and thyroid dysfunction (Chen, A. C. et al., 2004; Kursunluoglu R. et al., 
2009). 
The following 169 animal studies were excluded: Adams, N. R. et al., 2000 ; Alb, M. et al., 
2005; Alt, J. A. et al., 2003 ; Amador-Noguez, D. et al., 2005; Amills, M. et al., 2003 ; 
Andrade, P. C. et al., 2008; Anisimov, V. N. et al., 2004 ; Anzo, M. et al., 2008 ; Beamer, 
W. G. et al., 2000 ; Beccavin, C. et al., 1999 ; Beccavin, C. et al., 2001 ; Behl, R. et al., 
2006 ; Behringer, R. R. et al., 1990 ; Bennett, A. K. et al., 2006 ; Bessone, S. et al., 1999 ; 
Bian, L. H. et al., 2008; Bikle, D. D. et al., 2002 ; Boge, A. et al., 1995 ; Camarero, G. et 
al., 2001 ; Cao, Y. et al., 1995 ; Casas-Carrillo, E. et al., 1997 ; Chagnon, M. J. et al., 
2006 ; Chakravarty, G. et al., 2003 ; Chandrashekar, V. et al., 2007 ; Chase, C. C. et al., 
1998 ; Chase, K. et al., 2005 ; Corva, P. M. et al., 2000 ; Coschigano, K. T. et al., 2000 ; 
Coschigano, K. T. et al., 2003 ; Curi, R. A. et al., 2005; Da Silva, A- et al., 2009 ; 
Danilovich, N. et al., 1999 ; Daugaard, J. R. et al., 1998 ; Daugaard, J. R. et al., 1999 ; 
Davis, M. E. et al., 2000 ; Day, J. K. et al., 2001 ; de Lima, A. R. et al., 2007 ; D`Ercole, A. 
J. et al., 1994 ; Desbois-Mouthon, C. et al., 2006 ; Dewil, E. et al., 1999 ; De Cola, G. et 
al., 1997 ; Dierkes, B. et al., 2000 ; Doublier, S. et al., 2000 ; Doublier, S. et al., 2001 ; 
Dozmorov, I. et al., 2001 ; Ealey, K. N. et al., 2008 ; Eckstein, F. et al., 2002 ; Elchebly, 
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M. et al., 1999 ; Elzaouk, L. et al., 2003 ;  Estany, J. et al., 2007 ; Femiano, P. et al., 2005 ; 
Fiorotto, M. L. et al., 2003 ; Flyvbjerg, A. et al., 1992 ; Fournier, M. & Lewis, M. I. et al., 
2000 ; García-Tornadú, I. et al., 2006 ; Gardan, D, et al., 2008 ; Garigan, D. et al., 2002 ; 
Gao, W. Q. et al., 1999 ; Gao, X. et al., 2006 ; Ge, W. et al., 2001 ; Ge, W. et al., 2002 ; 
Goddard, C. et al., 1996 ; Gonzalez, E. et al., 2003 ; Gore, M. T. et al., 1994 ; Grégoire, F. 
M. et al., 1995 ; Grochowska, R. et al., 2001 ; Guernec, A. et al., 2003 ; Hansen, P. J. et al., 
2007 ; Harada, N. & Okjima, K., 2007 ; Harada, N. et al., 2007 ; Harper, J. M. et al., 2003 ; 
Hausman, G. J. et al., 1991 ; Hausman, G. J. et al., 1992 ; Herman, A. C. et al., 2004 ; 
Harper, C. E. et al., 2007 ; Hirose, Y. et al., 2004 ; Hoeflich, A. et al., 1999 ; Holland, M. 
D. et al., 1997 ; Høj, S. et al., 1993 ; Huybrechts, L. M. et al., 1987 ; Jenet, A. et al., 2006 ; 
Johnson, K. R. et al., 2007 ; Khan, A. S. et al., 2003 ; Kadowaki, T. et al., 1996 ; Katoh, K. 
et al., 2008 ; Kim, M. H. et al., 2004 ; Klindt, J. et al., 1992 ; Klindt, J. et al., 1995 ; Lee, 
Y. H. et al., 1997 ; Lei, M. et al, 2007 ; Lei, M. et al., 2008; Leininger, M. T. et al., 2000 ; 
Li, C. et al., 2004 ; Li, M. H. et al., 2006 ; Li, J. Q. et al., 2003 ; Liu, J. L. et al., 1998 ; Liu, 
J. P. et al., 1993 ; Liu, Z. et al., 2008; Longobordi, S. et al., 2000 ; Ma. et al., 2008; 
Macrae, V. E. et al., 2009; Mai, V. et al., 2003 ; Masternak, M. M. et al., 2005 ; 
McCampbell, A. S. et al., 2008; Medrano, J. F. et al., 1991 ; Meyer, C. W. et al., 2004 ; 
Michaylira, C. Z. et al., 2006 ; Mitchell, R. D. et al., 1995 ; Miller, R. A. et al., 2002 ; 
Moerth, C. et al., 2007 ; Moody, D. E. et al., 1996 ; Moore, T. et al., 2008; Morel, P. C. et 
al., 1994 ; Mostyn, A. et al., 2006 ; Movérare, S. et al., 2003 ; Naar, E. M. et al., 1991 ; 
Nagaraja, S. C. et al., 2000 ; Pausová, Z. et al., 2003 ; Peng, X. D. et al., 2003 ; Phatsara, 
C. et al., 2008; Pugliese, G. et al., 1997 ; Ramsey, M. M. et al., 2002 ; Rieusset, J. et al., 
2004 ; Rogler, C. E. et al., 1994 ; Rosenberg, L. A. et al., 2006 ; Rowland, J. E. et al., 
2005 ; Salih, D. A. et al., 2004 ; Sawczenko, A. et al., 2005; Schuenke, M. D. et al., 2008; 
Shefi-Friedman, L. et al., 2001 ; Shimokawa, I. et al., 2002 ; Shuldiner, A. R. et al., 1990 ; 
Simmen, F. A. et al., 1990 ; Spence, S. L. et al., 2006 ; Sperandeo, M. P. et al., 2007 ; 
Spicer, L. J. et al., 1993 ; Spicer, L. J. et al., 2002 ; Stefaneanu, L. et al., 1999 ; Sun, L. Y. 
et al., 2005; Sun, J. et al., 2006 ; Sutter, N. B. et al., 2007; Symons, A. L. et al., 2003 ; 
Tagami, M. et al., 1999 ; Tamemoto, H. et al., 1994 ; Tesseraud, S. et al., 2003 ; Tixier-
Boichard, M. et al., 1990 ; Tixier-Boichard, M. et al., 1991 ; Tomas, F. M. et al., 1991 ; 
van de Loo, F, A. et al., 1998 ; van de Ven, M. et al., 2006 ; Vasilatos-Younken, R. et al., 
1997 ;  Vicario-Abejón, C. et al., 2004; Vidal, O. et al., 2000 ; Wang, B. et al., 2009 ; 
Whisnant, C. S. et al., 1998 ;  Woitge, H. W. et al., 2000 ; Wu, G. Q. et al., 2007 ; 
Yamashita, K. et al., 2001 ; Yilmaz, A. et al., 2004; Zaczek, D. et al., 2002 ; Zhang, M. et 
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al., 2002 ; Zhang, Y. et al., 2008; Zhao, X. F. et al., 2007; Zigman, J. M. et al., 2005; 
Zhong, J. et al., 2002 ; Zhou, H. et al., 2005; Zhou, J. et al., 2000 ; Zinovieva, N. et al., 
1998.  
35 reviewes were also excluded: Bonjour, J. P. et al., 2007; Brauer, V. F. et al., 2004; 
Camacho- Hübner, C. et al., 2001; Dagogo- Jack, S. et al., 2001; DePrimo, S. E. et al., 
2001; Druckmann, R. et al., 2002; Dunger, D. et al., 2002; Dumitrescu, R. G. & Cotarla, I., 
2005; Edouard, T. et al., 2008; Eisman, J. A. et al., 1999; Franceschi, C. et al., 2005; 
Gennari, L. et al., 2001; Hansen, P. J., 2007; Hansen, P. J., 2007; Heald, A. et al., 2006; 
Higaki, Y., 2000; Holmström, G. et al., 2007; Holly, J. M. et al., 1999; Ichinose, K. et al., 
2007; Jiang, M. et al., 2004; Kang, D. et al., 2003; Kelemen, L. E., et al., 2008; Lea, R. G. 
et al., 1991; Lewinski, A. & Wojciechowska, K., 2007; Miedlich, S. et al., 2001; O`Dell, S. 
D. et al., 1998; Patalano, A. et al., 2009; Patel, A. C. et al., 2004; Rosenbloom, A. L. et al., 
2000; Sandhu, M. S. et al., 2005; Spector, T. D. et al., 2004; Wagner, K. et al., 2007; 
Walenkamp, M. J. et al., 2008; Woods, K. A. et al., 1999; Yamada, H. et al., 2005). 
In some studies genotype data was missing (Backström, M. C. et al., 2001; Blümel, P. & 
Mullis, P. E., 2001; Buckway, C. K. et al., 2001; Buckway, C. K. et al., 2002; Cadoret, A. 
et al., 2005; Dahlen, G. H. et al., 1994; dÀlesio, A. et al., 2005; David, A. et al., 2007; 
Däpp, C. et al., 2006; Espinos, C. et al., 2008; Fenton, J. I. et al., 2008; Finkeltov, I. et al., 
2002; Frayling, T. M. et al., 2002; Guo, H. et al., 2008; He, J. et al., 2007; Hernandez, M. 
I. et al., 2008; Holzenberger, M., 2004; Jernström, H. et al., 2006; Kelley, K. W. et al., 
2004; Kofoed, E. M. et al., 2003; Kojima, T. et al., 2004; Li, Q. et al., 2008; McColl, G. et 
al., 2005; Meyer, S. et al., 2009; Oliver, W. T. et al., 2005; Pantsulea, I. et al., 2005; Palles, 
C. et al., 2008; Platz, E. A. et al., 1999; Rietveld, I. et al., 2003; Rietveld, I. et al., 2004; 
Rowland, J. E. et al., 2005; Slattery, M. L. et al., 2005; Suh, Y. et al., 2008; Takada, D. et 
al., 2003;  Tran, N. et al., 2004; Voorhoeve, P. G. et al., 2006;  Walenkamp, M. J. et al., 
2005; Willcox, B. J. et al., 2008; Yilmaz, A. et al., 2005; Zafon, C. et al., 2003; Zaoh, J. et 
al., 2007). 
Studies excluded because of no IGF-I genotype content were: Abrahamsen, B. et al., 2006; 
Blum, W. F. et al., 2006; Carrascosa, A. et al., 2006; Devaney, J. M. et al., 2007; Hansen, 
J. A. et al., 1997; Inanlou, M. R. et al., 2005; Lichtenauer, U. D. et al., 2007; Lida, K. et al., 
1998; Oliveira, H. A. et al., 2003; Olney, R. C. et al., 2006; Patterson, J. L. et al., 2002; 
Pereira, R. M. et al., 2007; Ravio, T. et al., 1996; Rosenbloom, A. L. et al., 1998; Rouard, 
M. et al., 1997; Schreiner, F. et al., 2007; Syed, F. A. et al., 2005;  
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Finally, one study was published in french (Savage, M. O. et al., 1998) and two studies did 
not relate to an effect on muscle phenotype (DÀloisio, A. A. et al., 2009; Kato, I. et al., 
2003). 
 
 
 
 
 
 
 
Abbildung 8: Systematic search strategy for “(IGF-I OR IGF-1) AND genotype” in 
PubMed 
 
 
 
The IGF-II search delivered 267 appropriate publications (Abb. 9). But only a few 
accomplished the inclusion criterias. 67animal studies were excluded (Ainscough, J. F. et 
al., 1997; Amills, M. et al., 2003; Andrade, P. C. et al., 2008; Anisimov, V. N. et al., 2004; 
trials identified as potentially relevant: 
535 
trials included: 2 
35 reviews excluded 
169 animal studies excluded 
269 clinical trials excluded 
41 studies without genotype excluded 
2 studies had no phenotypic outcome 
17 studies not examining IGF-I excluded
nonathletics with intervention: 
2 randomised controlled trials 
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Beccavin, C. et al., 1999; Beccavin, C. et al., 2001; Bennett, S. T. et al., 1996; 
Braunschweig, M. H. et al., 2004; Burns, J. L. et al., 2007; Cadoret, A. et al., 2005;; 
Casola, S. et al., 1996; Charalambous, M. et al., 2003; Constância, M. et al., 2005;  
Corcoran, R. B. et al., 2008; Crossey, P. A. et al., 2002; DeChiars, T. M. et al., 1990; 
Denhardt, D. T. et al., 1991; DÈrcole, A. J. et al., 1994; Dewil, E. et al., 1999; Dikkes, P. et 
al., 2007; Dindot, S. V. et al., 2004; Duselis, A. R. et al., 2007; Dittmer, F. et al., 1998; 
Estelle, J. et al., 2005; Flisikowski, K. et al., 2007; Frank, D. et al., 2002; Gardan, D. et 
al.,2008; Gardner, R. L. et al., 1999; Goodall, J. J. et al., 2007; Gore, M. T. et al., 1994; 
Haddad, R. et al., 1997; Han, R. H. et al., 2008; Harper, J. et al., 2006; Hausman, G. J. et 
al., 1991; Hoeflich, A. et al., 1999; Holland, M. D. et al., 1997; Høj, S. et al., 1993; 
Kadlecova, M. et al., 2008; Kadowaki, T. et al., 1996; Kido, Y. et al., 2002; Kim, M. H. et 
al., 2004; Klindt, J. et al., 1992; Klindt, J. et al., 1995; Kolaríková, O. et al., 2003; 
Leighton, P. A. & Ingram, R. S., 1995; Leighton, P. A. et al., 1995; Li, E. et al., 1993; Liu, 
G. L. et al., 2003; Liu, J. P. et al., 1993; Ludwig, T. et al., 1994; McCampbell, A. S. et al., 
2008; Macrae, V. E. et al., 2009; Moerth, C. et al., 2007; Nezer, C. et al., 2003; Nolan, C. 
M. et al., 1999; Ojeda, A. et al., 2008; Pravtcheva, D. D. et al., 1998; Ripoche, M. A. et al., 
1997; Rohbe, L. et al. 2004; Rogler, C. E. et al., 1994; Schmidt, J. V. et al., 1999; Schori, 
H. et al., 2007; Smith, J. et al., 2000; Sperandeo, M. P. et al., 2007; Szabo, P. E. et al., 
1996; Tamemoto, H. et al., 1994; Tesseraud, S. et al., 2003; Todoka, N. et al., 2000; Van 
den Magdenberg, K. et al. 2004; Van den Magdenbergg, K. et al., 2007; Wanderling, S. et 
al., 2007; Wang, G. et al., 2005;  2008; Wise, T. L. et al., 1997;  Zaina, S. et al., 2003; 
Zaina, S. et al., 1998; Zechner, U. et al., 2002). 
Most of the excluded studies were clinical trials: Algar, E. et al., 2000; Awata, T. et al., 
1997; Bachner-Melman, R. et al., 2005; Bachner-Melman, R. et al., 2007; Bajoria, R. et al., 
2001; Barlaskar, F. M. et al., 2007; Binder, G. et al., 2006; Binder, G. et al., 2008; 
Bermingham, J. et al., 2000; Boquist, S. et al., 2008; Cano-Gauci, D. F. et al., 1999; 
Casola, S. et al., 1997; Cerrato, F. et al., 2008; Chen, C. L. et al., 2000; Chia, V. M. et al., 
2008; Choi, Y. S. et al., 2009; Chokkalingam, A. P. et al., 2001; Christofori, G. et al., 
1995; Cui, H. et al., 1997; Cui, H. et al., 2003; Dahlén, G. H. et al., 1994; dÀlesio, A. et 
al., 2005; Day, I. N. et al., 2006; de Fraipont, F. et al., 2000; De Souza, 1995; Doria, A. et 
al., 1996; Doublier, S. et al., 2001; Duarte, A. et al., 1998; Dunai, G. et al., 2008; el-
Naggar, A. K. et al., 1999; Engel, J. R. et al., 2000; Enomoto, A. et al., 2001; Fielder, P. J. 
et al., 1991; Fielder, P. J. et al., 1992; Fournet, J. C. et al., 2001; Giannoukakis, N. et al., 
 89
1993; Gicquel, C. et al., 1994; Gicquel, C. et al., 1997; Hashimoto, K. et al., 1996; Hattori, 
H. et al., 2000; He, W. Z. et al., 2004; Heath, K. E. et al., 2008; Heude, B. et al., 2007; 
Hernandez, L. et al., 2003; Herault, J. & Petit, E., 1994; Herault, J. et al., 1994; Hess, O. et 
al., 2007; Ho, G. Y. et al., 2003; Iida, K. et al., 1998; Inaba, T. et al., 1989; Ingrosso, D. et 
al., 2003; Jandziszak, K. et al., 1998; Jimeno, L. et al., 2005; Julier, C. et al., 1991; Kaku, 
K. et al., 2007; Kaur, R. et al., 2005; Kim, H. S., 2001; Kim, S. J. et al., 2002; Kim, Y. J. et 
al., 2006; Kondo, Y. et al., 1999; Kong, F. M. et al., 2000; Kotsinas, A. et al., 2008; Lai, 
M. T. et al., 2005; Lakatos, P. L. & Bajnok, E., 2004; Lakatos, P. L. et al., 2004; Li, E. et 
al., 1993; Li, H. & Zhang, N., 2004; Li, S. R. et al., 2004; Li, Z. Q. et al., 2007; Li, X. et 
al., 1997; Majores, M. et al., 2002; Mariani, S. et al., 2003; McCann, J. A. et al., 2004; 
Micha, A. E. et al., 1999; Mitchell, S. M. et al., 2004; Mosse, Y. P. et al., 2007; Moulton, 
T. et al., 1994; Moulton, T. et al., 1996; Möller, B. et al., 2007; Mu, L. et al., 2008; 
Murrell, A. et al., 2004; Nagai, M. et al., 1999;Nakagawa, H. et al., 2001; Nyström, A. et 
al., 1992; Ober, C. et al., 1989; Ogawa, O. et al., 1993; Ohshima, K. et al., 2000; Oliveira, 
H. A. et al., 2003; Ong, K. K. et al., 2004; Ostojić, S. et al., 2008; Patel, R. et al., 2000; 
Perrotti, D. et al., 1990; Petry, C. J. & Ong, K. K., 2005; Petry, C. J. et al., 2005; 
Polychronakos, C. et al., 1995; Ramocki, N. M. et al., 2008; Ransohoff, D. F., 2003; 
Rivera, E. J. et al., 2005; Rodriguez, S. et al., 2004; Rodriquez, S. & Gaunt, R., 2006; 
Rodriquez, S. et al., 2006; Sandovici, I. et al., 2003; San Schofield, P. N. et al., 1995; 
Millán, J. L. et al., 2004; Schneid, H. et al., 1991; Schwienbacher, C. et al., 2000; Spencer, 
H. G. et al., 1995; Sperandeo, M. P. et al., 2000; Shih, D. Q. et al., 2000; Sten-Linder, M. 
et al., 1993; Stessman, J. et al., 2005; Stier, S. et al., 2006; Sutherland, G. et al., 2008; Tait, 
K. F. et al., 2004; Takada, D. et al., 2003; Tauber, M. T. et al., 1998; Tessema, M. et al., 
2005; Theiss, A. L. et al., 2005; Thorvaldsen, J. L. et al., 1998; Tomlinson, G. E. et al., 
1992; Tsai, F. J. et al., 2003; Ulaner, G. A. et al., 2003; Vafiadis, P. et al., 1996; Vafiadis, 
P. & Grabs, R., 1998; Vafiadis, P. et al., 1998; Villuendas, G. et al., 2006; Voskuil, D. W. 
et al., 2004; Vuononvirta, R. et al., 2008; Wagner, K. et al., 2004; Wasserman, L. et al., 
2004; Weksberg, R. et al., 1993; Wilkin, F. et al., 2000; Woods, K. A. et al., 1997; Wu, H. 
K. & Weksberg, R., 1997; Wu, H. K. et al., 1997; Xu, Y., et al., 1993; Xu, W. et al., 2006; 
Yamada, T. et al., 1997; Yang, X. F. et al., 1996; Yun, K. et al., 1998; Yun, K. et al., 1999; 
Zankl, A. et al., 2000; Zatkova, A. et al., 2004; Zavras, A. I. et al., 2003; Zhai, G. et al., 
2004.  
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5 studies could not be approached because of missing genotype data: Adkins, R. M. et al., 
2007; DeLuca, M. et al., 2001; Lee, H. J. et al., 2005; Paquette, J. et al., 1998; Tost, J. et 
al., 2006.  
The same amount of studies showed genotype measurements but the effect on muscle 
phenotype was missing: Cox, N. J. et al., 1988; Gaunt, T. R. et al., 2001; Giannoukakis, N. 
et al., 1996; Gomes, M. V. et al., 2005; Gu, D. et al., 2002; O`Dell, 1997; O`Dell, 1999; 
Roth, S. M. et al., 2003. 
Some studies were excluded because they did not relate to IGF-II: 
Abu- Amero, S. et al., 1997; Chen, J. et al., 2008; Frankish, H., et al., 2001; Goddard, A. 
D. et al., 1997; Harvey, J. J. et al., 2008; Killian, J. K. et al., 2001; McGinnis, R. E. et al., 
1994; Pritlove, D. C. et al., 2004; Rosenblum, A. L. et al., 1994; Sun, A. et al., 2005; 
Suzuki, M. et al., 2008. 
Finally all reviews were excluded (Barlaskar, F. M. et al., 2007; Chen, C. P. et al., 2007; 
Geenen, V. et al., 2005; Haig, D. & Graham, C., 1991; Han, V. K., 1993; Moore, T. et al., 
2001; O`Dell, S. D. & Day, I. N., 1998; Ong, K. K. et al., 2004; Patalano, A. et al., 2009; 
Spector, T. D. et al., 2004; Squire, J. & Weksberg, R., 1996; Ukkola, o. et al., 2004; 
Utsunomya, J., 2005; Wilkin, F. et al., 2000; Witte, D. P. & Bove, K. E., 1994; Zaina, S. & 
Nilsson, J., 2003). 
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Abbildung 9: Systematic search strategy for “(IGF-II OR IGF-2) AND genotype” in 
PubMed 
 
 
The search for myostatin also delivered a small output of included studies (Abb. 10). Out 
of the 66 potentially relevant surveys 55 animal studies were excluded (Antoniou, E. & 
Grosz, M., 1999; Bouley, J. et al., 2005; Bünger, L. et al., 2004; Casas, E. et al., 1999; 
Cornelison, D. D. et al., 2000; De la Rosa, X. F. & Rodrguez Perez, M. A., 2006; De la 
Rosa-Reyna, X. F. et al., 2006; Deveaux, V. et al., 2001; Di Stasio, L. & Rolando, A., 
2005; Dunner, S. et al., 2003; Esmailizadeh, A. K. et al., 2008; Fahrenkrug, S. C. et al., 
1999; Grobet, L. et al., 1997; Grobet, L. et al., 1998; Gu, Z. L. et al., 2002; Guernec, A. et 
al., 2003; Hadjipavlou, G. et al., 2008; Hamelin, M. et al., 2006; Hamrick, M. W. & 
Pennington, C., 2006; Hamrick, M. W. et al., 2006; Johsnon, P. L. & McEwan, J. C., 2005; 
Scheuermann, G. N. et al., 2004; Jiang, Y. L. et al., 2001; Jiang, Y. L. et al., 2002; 
Johnson, P. L. et al., 2005; Keele, J. W. et al., 2001; Kellum, E. et al., 2009; Kijas, J. W. et 
al., 2007; Klauzinska, M. et al., 2001; Lehnert, S. A. et al., 2007; Li, X. L. et al., 2006; Li, 
trials identified as potentially 
relevant: 267  
trials included: 3 
17 Reviews excluded 
77 animal studies excluded 
149 clinical  trials excluded 
5 studies without genotype excluded 
11 studies not examining IGF-II excluded 
5 studies had no phenotypic outcome 
intervention: 
1 study 
without intervention: 
2 studies 
 
nonathletics: 2 cohort sudies nonathletics: 1 cohort study 
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Z. F. et al., 2005; Lin, J. et al., 2003; Martyn, J. K. et al., 2004; McPerron, A. C. et al., 
1997; Mosher, D. S. et al., 2007; Oldham, J. M. et al., 2009; Parsons, S. A. et al., 2006; 
Phoca, F., 2009; Sadkowski, T. et al., 2008; Sellick, G. S. et al., 2007; Short, R. E. et al., 
2002; Smith, J. A. et al., 2000; Szabo, G. et al., 1998; Varga, L. et al., 2003; Varga, L. et 
al., 2005; Walling, G. A. et al., 2004; Wheeler, T. L. et al., 2001; Wiener, P. et al., 2002; 
Ye, X. et al., 2007; Yu, L. et al., 2007; Zhiliang, G. et al., 2004; Zuh, Z. et al., 2007). 
2 clinical trials were excluded (González-Freire, M. et al., 2009; Zhang, Z. L. et al., 2008) 
and  2 studies without genotype were excluded (Munies, C. A. et al., 2008; Williams, M. 
S., 2004). Another 2 studies turned out not to examine myostatin (McPherron, A. C. et al., 
1999; Walsh, S. et al., 2007) and in 1 study the effect on muscle phenotype was absent 
(Saunders, M. A. et al., 2006). At least 2 reviews were excluded (Rodgers, B. D. et al., 
2008; Vainzof, M. et al., 2008). 
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Abbildung 10: Systematic search strategy for „(myostatin OR GDF8) AND genotype“ in 
PubMed 
 
 
 
 
 
 
 
 
 
trials identified as potentially 
relevant: 66 
potentially appropriate trials: 4 
 
trials included: 6 
2 trials found by hand search 
2 reviews excluded 
55 animal studies excluded 
2 clinical trials excluded 
2 studies without genotype excluded 
1 study had no phenotypic outcome 
intervention: 
3 studies 
without intervention: 
3 studies 
nonathletics: 
2 randomised controlled trials 
1 case-controll trial 
nonathletics: 
2 randomised controlled trials 
1 case-controll trial 
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7 Discussion 
 
The outcome of  twentyfive relevant studies for ACTN3 gene yielded nineteen studies with 
effect on muscle phenotype (eleven athletic and eight nonathletic cohorts) and six studies 
detected no significant relation (four athletic and two nonathletic investigations). The 
ACTN3 athletics group without intervention had the highest output in relevant studies. 
Internal relationships with genotype effects in this group will be discussed later. Five 
studies reporting associations with training response all showed positive effects of ACTN3 
on muscle phenotype. The physical performance phenotypes for which genetic data were 
available include cardiorespiratory endurance, elite endurance athlete status, muscle 
strength and other muscle performance traits. The speciall point of view for this gene is, 
that regardless the heterogeneity and distribution of different types of fiber in skeletal 
muscle, the structural organization of the contractile apparatus is dependent on protein 
complexes which bind the sarcomeres among each other and sustain them in the muscle 
fiber. Within this context α-actinin constitutes the predominant protein. Interestingly, α-
actinin-3 deficiency does not derive in a pathological phenotype as muscular dystrophy or 
myopathies, suggesting that the ACTN2 isoform with 80% homology in amino acid 
sequence could compensate for the absence of α-actinin-3 and hence counteract the 
phenotypic consequencies of the deficiency. As all muscle fiber types express α-actinin-2, 
Norman (2009) demonstrated that the expression of ACTN-2 is affected by the content of 
α-actinin-3 in moderately well trained men. The author also suggested that α-actinins do 
not play a significant role in determining muscle fiber type composition. In contrary, 
Vincent (2007) showed a possible role of the ACTN3 gene in the determination of fiber 
type distribution in young men. α-actinin-3 was present in all type IIa fibers of RR carriers 
and systematic higher levels of α-actinin-3 in IIx fibers. In XX- homozygotes. No extra 
compensation seemed to occur concerning the lack of α-actinin-3. Both studies measured 
static and dynamic tourques of the knee-extensor muscles at baseline and after exercise 
intervention. In older women (64 years), knee extensor concentric peak power with 
strength training was found to be higher in X allele homozygotes compared with RR 
genotype individuals (Delmonico et al., 2007). Clarkson and colleagues (2005) reported no 
association between ACTN3 R577X genotype and muscle phenotype in men when 
investigating isometric elbow flexor strength (1-RM gains in response to a 12-wk strength 
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training), although these authors reported that women homozygous for the XX allele had 
lower baseline isometric strength compared with RX. Clarkson also (2005) examined 
genotypes in the ACTN3 and myosin light chain kinase (MLCK) gene in another study. In 
157 predominantly Caucasian men and women genotype associations with exertional 
muscle damage after isometric and eccentric elbow flexor exercise where determined. 
Creatin kinase (CK), myoglobin and isometric strength were tested before and after the 
exercise bout. Although subjects homozygous for the 577X allele had the lowest muscle 
strength and the lowest resting CK activity (which may indicate that these individuals are 
less active and/or have lower type II fiber composition), no associations were observed for 
other phenotypes before or after exercise. Polymorphisms in the MLCK gene were 
associated with baseline muscle strength, CK and myoglobin responses and strength loss 
after the eccentric exercise bout.  
Taken together, the variation of fiber type in skeletal muscle is a phenotype well 
characterised in athletes and nonathletes and this is explained to approximately 45% by 
genetic factors (Simoneau, J. & Bouchard, C., 1995, S.1091-1095) While cross-sectional 
studies have constantly shown that the XX genotype is under-represented in sprint-related 
athletes or associated with inferior performance, longitudinal studies have produced more 
mixed results as further review will clarify. It is hypothesized that ACTN3 might be a 
genetic factor important to normal phenotype variation in muscle function. The X allele 
seems to be functional and the XX genotype completely disables the ACTN3 protein. 
Especially located in Type II muscle fibers ACTN3 arises the key question, if the lack of 
ACTN3 protein in Type II muscle fibers in X-homozygotes effects muscular performance? 
A group surrounding MacArthur D. (1999) sought to answer this question by performing a 
case-controll study. Significant associations between the presence of α-actinin-3 and sprint 
performance at an elite level were considerable, suggesting a role for α-actinin-3 in the 
generation of force at high velocity. The frequency of the XX genotype was threefold 
lower in sprint athletes compared to controls, and more than four-fold lower in sprinters 
compared to endurance athletes (Tab. 3). If α-actinin plays an important role in type II 
muscle fibers, it would be reasonable to predict differences in skeletal muscle funtion 
among individuals with different genotypes (R577X). This activated several research 
groups to clarify frequency of XX genotype in endurance athletes. In a follow-up study 
Yang and colleagues (2003) hypothesized that the deficiency of ACTN3 would reduce 
performance in strength-related sports and would therefore be less frequent in elite sprint 
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athletes. In other words the XX genotype would be a disadvantage in sprint or power- 
related sports, in which Type II fibers are recruited. The strength of the study was the size 
of the sample and the quality of the subjects tested. The genotype was examined in 429 
Australian elite athletes from 14 different sports grouped in sprint/power (n=107), 
endurance sports (n=194) and 436 control subjects. There were significant allele frequency 
differences between sprint athletes and controls for both males and females. An interesting 
point was that strength/power and endurance athletes showed allele frequencies in opposite 
directions. Sprint athletes had a lower frequency of XX genotype (6%) than controls (18%) 
and endurance athletes (24%). The sprint athlete group also had a higher frequency of the 
RR genotype (50%) than controls (30%) and endurance (31%). None of the female elite 
sprint athletes were XX and in fact the XX genotype was completely absent in both female 
sprint and power athletes and male and female olympic sprint and power athletes. The 
authors concluded that the R allele of the ACTN3 R577X polymorphism provides an 
advantage for sprint or power related activities compared to the X allele and that the effect 
of ACTN3 genotype on performance differs between males and females. These findings 
have been supported by the independent replications in cross-sectional studies of Nijemi & 
Majamaa (2005), including three pairs of twins and five pairs of siblings. The frequency of 
ACTN3 XX genotype was lower (frequency of XX genotype: 0 vs. 9.2%) in sprint athletes 
compared to endurance athletes. Confirming Yang and colleagues, non of the top Finnish 
sprinters carried the XX genotype. It seemed that the athletic gene has been found and all 
people can be genetically screened to determine if they are a “good” athlete or a “bad” 
athlete, marking the 577R as “good” and the 577X as “bad” allele. Popular press articles 
speculated that athletic ability could be based solely on the ACNT3 gene. But 
controversely to the findings of Yang and his colleagues, Lucia et al., (2006) reported no 
significant differences in indices of endurance performance. Comparing cohorts of 
professional spanish cyclers with olympic male endurance runners and a control group, the 
genotype distribution of the ACTN3 gene and the frequency of the R and X alleles were 
similar in the three groups. Interestingly, all the three genotypes were present in the seven 
top cyclers. The researchers came to the conclusion that deficiency of α-actinin-3 in 
working muscle does not necessarily confer a performance benefit in ultra-endurance 
events in males. A fact that reconciders the point of view on the ACTN3 gene, although the 
small sample size decreases the statistical power. Another potential limitation in this study 
comes from the fact that female athletes did not participate in the study. The study of Yang 
reported significantly higher frequency distribution of the XX genotype in female 
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endurance athletes than in controls. In this regard, Clarkson et al. (2005) hypothesized, that 
ACTN3 could have a potentially smaller effect in men than in women. The research group 
evaluated associations between ACTN3 genotype and muscle size (cross-section area of 
the biceps brachii and elbow flexor MVC and 1-RM). The large group of nonathletic men 
and women enrolled in 24 supervised elbow flexor/extensor resistance training sessions of 
the nondominant arm. Significant associations of ACTN3 with muscle phenotypes in 
women were found with ACTN3 explaining ~2% of all variations within the associated 
phenotypes. Absence of ACTN3 protein indicated greater response to training compared 
with presence. Despite greater absolute gains in men, the profound data showed that 
women gain significantly more isometric strength than men (22 vs. 16%) and significantly 
more relative dynamic strength than men (64 vs. 40%) with resistance training. Three years 
later Walsh S. and his group examined this appearent benefit in strength in women across 
age 22 to 90 years. ACTN3 genotype associations with muscle phenotypes and knee 
extensor shortening and lengthening peak tourque as well as FFM were determined. 
Although no genotype-related differences were observed in men, the absence of α-actinin-
3 in women displaced lower knee extensor shortening and lengthening peak torque values 
compared with women grouped for the R allele. These differences in muscle strength 
appeared to be driven by lower levels of body and lower limb FFM. Sex-related 
associations have also been found in the athletic group by Li-Ling Chiu (2005) in 
Taiwanese women. The frequency of ACTN3 577X was significantly lower in individual 
sports compared to teamsports and the control group. Individuals carrying both RR and RX 
genotype showed the highest genotype frequencies. A possible outcome may hypothesize 
that success in more complex sports is less influenced by the RR genotype. It is not 
obvious which kinds of sport the individual sports group is refering to, but it is considered 
that individual sports can be equated with endurance performance and teamsports with 
sprinting ability. A closer look on sex differences suggests that this may be partially due to 
sex-specific hormonal differences between men and women. According to MacArthur and 
North the lower average levels of testosterone in female athletes compared to men could 
increase the influence that variations in some biological parameters have on athletic 
performance.  
For some authors the gender differences are not that appreciated. In a study with power 
athlete status in Russians Drzhevskaya and her colleagues evaluated an under-represented 
XX genotype in both sexes compared to controls (males: 6.4 vs. 16.4%; females: 6.5 vs. 
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12.5%). The ACTN3 X allele frequencies in men (34.3 vs. 39.8%) and women (30.5 vs. 
37.8%) were significantly different compared to controls. In a small nonathletic population 
Norman (2009) and researchers also did not find sex specific effects of ACTN3 genotype 
and differences in fiber- type composition.  
San Juan et al. (2006) reported similar findings in a small population of women X-
homozygotes mean age ~70 years. In this population group complete defficiency of α-
actinin-3 did not affect ventilatory threshold and peak oxygen uptake performance during 
functional tests or maximal muscle strength. The subjects in this study were elderly 
women. In particularly aging leads to an increase in mtDNA mutations. As humans age, 
there is an accumulation of mtDNA mutations and a decrease in mitochondrial enzyme 
activity and it is hypothesized that this leads to a decrease in the oxidative capacity of 
muscle tissue (Cortopassi, Shibata, Soong & Arnheim (1992), S.7370-7374). From this 
point of view aging is a slow form of mitochondrial desease and exercise can improve 
performance both in aging individuals and in those with myopathies, altough it does not 
reverse the mitochondrial defects present. According to Lindle, Metter, Lynch (1997, S. 
1581-1587) skeletal muscle gradually declines starting at about 45 years. As women lose 
muscle mass with age, ACTN3 genotype may further reduce muscle mass and strength in 
XX women. Women who are defficient in α-actinin-3 appear to be at disadvantage for 
muscular strength and this may help to contribute the lower extremity limitations that 
occur with aging shown in the longitudinal study of Delmonico. In the five- year follow-up 
study, Delmonico and his colleagues demonstrated that 70- to 79 years old X-homozygote 
women had an ~35% greater risk of incident persistent lower extremity limitation 
combared to R-homozygotes. Altough no strength differences were observed among 
ACTN3 genotype groups in that investigation, men of the same age homozygous X 
exhibited significantly greater increases in 400m walk time compared with R-homozygotes 
and heterozygotes. A previous report by Delmonico et al., (2007) found unexpectedly 
higher muscle strength in X-homozygotes compared with R-homozygote older women. 
According to the study, increases in knee extensor peak power with strength training were 
influenced by ACTN3 R577X genotype in both men and women, such that older adults 
who are R-allele homozygotes had a greater PP response to strength training than X-
homozygotes had. There was a big sample size of 50 to 85 years old sedentary adults, 
whose muscle function values may not correspond to those highly trained young athletes of 
Yang and colleagues. Nevertheless, this data show greater improvements in RR men and 
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women in response to strength training, consistent with the findings of Yang and 
colleagues, suggesting a gene - environment interaction with training necessary to elicit 
performance differences among ACTN3 genotype groups. There is a big amount of studies 
supporting the interaction of environment, genetics and training and it seems that muscle 
phenotype is likely influenced by numerous genes and polymorphisms, as well as other 
environmental factors that may be interacting with these genes in unknown ways. Cote, J., 
Macdonald, D. J., Baker, J. & Abernethy, B. (2006) compiled the birthplaces of 
professional athletes in the USA and Canada and came to the conclusion that cities over 
500.000 in population are consistently under-represented in terms of proceeding athletes. 
According to that study environment plays a role in determining the outcome of an athlete 
and small cities seem to provide early opportunities for athletic progressions that are not 
matched by large cities. Emmanuel Van Praagh estimates the components to the total 
phenotypic variation in human maximal anaerobic performance phenotypes with 50% 
genetic variance, 30% environmental variance, 15% genotype-training interaction and 5% 
technical variance (Van Praagh, 1998, S. 18). The X allele has been observed in all human 
populations so far. The lowest X allele frequencies occur in Kenian, Nigerian and South 
African populations (8-11%), resulting in approximately 1% XX genotype frequency. A 
circumstance that has been brought in connection with the success of the East African elite 
endurance runners relative to their source populations. This hypothesis has not been 
supported by the study of Yang, N. (2007) investigating the ACTN3 R577X polymorphism 
in East and West African athletes. The XX genotype was absent in Nigerians, extremely 
low in Kenyans and higher in Ethiopians. There was no evidence found for an association 
between the R577X polymorphism and endurance performance in East African athletes. 
One reason may be that many East Africans are subject to environmental influences, such 
as living and training at altitude and high levels of incidental running during childhood. 
Another possibility could be that Ethiopians expirienced considerable genetic interaction 
with neighboring Arabian populations in recent time, so gene flow from non-African 
populations may explain the higher frequency of the X allele in Ethiopians relative to 
Kenyans. The distribution of SNPs around the R577X polymorphism suggests that the 
polymorphism has existed for a considerable amount of evolutionary time and that 
balancing selection may have been involved in its maintenance. The fact that the X allele is 
evolutionary conserved, forms a basis for the hypothesis that the X allele confers an 
advantage in endurance performance, although the mechanism by which this occurs is not 
clear and may involve uncharacterised genetic interactions. Moran (2007) showed a 
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complexity of phenotype associated with the R577X polymorphism. In a population of 992 
adolescent greeks significant associations between the R577X polymorphism and 40m 
sprint time occurred. The polymorphism was not associated with power phenotypes related 
to 40m sprint, nor with an endurance phenotype. Furthermore, the polymorphism was not 
associated with obesity-related phenotypes, which would have indicated a possible thrifty 
effect of the polymorphism on metabolism. Papadimitriou (2007) provided ACTN3 
genotype analysies in elite Greek Track and Field athletes. Concluding this study, ACTN3 
is the first skeletal muscle gene which demonstrated a completely absence of XX in three 
different population groups (Australia, Finnish, Greece) in sprinters competing at the 
Olympic, world and European level. As the RR genotype was highly present in endurance 
runners (57%) the study also supports the hypothesis of Lucia et al., that top-level 
endurance runners require not only slow-twitch myofibres, but also the ability to recruit 
type II fast-twitch myofibres during phases in which they must effectively sprint for short 
distances in competition. The beneficial effect of α-actinin-3 deficiency on endurance 
performance seems to be less important than its presence on spriniting- power 
performance, as sprinters had an α-actinin-3 deficient XX genotype, but many of the 
endurance athletes had an RR genotype. The high speeds and near-maximal intensities 
during races support the notion that both strength and power are important traits in rowing. 
Except the fact that rowing times become approximately 0.7 sec faster per year, this 
circumstance is confirmed by  studies of Ahmetov (2008) in Russian and Muniesa (2008) 
in Spanish rowing athletes. The frequencies of the ACTN3 577XX genotype and 577X 
allele were significantly lower in endurance oriented athletes and none of the highly elite 
athletes had the 577XX genotype. Rowers with ACTN3 577RR genotype showed better 
results in long-distance rowing than carriers of 577RX or 577XX genotypes. Next to the 
studies mentioned before on Finnish (n=40), Spanish (n=102), Ethiopian (n=76) and 
Kenyan (n=284) athletic populations, the hypothesis that α-actinin-3 deficiency may 
confer some advantage in endurance performance events has also not been supported by 
the independent studies of Italian (n=42) endurance athletes (Paparini et al., 2007) and 
(Saunders et al., 2007) Caucasian triathletes (n=457). On the other hand three recently 
published studies support the hypothesis that the performance constraint, in which athletes 
are called upon to perform at high levels in both sprint and endurance races, may have a 
genetic basis. Santiago et al. (2008) found significant associations between elite soccer 
players and sprint/power genotype. Gomez-Gallego et al. (2008) reported that professional 
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road cyclists with the ACTN3 RR/RX genotypes had significantly higher peak power 
output and ventilatory threshold values than their XX counterparts. Stephen M. Roth 
evaluated low XX genotype frequencies in black and white elite-level strength athletes. 
The XX genotype was significantly lower in white athletes (9.7%) vs controls (19.9%) and 
no black athlete carried the XX genotype. This is consistent with the findings of X-allele 
frequencies in African-descent populations.  
This controversal discussion on ACTN3 XX and RR genotype may be due to different 
reasons. First of all rowers, cyclists, runners or other athletes who participate in overall 
endurance sports cannot be grouped together in genetic association studies. Further 
performance in competition is unlikely to be reducable to a single phenotypic trait. Least, 
according to training principle of individuality, each athlete responds differently to the 
same quantitative and qualitative training stimuli (Rushall & Pyke, 1990, S. 57-64), 
leading to a range of responses among athletes who have experienced otherwise identical 
training programmes. It is unknown whether the ACTN3 R577X polymorphism defines the 
athlete`s initial levels of power ability or it actually affects the response to training.  
The IGF-I search delievered a small output of two studies, both obtaining nonathletics with 
intervention. There is a high level of evidence for both studies characterised as randomised 
controlled trials. There were similar presuppositions for both studies and in fact the studies 
were undertaken from the same laboratory. Both studies relate to older men and women 
age 50 to 83 years. The exercise interventions were unilateral knee extensions of the 
dominant leg three times per week for ten weeks. The IGF-I promoter polymorphism and 
single-nucleotide polymorphisms were genotyped. Muscle volume, muscle quality and 1-
RM strength were assessed at baseline and after 10 weeks of training. While the study of  
Kostek (2005) investigated sixtyseven Caucasian men and women, the follow-up study of 
Hand (2007) included onehundred-twentyeight subjects of Caucasian and African 
American ethnicity. Different ethnic groups show different prevalence of the 
polymorphism with ethnicity. Kostek found that the development of muscular strength in 
response to a resistance training programm was associated with the cytosin adenine (CA) 
dinucleotide repeat polymorphism in the promoter region of the IGF-I gene such that 
carriers for 192 gained significantly more strength than noncarriers. Although no nonsense, 
missense or functional polymorphisms have been identified for the IGF-I gene, it is 
plausible that other polymorphisms within the IGF-I pathway could be involved in 
muscular hypertrophy and strength response to strength training. On this background, 
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Hand was evaluating additionally genes within the IGF pathway such as insulin-like 
growth factor binding protein 3 (IGFBP3) and calcineurin B (PPP3R1). The 1-RM strength 
of the trained leg did not differ significantly at baseline muscle phenotypes among IGF-I 
CA repeat genotype groups which is also valid for IGFBP3 A-202C and PPP3R1 I/D. Men 
showed greater mean values than women for baseline 1-RM strength and African 
American subjects had greater MV results than Caucasians at baseline. Although all groups 
increased significantly with training, the IGF-I promoter allele carriers increased their 1-
RM strength significantly more than noncarriers when covaried for sex and age. In both 
studies no significant differences between the absolute or relative changes in MV or MQ 
with strength training have been found. In addition there were no significant differences 
between Caucasian and African American individuals for absolute or relative changes in 
MV with strength training, but there was a significant difference in the absolute change in 
MQ in African Americans compared with Caucasian individuals. Hand also observed 
significant race x sex interactions for change in muscle strength but not for gene x race 
interactions for the changes in 1-RM strength, MV or MQ. Combined Caucasian and 
African American genotype analysis showed significant effects including both IGF-I CA 
repeat main effect and IGF-I CA repeat x PPP3R1 I/D gene x gene interaction effect on 
change in strength with strength training. Interestingly, no significant combined effects for 
PPP3R1 I/D on changes in strength and MQ were observed, suggesting that the influence 
of calcineurin on muscle phenotypic response to strength training may be less than that of 
IGF-I because of the presence of other IGF-I linked signaling pathways influencing muscle 
phenotypic responses to strength training. The role of calcineurin in the muscle phenotypic 
response is discussed controversely in literature and the effect that Hand observed no 
significant combined gene effects for PPP3R1 I/D on changes in strength and MQ suggests 
that the influence of calcineurin on the muscle phenotypic response to strength training 
may be less than that of IGF-I because of the presence of other IGF-I linked signaling 
pathways influencing muscle phenotype during exercise. In light of the trend for a 
significant IGFBP3 A-202C x race interaction it is possible, that race effects may play a 
greater role than genotype effects on muscle phenotypic responses to strength training. 
Although a causal relationship between acute or chronic muscle contraction and IGF-I 
expression has not been documented in humans, IGF-I remains one of the strongest 
candidate genes for strength training- induced increases in muscle mass and strength and 
there is a need to investigate other IGF-I-dependent mechanical signaling pathways that 
influence muscle phenotypic responses to strength training. 
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Two studies with nonathletic cohorts reported significant associations of IGF-II ApaI 
polymorphism and muscle phenotypes. Sayer (2002) found the ApaI polymorphism of the 
IGF-II gene was associated with grip strength for men but not women in a large sample of 
397 men and 296 women in the UK. In a longitudinal study Schrager (2004) genotyped 
subjects for the IGF-II ApaI polymorphism from cohorts of prior studies and tested for 
associations with arm and leg strength and body composition. For men, arm strength was 
greater for the homozygous wildtype than the homozygous rare alle group, while for 
women the homozygous rare allele group showed lower arm and leg strength and lower 
FFM compared with homozygous wildtype. In contrast to Sayer, who found significantly 
higher grip strength in GG men compared with AA men, Schrager found no significant 
genotype association with grip strength. Summarizing, IGF-II does not explain associations 
between eayrly growth and grip strength, but it may influence muscle mass and function in 
later life.  
Reports on association studies of myostatin polymorphisms with baseline muscle strength 
or responses to strength training in humans are scarce. The interventional studies mostly 
observed muscle volume, meanwhile observational studies determined the relation of 
genotype with strength. Out of the six studies included in this review, four studies showed 
genotype associations with muscle phenotypes (Ivey, F. M. et al., 2000; Seibert, J. M. et 
al., 2001; Corsi, A. M. et al., 2002; Huygens, W. et al., 2004) and in two studies no 
significant relations were obvious (Ferrel, R. E. et al., 1999; Thomis, M. et al., 2004).  
Ferrell (1999) first determined the nucleotide sequence for human myostatin gene in fourty 
individuals and discovered that two missense subtitutions, specifically an A to G change on 
codon 55 in the exon 1 (A55T) and an A to G substitiution in exon 2 (K153R), were 
appreciably represented in Caucasian and African American populations. In contrary to the 
bovine gene mutation acting as a missense polymorphism. Allele frequencies for the less 
frequent 153R allele were 0.037 in the Caucasian sample of the general population and 
0.16 in African Americans. Similar differences in allele frequencies were found for the 
55T allele with 0.036 and 0.12 in both ethnic groups respectively. In a substudy comparing 
elite athletes with previously untrained subjects and nonathletes (extreme responder- , 
responder- and nonresponder groups) none of the high responder athletes were carriers of 
the R153R genotype. Neither of these common polymorphisms had significant effect on 
the magnitude of increment of muscle mass in response to heavy resistance training of the 
quadriceps muscle, although K153R was overrepresented in the nonresponders cohort. 
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Homozygote myostatin R153R carriers were rare and only observed in the African 
American non- responders. Researchers from the same group tested whether the K153R 
genotype could explain hyperthrophy in MV of quadriceps muscle group after a 9-week 
heavy-resistance knee extension training program (Ivey et al., 2000). Women with the less 
common myostatin allele exhibited a 68% larger increase in MV in response to strength 
training. This trend maintained when baseline MV was covaried. Although the K153R 
polymorphism has a rare allele frequency, the effect it has on the phenotype seems to be 
meaningful. The trend observed in quadriceps MV increases in response to strength 
training in female carriers (n=5) of the myostatin K153R genotype indicates relevant 
effects on individual variability in training responses. Tomis (2004) found only one carrier 
of the K153R genotype in twentyfive pairs in the Leuven Twin and Training study. Male 
monozygotic twins age 17-30 participated in a program of ten weeks elbow flexor training.  
Genotype dependent similarity in pre- and posttraining responses and genotype x training 
interaction were not significant in this small sample size. Genetic association studies 
without training intervention also showed a rare K153R allele frequency in other cohorts of 
young and older subjects. In the WHAS II study of Seibert (2001) variant genotypes for 
A55T and K153R were also very uncommon in Caucasian population with gene 
frequencies of less than 0.02. A higher allele frequency for three variant alleles was noted 
in the African-American participants (0.05). Association studies between K153R and 
strength measuerements suggested lower muscle strength in women with the R genotype. 
As African Americans tended to have a greater overall strength, genotype was a significant 
predictor of overall strength. The race x genotype interaction was not significant. Hip, knee 
and grip strength in addition to the overall strength measurement identified a significant 
difference in hip flexion strength by K153R myostatin genotype. This may be due to the 
fact that the iliapsoas muscle is primarily composed of type 1 muscle fibers. As myostatin 
is expressed at higher levels in type 1 muscle fibers (Sakuma, Watanabe & sano, 2000, S. 
77-88) the gene may therefore have a more significant functional impact in this muscle 
group. The WHAS II study is also supported by Corsi (2002), who reported lower muscle 
strength in older men and women (mean age 70) carrying the R-allele, though the sample 
size was small. Since the allele frequencies of the polymorphism in human myostatin are 
very low, association studies with this missense polymorphism are difficult. Huygens 
underwent this problem by using markers in a linkage analysis of myostatin pathway genes 
with knee strength in humans. In this Leuven Genes for Muscular Strength Study (LGfMS)  
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the role of the myostatin pathway explaining interindividual variation in estimated muscle 
cross-sectional area and strength were explored in 329 male Caucasian sibs (including sib-
pairs, trios and quads). Linkage was mainly found with strength phenotypes, but only 
marginal evidence was present for its effects on estimated muscle cross-sectional area. 
Since the myostatin polymorphism described in animals mainly affects muscle mass and 
muscle mass is more correlated with isometric strength, it is not surprising that the research 
group found more suggestive linkage signals with slower velocities.  
Myostatin is physiologically more related to muscle mass through possible effects of 
hyperplasia and hypertrophy than it is to strength. Although most studies evaluated the 
relationship between myostatin and muscle mass rather than muscle strength. Muscle mass 
does not always correlate directly with muscle strength and muscle strength loss cannot 
uniformly be explained by changes in muscle size.  
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9 Appendix 
 
PUBMED search strategy: 
1.: ACTN3 genotype phenotype (13 matches) 
2.: α-actinin-3 genotype phenotype (12 matches) 
3.: R577X genotype phenotype (11 matches) 
4.: ACTN3 genotype exercise (11 matches) 
5.: α-actinin-3 genotype exercise (11 matches) 
6.: R577X genotype exercise (9 matches) 
7.: ACTN3 genotype phenotype exercise (6 matches) 
8.: α-actinin-3 genotype phenotype exercise (6 matches) 
9.: R577X genotype phenotype exercise (5 matches) 
10.: ACTN3 genotype training (5 matches) 
11.: α-actinin-3 genotype training (4 matches) 
12.: R577X genotype training (4 matches) 
13.: ACTN3 genotype phenotype training (2 matches) 
14.: α-actinin-3 genotype phenotype training (0 matches) 
15.: R577X genotype phenotype training (1 matches) 
16.: ACTN3 genotype strength (11 matches) 
17.: α-actinin-3 genotype strength (11 matches) 
18.: R577X genotype strength (10 matches) 
19.: ACTN3 genotype phenotype strength (4 matches) 
20.: α-actinin-3 genotype phenotype strength (4 matches) 
21.: R577X genotype phenotype strength (3 matches) 
22.: ACTN3 genotype muscle (22 matches) 
23.: α-actinin-3 genotype muscle (21 matches) 
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24.: R577X genotype muscle (17 matches) 
25.: ACTN3 genotype muscle strength (10 matches) 
26.: α-actinin-3 genotype muscle strength (10 matches) 
27.: R577X genotype muscle strength (10 matches) 
28.: ACTN3 polymorphism phenotype (10 matches) 
29.: α-actinin-3 polymorphism phenotype (10 matches)  
30.: R577X polymorphism phenotype (9 matches) 
31.: ACTN3 polymorphism exercise (9 matches) 
32.: α-actinin-3 polymorphism exercise (9 matches) 
33.: R577X polymorphism exercise (9 matches) 
34.: ACTN3 polymorphism phenotype exercise (4 matches) 
35.: α-actinin-3 polymorphism phenotype exercise (4 matches) 
36.: R577X polymorphism phenotype exercise (4 matches) 
37.: ACTN3 polymorphism training (5 matches) 
38.: α-actinin-3 polymorphism training (5 matches) 
39.: R577X polymorphism training (5 matches) 
40.: ACTN3 polymorphism phenotype training (2 matches) 
41.: α-actinin-3 polymorphism phenotype training (2 matches) 
42.: R577X polymorphism phenotype training (2 matches) 
43.: ACTN3 polymorphism strength (9 matches) 
44.: α-actinin-3 polymorphism strength (9 matches) 
45.: R577X polymorphism strength (9 matches) 
46.: ACTN3 polymorphism phenotype strength (2 matches) 
47.: α-actinin-3 polymorphism phenotype strength (2 matches) 
48.: R577X polymorphism phenotype strength (2 matches) 
49.: ACTN3 polymorphism muscle strength (9 matches) 
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50.: α-actinin-3 polymorphism muscle strength (9 matches) 
52.: R577X polymorphism muscle strength (9 matches) 
53.: ACTN3 genotype anaerobic phenotype (0 matches) 
54.: α-actinin-3 genotype anaerobic phenotype (0 matches) 
55.: R577X genotype anaerobic phenotype (0 matches) 
56.: ACTN3 polymorphism anaerobic phenotype (0 matches) 
57.: α-actinin-3 polymorphism anaerobic phenotype (0 matches) 
58.: R577X polymorphism anaerobic phenotype (0 matches) 
59.: IGF-I genotype phenotype (115 matches) 
60.: Insulinlike growth factor genotype phenotype (134 matches) 
61.: IGF-I genotype exercise (11 matches) 
62.: Insulinlike growth factor genotype exercise (8 matches) 
63.: IGF-I genotype phenotype exercise (2 matches) 
64.: Insulinlike growth factor genotype phenotype exercise (2 matches) 
65.: IGF-I genotype training (4 matches) 
66.: Insulinlike growth factor genotype training (4 matches) 
67.: IGF-I genotype phenotype training (1 match) 
68.: Insulinlike growth factor genotype phenotype training (1 match) 
69.: IGF-I genotype strength (16 matches) 
70.: Insulinlike growth factor genotype strength (14 matches) 
71.: IGF-I genotype phenotype strength (5 matches) 
72.: Insulinlike growth factor genotype phenotype strength (3 matches) 
73.: IGF-I genotype muscle (48 matches) 
74.: Insulinlike growth factor genotype muscle (78 matches) 
75.: IGF-I genotype muscle strength (6 matches) 
76.: Insulinlike growth factor genotype muscle strength (8 matches) 
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77.: IGF-I polymorphism phenotype (49 matches) 
78.: Insulinlike growth factor polymorphism phenotype (56 matches)  
79.: IGF-I polymorphism exercise (11 matches) 
80.: Insulinlike growth factor polymorphism exercise (9 matches) 
81.: IGF-I polymorphism phenotype exercise (2 matches) 
82.: Insulinlike growth factor polymorphism phenotype exercise (2 matches) 
83.: IGF-I polymorphism training (5 matches) 
84.: Insulinlike growth factor polymorphism training (6 matches) 
85.: IGF-I polymorphism phenotype training (1 match) 
86.: Insulinlike growth factor polymorphism phenotype training (1 match) 
87.: IGF-I polymorphism strength (11 matches) 
88.: Insulinlike growth factor polymorphism strength (11 matches) 
89.: IGF-I polymorphism phenotype strength (3 matches) 
90.: Insulinlike growth factor polymorphism phenotype strength (3 matches) 
91.: IGF-I polymorphism muscle strength (3 matches) 
92.: Insulinlike growth factor polymorphism muscle strength (7 matches) 
93.: IGF-I genotype anaerobic phenotype (0 matches) 
94.: Insulinlike growth factor genotype anaerobic phenotype (0 matches) 
95.: IGF-I polymorphism anaerobic phenotype (0 matches) 
96.: Insulinlike growth factor polymorphism anaerobic phenotype (0 matches) 
97.: IGF-II genotype phenotype (58 matches) 
98.: IGF-II genotype exercise (0 matches) 
99.: IGF-II genotype phenotype exercise (1 match) 
100.: IGF-II genotype training (0 matches) 
101.: IGF-II genotype phenotype training (0 match) 
102.: IGF-II genotype strength (4 matches) 
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103.: IGF-II genotype phenotype strength (1 match) 
104.: IGF-II genotype muscle (43 matches) 
105.: IGF-II genotype muscle strength (3 matches) 
106.: IGF-II polymorphism phenotype (29 matches) 
107.: IGF-II polymorphism exercise (2 matches) 
108.: IGF-II polymorphism phenotype exercise (1 match) 
109.: IGF-II polymorphism training (0 matches) 
110.: IGF-II polymorphism phenotype training (0 match) 
111.: IGF-II polymorphism strength (5 matches) 
112.: IGF-II polymorphism phenotype strength (1 match) 
113.: IGF-II polymorphism muscle strength (4 matches) 
114.: IGF-II genotype anaerobic phenotype (0 matches) 
115.: IGF-II polymorphism anaerobic phenotype (0 matches) 
116.: Myostatin genotype phenotype (28 matches) 
117.: GDF-8 genotype phenotype (28 matches) 
118.: Growth differentiation factor-8 genotype phenotype (28 matches) 
119.: Myostatin genotype exercise (6 matches) 
120.: GDF-8 genotype exercise (6 matches) 
121.: Growth differentiation factor-8 genotype exercise (6 matches) 
122.: Myostatin genotype phenotype exercise (2 matches) 
123.: GDF-8 genotype phenotype exercise (2 matches) 
124.: Growth differentiation factor-8 genotype phenotype exercise (2 matches) 
125.: Myostatin genotype training (4 matches) 
126.: GDF-8 genotype training (4 matches) 
127.: Growth differentiation factor-8 genotype training (4 matches) 
128.: Myostatin genotype phenotype training (2 matches) 
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129.: GDF-8 genotype phenotype training (2 matches) 
130.: Growth differentiation factor-8 genotype phenotype training (2 matches) 
131.: Myostatin genotype strength (8 matches) 
132.: GDF-8 genotype strength (8 matches) 
133.: Growth differentiation factor-8 genotype strength (8 matches) 
134.: Myostatin genotype phenotype strength (3 matches) 
135.: GDF-8 genotype phenotype strength (3 matches) 
136.: Growth differentiation factor-8 genotype phenotype strength (3 matches) 
137.: Myostatin genotype muscle (54 matches) 
138.: GDF-8 genotype muscle (54 matches) 
139.: Growth differentiation factor-8 genotype muscle (54 matches) 
140.: Myostatin genotype muscle strength (8 matches) 
141.: GDF-8 genotype muscle strength (8 matches) 
142.: Growth differentiation factor-8 genotype muscle strength (8 matches) 
143.: Myostatin polymorphism phenotype (15 matches) 
144.: GDF-8 polymorphism phenotype (15 matches) 
145.: Growth differentiation factor-8 polymorphism phenotype (15 matches) 
146.: Myostatin polymorphism exercise (2 matches) 
147.: GDF-8 polymorphism exercise (2 matches) 
148.: Growth differentiation factor-8 polymorphism exercise (2 matches) 
149.: Myostatin polymorphism phenotype exercise (3 matches) 
150.: GFD-8 polymorphism phenotype exercise (0 matches) 
151.: Growth differentiation factor-8 polymorphism phenotype exercise (0 matches) 
152.: Myostatin polymorphism training (2 matches) 
153.: GDF-8 polymorphism training (2 matches) 
154.: Growth differentiation factor-8 polymorphism training (2 matches) 
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155.: Myostatin polymorphism phenotype training (3 matches) 
156.: GDF-8 polymorphism phenotype training (0 matches) 
157.: Growth differentiation factor-8 polymorphism phenotype training (0 matches) 
158.: Myostatin polymorphism strength (3 matches) 
159.: GDF-8 polymorphism strength (3 matches) 
160.: Growth differentiation factor-8 polymorphism strength (3 matches) 
161.: Myostatin polymorphism phenotype strength (1 match) 
162.: GDF-8 polymorphism phenotype strength (1 match) 
163.: Growth differentiation factor-8 polymorphism phenotype strength (1 match) 
164.: Myostatin polymorphism muscle strength (3 matches) 
165.: GDF-8 polymorphism muscle strength (3 matches) 
166.: Growth differentiation factor-8 polymorphism muscle strength (3 matches) 
167.: Myostatin genotype anaerobic phenotype (0 matches) 
168.: GDF-8 genotype anaerobic phenotype (0 matches) 
169.: Growth differentiation factor-8 genotype anaerobic phenotype (0 matches) 
170.: Myostatin polymorphism anaerobic phenotype (0 matches) 
171.: GDF-8 polymorphism anaerobic phenotype (0 matches) 
172.: Growth differentiation factor-8 polymorphism anaerobic phenotype (0 matches) 
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Staatsangehörigkeit  Österreich 
 
Geburtsdatum  5.12.1975 
 
 
 
 
  
• Seit 2008  EA- Generali 
• Beruf oder Funktion  Trainer 
• Tätigkeiten und 
Zuständigkeiten 
 Planung und Organisation von Aerobicstunden (High-Low, Kräftigung, 
Freestyle), Spezialgymnastikstunden (Yoga, Tai chi, Pilates, Smart 
Bells) und Massagestunden 
 
 
• Seit 2007  U4- Fitnesscenter 
• Beruf oder Funktion  Trainer, Kraftkammerleiter 
• Tätigkeiten und 
Zuständigkeiten 
 Planung und Organisation von Kraftkammereinheiten und Personal 
Trainerstunden 
Muskelfunktionstests nach Janda,  
Körperfettmessung mit Kaliper,  
Dynamometrie mit Dr. Wolff back check test, Belastungsergometrie,  
gezielte Trainingsplanerstellung anhand der erhobenen Parameter zum 
Ausgleich muskulärer Dysbalancen und je nach Zieldefinition 
Verbesserung der Ausdauerleistungsfähigkeit,  
Betreuung von Kunden mit besonderen Bedürfnissen wie zum Beispiel  
Downsyndrom, Multiple sklerose, Osteoporose, Skoliose, 
L E B E N S L A U F  
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Rückenschmerzen sowie muskuläre Stabilisation nach Schulter- Hüft- 
bzw. Knieoperationen,  
Betreuung der Kunden im Kraft- und Ausdauertrainingsbereich,  
Individuelle Betreuung „on-the-floor“,  
Leitung von Gymnastikstunden verschiedenster Zielgruppen  
(Rückentraining, Seniorengymnastik, Aerobic, Zirkeltraining, Spinning), 
 
 
   
• Seit 2005  Schwimmschule Waterfly 
• Beruf oder Funktion  Leitung von Schwimmeinheiten verschiedenster Zielgruppen 
(Kinderschwimmen, Seniorengymnastik, Mastersschwimmen), 
Schwimmtrainer 
• Tätigkeiten und 
Zuständigkeiten 
 individuelle Betreuung mit Technikverbesserung Schwimmen 
ganzjährige Betreuung von Hobbytriathleten 
 
 
• 2005 bis 2007  American International School Schwimmtraining 
• Beruf oder Funktion  Schwimmlehrer 
• Tätigkeiten und 
Zuständigkeiten 
 Leitung von Beginner, Intermediate und Expert Schwimmeinheiten für 
Kinder des Alters von 3- 14 Jahren 
 
 
• 2001 bis 2007  Baxter- Immuno Wellness Center des Pharmakonzerns Baxter 
• Beruf oder Funktion  Kraftkammerleiter, Personal Trainer, Betreuung der Mitarbeiter 
• Tätigkeiten und 
Zuständigkeiten 
 Koordination und Planung von Kursen, Teamorganisation 
Belastungsergometrie ( Conconi- , Cooper- Tests),  
Muskelfunktionstests,  
ganzheitliche Trainingsplanerstellung (Kraft, Ausdauer, Koordination),  
Leitung von Ausdauertrainingskursen, Krafttrainingskursen, 
Therabandkursen, Progressive Muskelrelaxation, Dehnübungen, Core- 
Stability, MFT 
 
 
•2001 bis 2002   Fitnessstudio Simmafit Dr. Blanka  
• Beruf oder Funktion  Personal Trainer 
• Tätigkeiten und 
Zuständigkeiten 
 Trainingsplanerstellung im Bereich Krafttraining,  
Kontrolle und Motivation der Mitglieder 
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• seit 17.10.2007  Magisterstudium Sportwissenschaft, Universität Wien 
 
Die vorliegende Diplomarbeit bildet den Abschluss meines 
Magisterstudiums im Fachbereich der Sport- und Leistungsphysiologie.  
Das Magisterstudium der Sportwissenschaft befähigt mich, ausgewählte 
Forschungsmethoden der Sportwissenschaften kompetent und 
wissenschaftlich reflektiert für die Lösung von Praxisfragen einzusetzen. 
Ich verfüge über fachwissenschaftliche und forschungsmethodische 
Qualifizierung im Bereich der angewandten und der 
grundlagenbezogenen Forschung über sportwissenschaftliche 
Kompetenzen in der Anwendung von Forschungsmethoden, in 
fundierter Planung und Steuerung von Trainingsprozessen, in der 
Organisation fachwissenschaftlich fundierter Planung und Steuerung 
von Maßnahmen der Vorbeugung und Rehabilitation durch Bewegung 
und Sport, in der fundierten Anwendung leistungsphysiologischer und  
trainingswissenschaftlicher Kenntnisse in der sport- und 
bewegungsbezogenen Praxis, in der Erarbeitung wissenschaftlicher 
Konzepte für die Primär-, Sekundär-, und Tertiärprävention sowie in der 
Auswahl und Anwendung von sportinformatorischen und 
biomechanischen Methoden und Werkzeugen. Ich besitze höchste 
fachliche Qualifikation in der zielgerichteten und langfristig orientierten 
Förderung und Betreuung von Kindern, Jugendlichen und Erwachsenen 
aller Leistungsstufen in ausgewählten Sportarten und Sportbereichen 
sowie im Coaching in Wettkampf- und Belastungssituationen unter 
Einbeziehung eines umfassenden Grundlagenwissens aus der 
Sportmedizin, den verschiedenen Fachbereichen der 
Bewegungswissenschaft, der Sportpädagogik und Sportpsychologie 
sowie weiterer relevanter Erkenntnisse der Natur- und  
Sozialwissenschaften.  
Im Projekt- und Qualitätsmanagement erwarb ich Kompetenzen in der 
Organisations- und Projektgestaltung mit dem Schwerpunkt des 
Prozessmanagements und der Sicherung und Entwicklung umfassender 
Qualität im Sportbereich. Dies basiert auf einer beschreibenden und 
darstellenden Ebene einerseits sowie einer steuernden und verändernden 
Ebene andererseits. Kompetenzen wurden in den Bereichen 
Auftragsgestaltung, Konzeption, (Finanz)Controlling, wissenschaftliche 
Formen der Evaluation, Marketing, MitarbeiterInnen- Führung und -
entwicklung, Schnittstellenorganisation, Prozesssteuerung und 
Medienarbeit vertieft aufgebaut. Weiters ist Wissen über Konzeption, 
Durchführung und Evaluation von Beratungen im Projekt- und 
Programmbereich sowie in Sportorganisationen vermittelt worden. 
 
 
• 01.10.2003 - 16.10.2007   Bakkalaureatsstudium Gesundheitssport, Universität Wien mit 
Abschluss als  
Bakk.rer.nat. Gesundheitssport 
 
Während des Bakkalaureatsstudiums Sportwissenschaft an der 
Universität Wien erwarb ich mir  
zentrale sportwissenschaftliche, sportdidaktische, sportorganisatorische 
und trainingsspezifische Kompetenzen, die dazu qualifizieren, 
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Tätigkeiten in vielfältigen bewegungs- und sportbezogenen 
Berufsfeldern erfolgreich aufzunehmen. Die Studienausbildung 
ermöglichte es mir, sowohl eigenständig als auch in einem Team unter 
Berücksichtigung von Erkenntnissen aus unterschiedlichen 
sportwissenschaftlichen Disziplinen Lösungen für praxisbezogene 
Problemstellungen im Feld Bewegung und Sport erarbeiten und konkret 
umsetzen zu können. Als Absolvent des Bakkalaureatsstudiums 
Sportwissenschaft an der Universität Wien bin ich befähigt im 
Zusammenhang mit Bewegung und Sport stehende Themen und 
Fragestellungen auf der Basis sportwissenschaftlicher Erkenntnisse zu 
bearbeiten und in zielgruppenadäquate 
Konzepte sowie sportpraktische Angebote umzusetzen. Dabei lernte ich, 
mich an die Erfordernisse neuer Praxisfelder und Zielgruppen 
anzupassen und die eigene Geschlechterrolle zu reflektieren. Im Laufe 
des Studiums erhielt ich fachwissenschaftliche und sportpraxisbezogene 
Kenntnisse, sodaß ich über grundlegende Kompetenzen zur Anleitung 
unterschiedlicher Gruppen im Sport verfüge. 
Schlüsselqualifikationen im Umgang mit modernen Medien wurden 
durch eine kontinuierliche flexible Form des Studierens im Sinne des 
Blended Learning Konzepts (Kombination von Präsenz- und Online-
Phasen) in unterschiedlichsten Phasen des Bakkalaureatsstudiums 
erworben. Dies wurde durch ein peer-to-peer Mentoringprogramm 
unterstützt bzw. kompensiert. Zusätzlich wurden die Lernprozesse 
gefördert durch Verwendung von multimedialen Materialien, 
angeleitetem Selbststudium, Selbstevaluationstools und problem- und 
teambasierten Lernszenarien.  
 
 
 
 
• 1.3.2001- 7.11.2003  Studium der Leibeserziehung und Italienisch, Universität Wien 
• 1999- 2001   Studium der Zahnmedizin, Karl- Franzens- Universität Graz 
• 1999  Externistenprüfung Latein, BRG Keplerstrasse, Graz 
•1998- 99   Studium der Medizin, Karl- Franzens- Universität Graz 
•1997- 98  Studium der Erdwissenschaften, Karl- Franzens- Universität Graz 
• 1996- 97  Ableistung des Präsenzdienstes als Sanitäter in Aigen/ Ennstal 
• 1993  Certificat de Langue Francaise- Centre International d`Antibes 
•1991-96  Borg Monsbergergasse Graz mit AHS- Matura- Abschluss 
•1986-91  BRG Körösistrasse, Graz 
•1983-86  Volksschule Muchargasse, Graz 
•1982-83  Volksschule Celtesgasse,  Wien 
